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Abstract
Acetaminophen, known as paracetamol in the UK and Tylenol in the United States, is
a widespread and commonly used painkiller all over the world. Taken in large enough
doses, however, it can cause fatal liver damage. In the U.S., 56000 people are admitted
to hospital each year due to acetaminophen overdose and its related effects, at great
cost to healthcare services.
In this thesis we present a number of different models of acetaminophen metabolism
and toxicity. Previously, models of acetaminophen toxicity have been complex and
due to this complexity, do not lend themselves well to more advanced mathematical
analysis such as the perturbation analysis presented later in this thesis. We begin
with a simple model of acetaminophen metabolism, studying a single liver cell and
performing numerical and sensitivity analysis to further understand the most important
mechanisms and pathways of the model. Through this we identify key parameters that
affect the total toxicity in our model. We then proceed to perform singular perturbation
analysis, studying the behaviour of the model over different timescales, finding a number
v
vi
of key timescales for the depletion and subsequent recovery of various cofactors as well
as critical dose above which we see toxicity occurring. Later in the thesis, this model
is used to model metabolism in a spheroid cell culture, examining the difference spatial
effects have on metabolism across a 3D cell culture.
We then present a more complex model, examining the difference the addition of
an adaptive response to acetaminophen overdose from the Nrf2 signalling pathway, has
on our results. We aim to reproduce an unexplained result in the experimental data
of our colleagues, and so analyse the steady states of our model when subjected to an
infused dose, rather than a bolus one. We identify another critical dose which leads
to GSH depletion in the infused dose case and find that Nrf2 adaptation decreases
toxicity and model sensitivity. This model is then used as part of a whole-body PBPK
model, exploring the effects that the distribution of the drug across the bloodstream
and different organs has. We explore the affects of that a delay in up-regulation from
the Nrf2 pathway has on the model, and find that with rescaled parameters we can
qualitatively reproduce the results of our collaborators.
Finally, we present the results of in vitro work that we have undertaken, the aim
of which was to find new parameters for the model in human hepatocytes, rather than
from rodent models, and find a new value for a parameter in our model from human
cell lines.
Publications
The work of Chapters 2 and 3 is published as “Timescale analysis of a mathemati-
cal model of acetaminophen metabolism and toxicity” by D. Reddyhoff, J. Ward, D.
Williams, S. Regan and S. Webb in the Journal of Theoretical Biology 386, 2015, 132-
146. [1].
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1Chapter 1
Introduction
1.1 An Introduction to Drug Discovery and Ad-
verse Drug Reactions
As technology progresses, drug discovery and manufacturing have progressed alongside
it. As more drugs are discovered and put to market, the difficulty of finding new
compounds and treatments becomes ever more difficult. Safety regulations have become
more stringent and multiple trials are required to get a drug to market. Along with this
rise in the difficulty of discovering new drugs and the safety tests required to get these
drugs to market, the cost of drug discovery has risen exponentially. The cost of creating
a new drug is now estimated to be $2.6 billion [4], and so a need for reliable testing
to ensure drugs get to market is required. However, drug attrition (drugs that fail in
2testing and therefore do not make it to market), is estimated to be around 90% [5].
Drug discovery follows a number of distinct stages. The discovery stage attempts to
find new compounds which could potentially become a drug, with the average time for
a new discovery being 5 years with up to 10000 compounds being examined [6]. Next,
approximately 250 drugs will reach the pre-clinical stage, this stage involves laboratory
and animal testing and will take 2 years on average for a drug to clear [7]. After
this human trials begin with around 5 remaining compounds, in three phases totalling
around 6 years and costing up to $20,000,000 per-study for each drug [8]. At the end of
this only one of the 10000 tested compounds would be expected to reach production [6].
Adverse drug reactions, or ADRs, are a major cause of this attrition and are therefore
an enormous burden on the pharmaceutical industry and the worldwide healthcare
industry as a whole. Solely in the U.S.A, adverse drug reactions in drugs that have made
it to market are between the 4th and 6th leading cause of death [9]. It is expected that
most adverse drug reactions can be predicted during the preclinical and clinical toxicity
assessment. Common causes of adverse reactions in the human population are errors
in prescriptions from healthcare professionals and interactions with other drugs the
patient has been prescribed [10]. Between 1975 and 1999, almost 3% of drugs that were
approved for the U.S market were withdrawn and around 10% acquired a boxed warning,
a warning from the FDA that medical studies indicate that the drug carries a significant
risk of ADRs [11]. However, some ADRs, such as those that are a result of the formation
3of chemically reactive metabolites are not predictable and are known as idiosyncratic
ADRs. Such adverse reactions are often not detected until the drug has already received
approval and is released to the general market. Hepatotoxicity, or chemical-driven liver
damage, is one such idiosyncratic ADR. The liver, in fact, is the organ most commonly
affected by reactive metabolite related ADRs and drug-induced liver failure (DILI) is
the leading cause of acute liver failure and transplantation in Western countries [12].
DILI is one of the leading causes of drug attrition in the drug discovery pipeline [13],
barring many drugs from progressing past the pre-clinical and clinical stages. Many
times DILI is only discovered once a drug has been approved for market and therefore
has to be withdrawn at an enormous cost to the manufacturer. One such example of
a drug capable of DILI which has made it to market is Acetaminophen (paracetamol;
APAP; Tylenol). Acetaminophen is responsible for 80% of drug-associated cases of
liver failure [14]. Generally, hepatotoxicity from acetaminophen overdose is predictable
due to having a well characterised metabolism. Studying acetaminophen can help to
illuminate how toxicity due to chemically reactive metabolites occurs through effects
on cells, transcription factors and the immune system. For this reason, acetaminophen
metabolism is the main focus of this thesis, as improved knowledge of a drug whose
toxicity is predictable can increase understanding of DILI in general. Binding of reactive
metabolites to proteins in the liver has been established using acetaminophen and
evidence suggests that formation of reactive metabolites through drug metabolisation
4is a precursor to various toxicities [15].
1.2 The Reliability of Animal Models
With the huge numbers of drugs that are now being developed, more and more animals
are being subjected to testing. Many organisations are committed to reducing the
number of animals in medical research with various possible solutions being offered.
One of the most important points to consider is how predictive animal models are
when looking at human cases. An animal model is expected to provide a controlled
environment for experimentation, and provide results that can be extended to human
clinical trials.
In 2009, Kilkenny et al. produced a systematic survey of the reporting, experimental
design and statistical analysis in 271 publications in the field of biomedical research
using laboratory animals. The purpose of this report was to ensure that good scientific
practice was being used in animal experimentation. In their study of the quality of
reporting in these publications they found that: 5% of the studies didn’t describe the
purpose of their study, 6% did not make it clear whether one or more experiments
were being undertaken, 26% did not report the sex of the animals and 24% reported
neither the age or weight of the animals. In regards to experimental design it was found
that only 12% of publications reported random allocation of animals to experimental
groups, and only 9% of the studies that used random allocation reported their method.
5They also concluded that a large number of the studies did not make the most of
their resources, including the animals [16]. A systematic review which compared the
treatment effects between animal experiments and clinical trials found that:
• Corticosteroids did not show any benefit in clinical trials but did in animal models.
• Antifibrinolytics reduced bleeding in clinical trials but the data was inconclusive
in animal trials.
• Trilazad was associated with a worse outcome in patients with ischaemic stroke,
but in animals reduced infarct (an obstruction of tissue blood supply) volume and
improved neurobehavioral scores.
The study concluded that “Discordance between animal and human studies may be due
to bias or to the failure of animal models to mimic clinical disease adequately.” [17].
Evidently, new methods of toxicity testing are required in order to better improve the
predictive capabilities of experiments before clinical stages.
Results of animal research can be looked at statistically using sensitivity (percentage
of correctly identified positives), specificity (correctly identified negatives) and positive
predictive value (proportion of correctly identified positives). In comparisons of drugs
tested on both animals and humans, the animal tests had a sensitivity of 0.52 and a
positive predictive value of 0.31 [18], which makes any claim of predictive value from
these particular models difficult. Further studies have been conducted on toxicity found
6in animal data prior to human clinical tests. Heywood et al. found that in a sample of
24 toxic drugs, toxicity was found in animal data first only 4 times [18] and Spriet et
al. found that just 6 out of 114 cases presented correlation between animal and human
toxicity [19]. A 1994 study by the Japanese Pharmaceutical Manufacturers Association
found that 39 of 91 clinical toxicities were not predicted from animal studies [20].
A real world example of this can be found in Troglitazone, an anti diabetic drug
manufactured in the late 90’s. The drug made it through pre-clinical and clinical testing
and was approved by the F.D.A in 1996. The drug was successful, however it caused
94 cases of acute liver failure, resulted in 66 deaths and 11 liver transplants and had to
be taken off the market [21].
Originally it was assumed that using animals that were physically similar to humans,
for example, a chimpanzee, would make sense as they are of a similar size and have a
genetic makeup close to our own. However, there is no guarantee that primates will
respond similarly to toxicity, as the metabolic and physiological pathways they use
to deal with hepatotoxicity may be different (such as the chimps ability to aromatise
quinic acid [22]), not to mention the ethical issues of using primates for medical testing.
Another option may be a porcine model, however in pigs, acetaminophen can oxidise
haemoglobin providing a confounding factor to results [23]. So there are more factors
then just physical similarity in selecting animal models.
Currently, due to ethical concerns, most tests are conducted on smaller animals
7such as rodents. Statistics from the Home Office in 2013 show that mice and rats
make up over 80% of animals used in animal research in the UK [24], and these are
the main animals involved in animal models for hepatotoxicity. There is a marked
difference in acetaminophen LD50 doses (lethal dose that kills 50% of a test sample)
between different species; rats have an LD50 of 2400 mg/kg [25], mice have an LD50
of 338 mg/kg [25] and humans have an LD50 of 400mg/kg [26]. In the excretion of
phenol (a chemical found in many pharmaceutical drugs, including acetaminophen), two
pathways are generally considered, sulphation and glucuronide conjugation. However,
rats and humans have different ratios of sulphate and glucuronide cofactors [27], and
this must be accounted for when extrapolating data from animal to human models.
When compared, it was found that rats needed three times the acetaminophen dose of
a standard mouse model to reach similar levels of toxicity. Rats also presented a delayed
drop in hepatic GSH depletion and APAP-protein binding when compared to mice [28]
(a full explanation of sulphation, glucuronidation and GSH depletion is given in Section
1.5). Studies of downstream affects of acetaminophen overdose have revealed that both
humans and mice have similar biomarkers following mitochondrial dysfunction brought
about by acetaminophen toxicity, however rats do not exhibit this. However it has been
found that humans and mice may have different enzymes responsible for acetaminophen
metabolism [28].
It is clear that new methods of toxicity testing need to be explored in order to
8improve both the reliability of the predictions of toxicological outcomes as well as
making more efficient use of animals used in research. The use of a mathematical
modelling approach such as the one found in the following chapters of this thesis can help
create a framework which will allow more targeted experimentation. These techniques
can be used to improve in vitro to in vivo extrapolation as well as providing insight
into data gaps and metabolic interactions which can be further extrapolated to provide
predictive models of toxicity without the need for excessive animal testing.
1.3 The Need for Improved Models of Hepatotox-
ocity
Two options for the replacement or at least reduction of in vivo testing is in vitro and
in silico modelling. In vitro testing involves using isolated cell lines to study toxicity,
which can then be applied to in vivo systems. In silico modelling uses mathematics and
computing to create models which mimic in vivo or in vitro systems and can provide
insight without the need for animals or cell lines.
Predictability of toxicology is hugely important to the pharmaceutical industry,
however currently in vitro tests do not sufficiently predict the potential for toxicity from
new compounds. The pharmaceutical industry has not put forward a combined effort
to find novel test systems or implement current systems across the entire industry [29].
9Therefore, there is a lack of understanding in how current in vitro test systems compare
physiologically with the human liver, and prediction of DILI is therefore difficult. It
is estimated that upwards of $100 million could be saved if a 10% improvement in the
prediction of failure from DILI [30]. DILI is responsible for:
• Drug attrition in preclinical trials due to toxicity
• Drug attrition in human patients in late stage trials
• Withdrawal from the market after the drug is released
• Box warnings from the FDA
• Serious illness in human patients [10]
As such DILI is a major safety concern for pharmaceutical companies as well as
regulatory bodies. In particular the increased costs from failed drugs and increased
development times are passed on to consumers. New systems that are able to identify
hepatotoxic compounds early could reduce the amount of drug attrition in the develop-
ment pipeline and reduce the cost of drug development, through less failed compounds
as well as time saved. An improved understanding of the mechanism or mechanisms of
hepatic toxicity in humans, as well as identifying why non-clinical studies do not always
detect hepatotoxic compounds could results in far better non-clinical testing. A deeper
understanding of the mechanisms of toxicity is critical if identification of hepatotoxic
chemicals in pre-clinical drug development is to be improved. Currently, in vitro tests
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do not sufficiently predict toxicity due to differences between the cells used in testing
and actual human hepatocytes within the body, as well as a lack of looking at toxicity
as a full body problem, where the liver acts as only a single site within a much larger
system [10].
Instead of in vitro testing, in silico testing can provide results without the need for
improved in vitro testing protocols. Using mathematics and systems biology approaches
as a basis, a number of biological systems can be studied such as drug/metabolite levels,
covalent binding levels, adaptive responses and biomarkers indicating hepatic damage.
These systems can be used hand in hand with in vitro models to improve their extrap-
olation to in vivo models in both animals and humans. By using mathematical models
instead of cell based models, methods can quickly be improved upon and multiple tests
can be carried out without the potentially large costs of in vitro testing. Mathematical
models are able to describe metabolism in simpler terms. These models can range from
complicated models that model individual genes, proteins, pathways etc. to basic mod-
els that describe metabolism in a reduced form but are easier to apply mathematical
techniques to. In silico modelling provides a way to combine existing data and use this
to predict future outcomes. By including metabolism from throughout the liver, models
can mimic human hepatocytes in a way cell lines used in in vitro testing can not as
well as being combined in to larger full body systems that could help predict possible
hepatotoxicity of new compounds early. Collecting necessary toxicological information
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using animal testing would be prohibitively costly and would pose ethical questions.
1.4 The 3R’s
The work in this thesis was made possible by a grant from the National Centre for the
Replacement, Refinement and Reduction of Animals in Research (NC3R’s). Established
by the UK government in 2004, the NC3R’s is an independent organisation which aims
to improve how animals are used in research. Their strategy comprises of tackling
three different areas of animal research. Replacement, whereby protected species are
not used in experiments, and instead other methods such as mathematical and computer
based modelling is used. Reduction, where the number of animals being used in each
individual experiment is minimised; and finally refinement, whereby the suffering an
animal undergoes during testing is minimised.
The work included in this thesis aims to follow this vision, using mathematical mod-
els as a form of replacement so that less animals can be used in testing and reducing
the number of animals that have to be used by revealing data gaps to provide more
targeted experimentation. The work presented will provide a starting point for com-
bining mathematical modelling with experimental work and help create a framework
which can be built upon in the future.
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1.5 Basics of Acetaminophen Toxicity
Acetaminophen (paracetamol; APAP N-acetyl p-aminophenol) is a widely used painkiller
and anti-inflammatory. In many countries acetaminophen can be sold over the counter
in pharmacies as well as being available off the shelf in shops, and is sold in packets
of up to 16 tablets, enough to cause significant liver damage if consumed in one dose.
In the U.S., an average of 56000 people are admitted to hospital each year as a result
of acetaminophen overdoses and their related effects. Over 450 people a year go on to
die from acetaminophen overdose [9]. As previously mentioned, adverse drug reactions
in the U.S. are ranked as being between the 4th and 6th leading cause of death [9]. In
the UK, 90 to 155 people died per year between 2000 and 2008 with additional deaths
due to drug-drug-interactions with acetaminophen [31]. A general lack of awareness
of the hazards of acetaminophen, combined with its ease of availability has resulted in
acetaminophen being responsible for 80% of drug associated cases of liver injury [14],
and as discussed earlier in the introduction, DILI is the most common cause of acute
liver failure and subsequently transplantation in Western countries [12].
Amongst the general public, acetaminophen is generally taken orally and is then
absorbed in to the bloodstream. Blood arrives in the liver through the hepatic portal
vein and progresses to the central vein as seen in Figure 1.1. As it moves through the
liver, acetaminophen is absorbed into the hepatocytes at which point it is metabolised.
Hepatocyte function is determined by position relative to the portal vein, and functions
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Figure 1.1: Structure of the liver [2]. Blood flows from the portal field (left)
to the central vein. APAP in the blood diffuses into the hepatocytes and is
metabolised.
differ depending on the hepatocytes proximity to either the blood inlet (periportal) or
outlet (centrilobular). This effect is known as zonation and is present across all areas of
the liver [32]. As with other phenol’s, acetaminophen is primarily (∼ 95%) metabolised
by the sulphation and glucuronidation pathways [33, 34], while approximately 5% is
metabolised via oxidation. This oxidation pathway forms N-acetyl p-benzoquinone imine
(NAPQI) [35], a toxic metabolite which binds with protein in the hepatocytes, dam-
aging and potentially killing them. Detoxification of these metabolites occurs through
conjugation with glutathione (GSH). As such, GSH-metabolite adducts in testing is a
potential sign of DILI. For this reason it is important that models of drugs which lead
to hepatotoxicity through protein binding include GSH conjugation. A full pathway di-
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agram of acetaminophen metabolism can be found in Figure 1.2, and a full explanation
of each pathways function can be found in the next chapter. Additionally, adaptive re-
sponses to an increased concentration of oxidative species such as NAPQI alter the way
these pathways behave. The Nrf2 protein can up-regulate the production of GSH in
response to an acetaminophen overdose. These effects are explored further in Chapter
4.
1.6 The Structure of This Thesis
This thesis is made up of 8 chapters. In Chapter 1 we have introduced the context of
our research as well as the basics of acetaminophen metabolism. Chapter 2 provides
a more in-depth explanation of acetaminophen metabolism. We then present a sim-
ple model for acetaminophen metabolism in a single hepatocyte, performing numerical
and sensitivity analysis to gain understanding of the important parameters and path-
ways. In Chapter 3 we perform singular perturbation analysis on this model, seeking
to examine the different timescales in our results, and find dominant mechanisms that
contribute to toxicity. In Chapter 4 we build upon this model, modelling the Nrf2
adaptive response and performing steady state analysis on the model in an attempt to
replicate experimental data from our collaborators. In Chapter 5 we include the work
of the previous chapter as part of a PBPK model, studying the full body affects of
acetaminophen metabolism, as well as its distribution through the blood plasma and
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Figure 1.2: A diagram of the cell scale metabolic network for APAP
metabolism. The abbreviations are: APAP, acetaminophen; UGTs,
UDP-glucuronosyltransferases; SULTs, sulfotransferase; NQO1, NADPH-
quinoreductase; CYPs, cytochrome P450; APAP-G, acetaminophen
glucuronide; APAP-S, acetaminophen sulphate; NAPQI, N-acetyl-p-
benzoquinone imine; GSTs, glutathione S-transferase; GSH, glutathione;
APAP-GSH, acetaminophen glutathione conjugate. Subscript ’B’ denotes
non-specific binding to a protein or lipid. Subscript ’P’ denotes binding to
non-specific protein [3]. Blue boxes are non specifically bound products,
yellow boxes are molecules, white boxes are isozymes, red boxes are pro-
tein bound molecules and green boxes are further metabolic systems not
described in this diagram.
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organs. In Chapter 6 we present a 3D spheroid model, to include spatial effects in our
results, as well as providing a framework for combining mathematical modelling with in
vitro multi-cell spheroid models. Chapter 7 presents the work of a 2 week period work-
ing in the labs at Liverpool university, in which we sought to parameterise our model
through an in vitro study involving a human cell line. Finally, Chapter 8 includes the
conclusion of this thesis as well as presenting potential future work.
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Chapter 2
Single Cell Model of
Acetaminophen Metabolism
In this chapter, we present a simple model of acetaminophen metabolism in a single
hepatocyte, using ODE’s and mass action kinetics. The work of this chapter has been
published in the Journal of Theoretical Biology as “Timescale analysis of a mathemat-
ical model of acetaminophen metabolism and toxicity” [1]. Firstly, however, we review
the existing literature in the subject.
2.1 Past Models of Acetaminophen Metabolism
Reith et al. [36], 2009, proposed a model designed to fit the data from an in vivo
study on the metabolism of acetaminophen. The aim of the article was to estimate the
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Michaelis-Menten constants, i.e. km and vmax in
reaction rate =
vmaxX
km +X
for a species X, of the major metabolic pathways of acetaminophen metabolism and
observe the affects of high acetaminophen doses on the modelled system. The model
included seven ordinary differential equations (ODE’s) which examined plasma and
urine concentrations of acetaminophen, APAP-G (the metabolite formed through ex-
cretion via the glucuronidation pathway) and APAP-S (the metabolite formed through
excretion via the sulphation pathway). The equations include terms for the respective
volumes of distribution as well as simple rate constants for the excretion of metabolites
in the urine. High Performance Liquid Chromatography (HPLC) assays were used to
analyse the metabolites in the plasma and urine of the patients and from these assays
the Michaelis-Menten constants km and vmax were estimated for the major pathways
involved in acetaminophen metabolism. The model included a total of 20 parameters
that needed to be estimated, which was reduced to 10 free parameters by using rate
constants from past models and fixing the volumes of distribution to population mean
results and scaling them with bodyweight. Two trials were performed on 20 patients in
order to collect the urine and plasma data. However, due to these tests being in humans,
overdose levels were not reached and therefore the results would not take in to account
the affect overdoses have on the various pathways. The paper concluded that their
Michaelis-Menten constants were of a similar order to those found via in vitro methods
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and their results showed “good correlation between predicted and observed values”.
While providing a good starting point for future experimentation, the complexity of
the model prevents investigation using more advanced mathematical techniques.
Remien et al. [37], 2012, created a model of acetaminophen toxicity intended to
predict time of overdose, extent of injury and likelihood of survival or death based on
an analysis of biomarkers in the patients blood which are measured upon admission
to hospital from an acetaminophen overdose. An 8 ODE tissue scale model was used,
which modelled acetaminophen, NAPQI and GSH levels as well as functional/dead
hepatocyte numbers and various biomarker levels. This model did not include specific
equations for either sulphation or glucuronidation. The model was parameterised from
the literature and tested against historic information from 53 patients, and predicted
patient death vs. recovery with 75% sensitivity and 95% specificity. While adequately
predicting toxicity in patients, this model leaves out key pathways of acetaminophen
metabolism such as sulphation, which is known to saturate and have a downstream
effect on toxicity at high initial acetaminophen doses [38] such as those in the overdose
cases being studied. Remien produced a follow up paper in 2013 [39] which used the
same ODE model but this time looked at a chronic dosing regimen (i.e. a continuous
dose instead of a single bolus dose). Stability and steady state analysis was performed
for different dosing scenarios and the effects on hepatocyte damage as well as the change
in metabolite concentrations was examined. The model provided good estimates of the
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extent of the liver injury experienced, but does not provide good estimates of the time
since the onset of the injury. The study also found that acetaminophen overdose has a
threshold whereby above this threshold, liver damage is rapid, and below it very little
injury is seen. They also conclude that chronic dosing of acetaminophen, even below
the threshold for liver damage, lowers intracellular GSH though did not provide an
analytical estimate of this effect. We have also reached this result independently in our
own model, presented in Chapter 3. This work is complimentary of the work found
throughout this thesis, where we have analytically found a similar result regarding
threshold doses of acetaminophen as well as similar results regarding changes in intra-
cellular GSH levels in response to none-lethal acetaminophen doses. We also expand
upon the steady state work conducted in this paper, including more complex pathways
as well as examining how adaptation in the nucleus can affect overall toxicity.
Ben-Shachar et al. [40], 2012, outlines a model of acetaminophen metabolism that
aims to reproduce clinical and experimental data on acetaminophen levels in plasma,
as well as metabolite levels in the urine and the effect of overdoses of GSH levels.
This data was published by Prescott et al., 1980 [41]. These results are then used to
study the timing and effects of N-acetylcysteine or NAC intervention, an antidote for
acetaminophen poisoning, on overdoses. The model is multi-compartmental, studying
five compartments representing the gut, liver, plasma, tissue and urine. The bulk of the
metabolism occurs in the liver (the author assumes 75% bioavailability) although the
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model also includes metabolism within the tissue compartment. The other compart-
ments feature as transporters for the drug and its metabolites. The model is a system
of 21 ODE’s using linear transport rates between the compartments which are taken
from the literature. Other parameters were estimated through data fitting. The model
reproduces the data well and captures the expected dynamics of the pathways involved
in acetaminophen metabolism. They also study the affects of long-term chronic dosing,
specifically multiple oral doses daily over a number of week, and again find a drop in
antioxidant capacity. The paper also explores the effects that changes in P450 activ-
ity (the enzymes responsible for metabolising APAP to NAPQI) has on acetaminophen
metabolism, finding that elevated P450 activity increases toxicity and this effect is com-
pounded by larger doses such as those seen in attempted suicide. The model reproduces
the data accurately but its complexity again makes it unsuitable for further analysis.
Also of note is that certain parameters are from rat data, but the data being fit to
is from humans. It has been shown that sensitivity to acetaminophen varies across
species [42] and so this method of fitting may not provide accurate clinical results.
Diaz Ochoa et al. [3], 2013, used a multi scale approach which combined cellular
models with a 2D liver model and finally a whole body model. The paper aimed to
start at the cellular level and then continue to scale the model upwards, aiming to
reproduce results from both in vitro toxicity data and experimental results. Another
aim of the work was to study the affects of inter-patient variability. A 32 ODE model
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examines a hepatocyte between a sinusoid and the bile canaliculi (see Figure 1.1). Ac-
etaminophen arrives in the sinusoid via passive diffusion and is metabolised. The model
takes the major pathways in to account, but also expands on GSH metabolism as well
as modelling the production of hydrogen peroxide, a pathway not studied in the rest
of the literature discussed here. A 2D spatial liver model using partial differential
equations (PDE’s) describes advection-diffusion affects across the sinusoid. Finally, a
six-compartment, whole body PBPK model describes absorption rates and changes in
concentration between the compartments. The model provides good approximations
of the time course data that was used to test it and was then used to run simula-
tions to study inter-patient variability. The results provide information on the spatial
distribution of acetaminophen in the liver as well as the affects of differing P450 en-
zyme levels on acetaminophen metabolism. Similarly to Reith et al., the complexity of
this model provides good numerical results and simulations but limits the applicabil-
ity of advanced analysis, which is required to fully understand the various timescales
that acetaminophen metabolism occurs over, as well as identifying dominant aspects of
metabolism.
2.1.1 Summary of the Literature Survey
We have presented a review of previous mathematical models of acetaminophen meta-
bolism. In general, past models have been highly complex in an attempt to capture
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the full metabolic profile of acetaminophen and to reproduce clinical results. The
limitations of models this complex is that further analysis is difficult if not impossible.
As such, the models do not include any of the sensitivity, variance-based or perturbation
analysis which is featured in this thesis. These models also do not include adaptive
affects from various transcription factors, such as Nrf2, which are explored in the coming
chapters. Remien et al. have numerically found evidence of a ‘threshold’ dose which
we explain analytically in this paper, and also include steady state analysis of a chronic
dosing regimen which we expand upon. None of these models include 3D effects which
can be found in the spheroid model presented in this thesis, although 2D work has been
undertaken. Past work in this field is complimentary of the work presented here and
provides a good framework, upon which we have built and produced novel work that
moves the field forward.
2.2 Acetaminophen metabolism and toxicity
In order to produce a model which was analytically tractable we simplified the path-
ways seen in Figure 1.2 and instead used a streamlined pathway diagram shown in
Figure 2.1. This reduced pathway diagram still contains the most important pathways
for acetaminophen metabolism and so is biologically relevant whilst simultaneously
being easier to work with mathematically.
The sulphation pathway involves the conjugation of APAP with the cosubstrate
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3’-phosphoadenosine 5’-phosphosulfate or PAPS. This cosubstrate is finite within the
liver cell and at toxic doses we expect PAPS levels to fall [38] and a saturation of the
sulphation pathway, leading to higher metabolism through glucuronidation and oxida-
tion. The cofactors associated with the glucuronidation pathway have a much higher
capacity than those of the sulphation pathway [36] and we assume in our modelling
that the pathway does not saturate at clinically relevant, high APAP doses. Via the
oxidation pathway, APAP is catalysed by a selection of enzymes from a ‘superfamily’ of
enzymes known as Cytochrome P450 [43]. The main enzymes involved in this reaction
in human cells are Cytochromes CYP2E1,CYP3A4 and CYP1A2 [43, 44, 45], however,
the sub-type and hence nomenclature of the enzymes varies by species when looking at
animal models. Metabolism through oxidation produces NAPQI, a chemically reactive
and toxic metabolite. NAPQI can be detoxified by GSH, an antioxidant which forms a
conjugate with NAPQI, preventing binding with essential proteins, and thus prevent-
ing damage to the liver. At sufficiently high doses, the sulphation cosubstrate, PAPS,
can be exhausted, diverting quantitatively more APAP through the oxidation pathway,
leading to higher amounts of NAPQI being produced. There are marked species differ-
ences in the sensitivity to APAP, e.g. rats are resistant to equivalent doses of APAP
compared with humans, and this is due to a much greater capacity for sulphation and
a lowered propensity for oxidation [46]. Oxidation has the effect of depleting GSH
levels in the liver, through binding with NAPQI and hence greater levels of protein
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Figure 2.1: Pathway Diagram for APAP Metabolism. Modelled species are
APAP (P ), NAPQI (N), PAPS (S), GSH (G) and Drug-Protein Adducts
(C).
adducts are produced. GSH can also be depleted by individual factors such as alco-
holism [47] and anorexia [48], though this inter-patient variability is beyond the scope
of the mathematical model to be presented in the following chapters.
The model presented in this chapter will be applicable to a broad range of drugs that
are metabolised in the liver via (1) a non exhaustible pathway (i.e. glucuronidation),
(2) an exhaustible pathway (i.e. sulphation) and (3) an oxidation pathway that leads
to GSH binding and toxic conjugate formation. In the next two chapters we present
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two separate forms of analysis on this model. Firstly, we examine numerical results and
their biological significance and then, to identify which parameters have the most effect
on the predicted outcome, we use sensitivity and variance-based analysis. Secondly, we
derive relatively simple formula, using singular perturbation analysis, for factors such as
critical initial dose and timescales for peak toxic activity. This will enable us to probe
the model to gain great insight in to how individual mechanisms in the model can affect
and influence these factors. Though the focus will be on APAP metabolism in humans,
the modelling and analysis is applicable to preclinical animal models also. We seek to
create a model that captures the most important aspects of APAP metabolism and tox-
icity at the cellular level. We then analyse the model both numerically and analytically
in order to develop a better understanding of the interactions in the modelled system.
We also wish to identify any data gaps which can then be pursued experimentally.
2.3 Derivation of the Model
Model Background.
We focus on the metabolism of paracetamol within a single hepatocyte, aiming to cap-
ture the main dynamics of APAP metabolism while maintaining enough simplicity that
analytical progress is possible. The full metabolic process is summarised in Figure 1.2
and, as stated before, broadly separates into three pathways. Describing all of the path-
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ways illustrated in Figure 1.2 would lead to an extremely complex model involving 20+
state variables and many more parameters. Instead, as a first approximation, we bun-
dle all the pathways in the glucuronidation route into a single pathway and likewise for
sulphation and oxidation. The reduced pathway diagram used for the model is shown
in Figure 2.1. We assume for sulphation and glucuronidation that the first reaction
down each pathway is non-, or negligibly, reversible, so that events downstream do not
directly affect paracetamol metabolism. For the oxidation pathway, we assume a single
generic CYP is involved which represents the combined actions of CYP2E1, CYP3A4
and CYP1A2.
Model Description.
We use mass action laws to derive a system of ordinary differential equations that
describe the dynamics over time of the different pathways illustrated in Figure 2.1.
The resulting model is the same as that presented, but not studied, in Williams et
al. [10], we will nevertheless outline the model derivation. The model variables are
listed in Table 2.1 and we note they represent quantities per cell.
Our model assumes an initial bolus dose being delivered. The metabolism depends
on the size of the initial dose. At regular doses the majority of APAP will be metabolised
by the sulphation and glucuronidation pathways [35]. APAP (P ) undergoes sulphation
by reacting with the PAPS enzyme (S) at rate kSSP , where kS is the rate constant
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Table 2.1: Model variables and their units.
Variable Interpretation Units
P Paracetamol (APAP) mol/cell
S Sulphate (PAPS) mol/cell
N NAPQI mol/cell
G GSH mol/cell
C Protein Adducts mol/cell
associated with the metabolism of APAP by PAPS, ultimately forming APAP-S. In
humans, PAPS is exhaustible and so at high doses may, in some situations, see a
saturation of the pathway. We define the rate constant for the production of PAPS by
the liver as bS and the rate constant for the natural decay as dS. In contrast, we assume
that the enzymes involved in glucuronidation are not exhaustible and are present at an
approximately constant concentration, hence APAP metabolism along this pathway is
in effect a natural decay at rate kGP .
The remaining APAP is metabolised via the oxidation pathway creating NAPQI
(N). We assume that cytochrome P450 enzymes are present continuously at an ap-
proximately fixed concentration, so that the oxidative pathway is described as a further
“natural decay” rate term, k450P . This reaction is assumed reversible at rate kNN .
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NAPQI is assumed to be metabolised via one of two pathways. The first is by
reaction with the antioxidant GSH (G) at a rate kGSHNG. At normal doses of APAP
we expect to see nearly all of the NAPQI produced being detoxified by this pathway.
Conjugation with GSH renders NAPQI harmless and it is excreted from the body with
no ill effects. In our model, GSH is assumed to be constitutively produced at a constant
rate bG and naturally decays at rate dGG. In fact, the production and regulation of GSH
production is quite complex, primarily synthesised in the liver [49] whilst also being
released from skeletal muscle [50] and regulated as an adaptive mechanism by Nrf2 [51];
at the level of detail of the current model we assume that constant bG is a reasonable
starting point for modelling single doses. The second pathway has NAPQI creating
drug-protein adducts (C) at a rate kPSHN . This binding to cellular macromolecules can
result in cell death if the proteins that are bound are essential for cell function/viability.
We do not consider the downstream events caused by drug-protein adducts and the
variable C represents the total accumulated amount of a toxic reaction (we therefore
hereon refer to C as toxins in that they are capable of inducing cell death).
We arrive at the following model describing the pathways in Figure 2.1 and including
the stated assumptions;
dP
dt
= − kSSP − kGP − k450P + kNN, (2.3.1)
dS
dt
= − kSSP + bS − dSS, (2.3.2)
dN
dt
= k450P − kNN − kGSHNG− kPSHN, (2.3.3)
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dG
dt
= − kGSHNG+ bG − dGG, (2.3.4)
dC
dt
= kPSHN. (2.3.5)
We assume in this study that the drug is introduced into cells as a single bolus dose
at t = 0 at a concentration PS, chosen by us to represent different dosing regimes.
We note that this differs to the parameter P0 found in Table 2.2, which is fixed such
that P0 = 1.32 × 10−13 mol/cell, which is the cellular concentration of APAP from a
4g dose and is used to estimate some of the parameters of our model and later non-
dimensionalise the model. The cells at this point are assumed to be at pretreatment
steady-state level. The initial conditions for this system are thus
P (0) = PS , S(0) =
bS
dS
, G(0) =
bG
dG
, N0 = 0, C(0) = 0. (2.3.6)
Table 2.2 lists the model parameters and their estimated values for the standard
simulation. Where possible, we obtained their values from the literature and any re-
maining parameters through repeated simulation, so that the numerical results matched
reasonably well with similar simulations from Remien et al. [37]. It is generally consid-
ered that anything more than 4g taken at once is considered an overdose, so we use 4g
as our safe dose case [52] (though it is recommended to take no more than a 1g dose at
4 hour intervals).
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Table 2.2: List of model parameters and values used in standard simulation
Parameter Value Units Notes
P0 1.32× 10−13 mol· cell−1 See (1)
dG 2 day
−1 [53, 54, 55]
bG 1.374× 10−14 mol· cell−1· day−1 [37]
kGSH 1.6× 1018 cell·mol−1· day−1 [15]
kG 2.99 day
−1 [36]
k
[∗]
S 2.26× 1014 cell·mol−1· day−1 See (2)
b
[∗]
S 2.65× 10−14 mol· cell−1· day−1 See (2)
d
[∗]
S 2 day
−1 Equal to dG
k
[∗]
450 0.315 day
−1 See (3)
k
[∗]
N 0.0315 day
−1 See (4)
kPSH[∗] 110 day
−1 See (5)
(1) 4g dosage, standard single dose assuming 80% of dose reaches liver.
(2) Assuming initial PAPS is 10% of standard APAP dose i.e. bS
dS
= P0
10
, and initially
sulphation and glucuronidation are about the same, i.e. kS =
kGdS
bS
i.e. amounts to
47.5% of APAP processing initially.
(3) Equal to kG
9.5
i.e. we assumed only 5% of APAP is oxidised initially.
(4) Assumed kN =
k450
10
i.e. forward reaction is dominant.
(5) Assuming at normal GSH concentration, bG
dG
, only 1% of NAPQI binds with the
hepatocytes, i.e. kPSH = 0.01
kGSHbG
dG
.
Parameters marked with [∗] indicate parameters chosen by us to produce
physiologically realistic results.
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2.4 Results
2.4.1 Simulation
Our aim is to understand the effect of different initial doses on both NAPQI production
and timescales of events in APAP metabolism. We solve the system of equations (2.3.1)
- (2.3.5) using the MATLAB routine ode15s [56], a variable order backwards difference
method. Unless otherwise stated, we use the parameter values listed in Table 2.2.
We first examine the single 4g dose case, i.e. a daily dose in a single bolus. We
expect GSH levels to remain non-negligible to ensure a safe low-level conjugation of
NAPQI. Consequently, protein adducts will then stay at very low levels. Both of these
features can be observed from the simulation in Figure 2.2 (left column).
It can be seen that neither GSH or Sulphation levels drop to zero, indicating that all
APAP in the system is being dealt with effectively. We do see a rise in NAPQI, however
overall levels are extremely low relative to our overdose case and therefore do not pose
any great risk. The same can be observed for the protein adducts, which remain at low
levels compared to the overdose case.
For the overdose case of 16g, a likely outcome is that both GSH and sulphate levels
will become exhausted at some stage of the metabolism process. This indeed occurs
as can be seen in Figure 2.2 (right column). Sulphates drop very rapidly to a near
zero level and take a long time to recover; this means that proportionally more APAP
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Figure 2.2: Plot of the evolution of, from top to bottom, APAP, PAPS,
NAPQI, GSH and protein adducts respectively. The units in each graph are
mol/cell, noting the two orders of magnitude difference between the levels in N and C.
Here 4g (left) and 16g (right) correspond to PS = 1.32× 10−13 and PS = 5.28× 10−13
mol/cell, respectively.
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will be conjugated into NAPQI. This leads to a rapid drop in GSH to negligible levels
that are sustained for a period of about 20 hours. This rise in NAPQI and subsequent
depletion of GSH results in a high level of formation of protein adducts in comparison
with our safe dose simulation. We note that a four-fold increase in dose leads to an
increase of approximately two orders of magnitude in accumulated protein adducts.
Figure 2.3 shows the affect of the initial dose on the total amounts of toxic protein
adducts produced, presented as C∞/PS , where C∞ represents the steady state level i.e.
C → C∞ as t → ∞ and the ratio C∞/PS represents the fraction of adduct molecules
produced per APAP molecule. At levels just slightly above a safe dose of 4g it can be
seen that the amount of protein adducts in the system rises rapidly. This rapid increase
in protein conjugate formation displays how dangerous overdoses involving APAP are.
Small increases in the dose above what is considered “safe” lead to huge increases in
the protein adducts being produced, which in turn can lead to extensive damage to the
liver. This threshold behaviour is due to the level of GSH depletion, which leads to
the fraction of protein adducts produced increasing 100-fold over a 3-5g dose (we note
that in Remien et al. the lowest doses for patients receiving treatment is about 5g).
The sensitivity of the model solutions to parameter variation is explored in the next
section, whilst the key parameters governing the threshold dose are established in the
analysis of Chapter 3. We note that as PS →∞, the sulphation pathway becomes less
significant and it follows that C∞/PS → k450/(kG + k450) ' 0.095 as PS →∞.
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Figure 2.3: Plot showing the effect of initial dose (P0) on final accumulated
toxins normalised as the ratio C∞/PS . The dashed line represents the value of P ∗0
which is found in Section 4.3.1. The stars represent the location of 4g (left) and 16g
(right) doses.
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Simulations investigating the effect of smaller regular doses are shown in Figure 2.4,
in particular those in the left column represent a typically prescribed 1g dose at 4
separate 4 hour intervals over a 5 day period. Here, we observe NAPQI progressively
building up in the initial days before settling in to a periodic profile. Protein adducts
increase linearly, although total levels still remain negligible. A drop in GSH levels
is also observed which, while not dangerous in isolation, would leave an individual
susceptible to liver damage if a large dose of acetaminophen was consumed whilst their
GSH levels remained low.
The right hand side of Figure 2.4 plots a higher than recommended chronic dose
case, this time with the patient taking 1.5g of APAP every 4 hours. This increase in
APAP leads to a rapid depletion of GSH resulting in much higher maximum NAPQI and
conjugate levels than in the 1g case. NAPQI and protein adducts both rise rapidly (after
a day) due to the lack of remaining GSH in the system to safely deal with the NAPQI
present. The plots once again show dramatic increase in toxic effects (represented by
an increase in adducts, C) following a modest overdose.
2.4.2 Parameter Sensitivity Analysis
The results in Section 2.4.1 demonstrated a notable sensitivity in our model to initial
dose. In this section we seek to establish the sensitivity of the model solution to
variations in parameter values. To do this systematically, we used the Latin Hypercube
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Figure 2.4: Plots showing evolution of pathways over time in response to a
1g per dose (left) and 1.5g per dose (right) chronic APAP regimen.
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method implemented using the “lhsdesign” routine [57] in MATLAB. To produce the
results that followed, the routine was set up to run 1000 iterations, each with a uniformly
random selection of parameters between set limits of 3x and 1
3
x their original value.
We used, for the sensitivity test, the total accumulated protein adducts C∞ (i.e. the
maximum value of C(t) as t → ∞), where we plotted this against each of the model
parameters. We look for trends in the resulting graphs, indicating higher or lower
numbers of protein adducts in response to a change in parameters. To confirm our
observation we also examined the Sobol indices to estimate the sensitivity of variance
of the model output, C, to the variance of the parameters [58], this is discussed in the
next section.
Shown in Figure 2.5 are the results of the sensitivity analysis for the safe dose of
4g. We observe that most of the graphs do not show any sort of trend in response to
differing parameter values, except that the k450 (oxidation rate constant) graph shows
an obvious upward trend in protein adducts in response to an increase in the parameter
value, whilst a downward trend is observed for kG (glucuronidation rate constant). The
sensitivity analysis for the overdose case of 16g is shown in Figure 2.6. Again we see
that changes in the value of k450 and kG produce the most distinct trends in the model.
These are the only 2 parameters with a notable effect on the model outcome in the
overdose regime.
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Figure 2.5: Final accumulated toxic levels from a 4g (‘safe’) dose against each
of the paramaters for 1000 iterations of randomly selected values between
the limits of 1/3x and 3x the nominal value listed in Table 2.2.
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Figure 2.6: Final accumulated toxic levels from a 16g overdose against each
of the paramaters for 1000 iterations of randomly selected values between
the limits of 1/3x and 3x the nominal value listed in Table 2.2.
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2.4.3 Variance-Based Analysis
Variance-based sensitivity analysis examines the importance of a factorXi on the output
of a model Y [58]. At its most basic, this analysis works by running the simulation
multiple times with random parameter sets and seeing the total effect the change in
the parameter has on the model output. In the case of our model, we want to find
the effect of varying model parameters on our maximum conjugate value, C∞. We
look at two indices, Si and STi . Si is the ‘main effect index’, which defines how much
varying a given parameter, Xi directly effects the variance of our output, C∞. A value
of Si > 0.05 indicates that the given parameter has a statistically significant effect on
the model output and below this level we conclude that the given parameter has little
effect on the model output. STi is the ‘total effect index’, which measures how much
varying a given parameter Xi effects our output, and this time includes all interactions
with other parameters of any order, and we interpret its value in a similar way to Si. We
include a full explanation of how these indices are found and how they are calculated
in the context of this analysis in the appendices.
To apply this analysis, we proceed as we did in the previous analysis and vary
our model parameters uniformly between 1/3× and 3× their original values found in
Table 2.2. We calculate our sensitivity indices as described in [58] using 10,000 runs,
using the total amount of protein adducts (C∞) as the model output to be measured
against. Indices can be between 0 and 1 and a high sensitivity index indicates that the
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parameter has a large affect on the total amount of protein adducts in the modelled
system and therefore on toxicity as a whole, whereas a low index indicates that a
parameter has little affect on total toxicity. Negative values are due to numerical errors
in the estimates which are a side effect of the method when the indices are close to zero
(indicating that they are unimportant in the model outcome). We first examine the 4g
dose case, the results of this analysis are found in Table 2.3.
The results of the variance-based analysis agree with our previous sensitivity analy-
sis, showing that kG and k450 are the most sensitive parameters and are the main cause
of variance in protein-adduct production, as shown by their high Si and STi values. It
can also be seen that in the safe dose case bG is a contributing parameter, however
it is no longer significant in terms of sensitivity in the 16g case. This suggests that
the turnover rate of GSH is important in none-overdose cases, but not at higher doses.
Biologically, this is to ensure that NAPQI is dealt with quickly before having a chance
to bind with proteins in the hepatocytes. By definition, STi is greater than Si or equal
to it in the case that Xi has no interactions with other parameters. Therefore we can
use STi −Si as a measure of how much a given parameter Xi is involved in interactions
with other input factors. Table 2.3 lists the values of STi−Si for each of our parameters,
we observe that
STkG − SkG = 0.23,
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Table 2.3: First order and total-effect indices for all model parameters for
the 4g dose case.
Parameter, Xi First-order Index, Si Total-order Index, STi STi − Si
kG 0.19 0.42 0.23
k450 0.42 0.70 0.28
bG 0.08 0.21 0.13
kGSH 0.01 0.02 0.01
dG 0.01 0.02 0.01
kS 0.01 0.02 0.01
bS 0.02 0.04 0.02
dS 0.01 0.02 0.01
kN 0.01 0.02 0.01
kPSH 0.01 -0.02 -0.03
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STk450 − Sk450 = 0.28,
and
STbG − SbG = 0.13.
So all three of these parameters are involved in interactions with other input factors in
the model.
For the 16g case, the results of this analysis are shown in Table 2.4.
Again, Si and STi for kG and k450 are above 0.05 and therefore have a significant effect
on the outcome of the model. However, the sensitivity index for bG is much lower
than previously, showing that it has a lesser effect after the toxic threshold has been
reached. In the overdose case, kG now has a larger effect on the model than k450 whilst
the opposite was true in the safe dose case. This suggests that in the safe dose case, the
capacity of the oxidation pathway is the most important factor, and in the overdose case
the capacity of the glucuronidation pathway is the most important factor. Referring to
Table 2.4 we observe that
STkG − SkG = 0.17
and
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Table 2.4: First order and total-effect indices for all model parameters for
the 16g case.
Parameter, Xi First-order Index, Si Total-order Index, STi STi − Si
kG 0.5 0.67 0.17
k450 0.31 0.37 0.06
bG 0.02 0.06 0.04
kGSH -0.01 0.01 0.02
dG -0.01 -0.01 0
kS -0.02 0 0.02
bS -0.01 -0.01 0
dS -0.01 -0.01 0
kN -0.01 -0.02 -0.01
kPSH -0.01 -0.01 0
46
STk450 − Sk450 = 0.06.
Evidently, both parameters are involved in interactions with other input factors in the
model. As all other parameters in the model have an STi ∼ 0 they can be fixed anywhere
within their distribution without having an affect on the variance of the output. In the
overdose case,
STbG − SbG = 0.04,
and therefore does not have any significant (where we define significant as STi − Si >
0.05) interactions with other input factors. This confirms the results of our visual
inspection of a global sensitivity distribution discussed in the previous section. The
results also indicate that parameters have a varying effect on total toxicity depending
on whether a safe or overdose case is being studied.
2.4.4 Effects of sensitive parameters on model output
This analysis suggests that the key mechanisms that govern toxicity from acetaminophen
metabolism are glucuronidation and oxidation, where increasing kG reduces toxicity and
increasing k450 enhances it. In the parameter range investigated, PAPS contributes only
up to about 10% of APAP metabolism, as sulphation is a secondary process in humans;
we note that the parameters for sulphation in rats lie outside the parameter range in-
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vestigated. Figures 2.7 and 2.8 show the dependence of the total toxins produced, C∞,
on the two most sensitive parameters k450 and kG, for the safe and overdose cases. The
results were generated from running the simulation to approximate C∞(t = 50), we
found this length of time sufficient to reach a steady state. From Figure 2.7 we see that
increased k450 will lead to more APAP being oxidised instead of being metabolised by
sulphation or glucuronidation. This will cause a rise in the amount of NAPQI in the
system, putting more strain on the GSH pathway. We anticipate that a higher value
for k450 will lead to more protein adducts being present in the system and therefore
increase the risk of liver damage.
The safe dose response shows a steady increase in conjugate levels initially, followed
by a rapid rise in maximum conjugate levels, with total protein adduct formation in-
creasing by over one order of magnitude. A less dramatic rise in protein conjugates is
observed for higher k450 values. For our overdose case we see a much faster rise in the
total protein adduct formation in response to higher k450 levels. We see an increase
of approximately three orders of magnitude in response to higher values of k450. After
the initial rapid increase in total protein adduct formation, increased k450 values have
a much lower affect on C∞. Once GSH is depleted in our system, all NAPQI that is
oxidised will produce protein adducts, the rate at which these protein adducts can be
formed is then dependent on how quickly NAPQI can be converted to conjugates, this
rate is governed by the rate constant kPSH . This suggests that after GSH is depleted
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Figure 2.7: Total protein adduct formation against k450 for the safe (4g,
dashed) and overdose (16g, solid) cases. The dotted line indicates the standard
value corresponding to data in Table 2.2.
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fully, conjugate production will be proportional to kPSH . The rate of APAP to NAPQI
metabolism can be affected by other factors such as caffeine consumption [59, 60] and,
for example, consumption of anti-convulsant drugs [61] which would result in a higher
value of k450.
In Figure 2.8 we observe, as expected, a decline in toxins produced as kG increases.
As with k450, there is a fairly sharp transition between high and low toxicity at a
certain value of kG. We note that a 10-fold increase in kG is required in the overdose
case (kG ∼ 18 /day) to produce minimal toxic levels in comparison to the safe doses
(kG ∼ 5/day). The critical role of GSH exhaustion is highlighted in Figure 2.9, which
plots the numerically predicted minimum value of GSH against parameters kG and
k450. Of particular note is how the value of kG and k450 at which the sharp jumps occur
correspond to jumps in Figure 2.7 and 2.8.
Figure 2.9 plots the minimum GSH levels in the cell against kG and k450. As kG
increases we see an increase in the minimum GSH level of ∼ 4 orders of magnitude.
This suggests that if the glucuorindation rate drops then GSH could fall low enough to
allow protein adducts to form, if for example a person has a genetic or environmental
deficiency, e.g. co-medication, that reduces the amount of glucuornidation cofactor it
could be dangerous for them to take paracetamol, even in safe doses. We observe in the
overdose case that only very large values of kG have a non-negligible affect on minimum
GSH levels. An increase in k450 leads to a drop in GSH of over 3 orders of magnitude
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Figure 2.8: Total protein adduct formation vs. kG for the safe (4g, dashed)
and overdose (16g, solid) cases. The dotted line indicates the standard value of kG
found in Table 2.2.
51
Figure 2.9: Plot showing minimum GSH levels in the hepatocytes against
kG (left) and k450 (right). The dotted vertical lines indicate the original parameters
values from Table 2.
in the safe dose case, at the normal value of k450 = 0.315 /day, minimum GSH levels
remain high in the cell. However, an increase in k450 leads to lower GSH levels which
could lead to the formation of protein adducts. Therefore, increased k450 can potentially
lead to liver damage via protein adduct formation even in safe dose cases.
2.4.5 Cellular dose variation
The structure of the liver lobule means that cells closer to the portal vein are likely
to receive more of the drug. As a a consequence, there will be a distribution of drug
dosage between cells in the liver. Some cells which receive higher doses are more likely
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to be damaged than others. Furthermore, differences in micro-environment due to
proximity to blood vessels and oxygen gradients could also affect drug metabolism.
The effects of the the micro-environment will be subject to a future publication, and
here we investigate how the distribution of the drug affects the probability of cell death.
In Figure 2.10, we assume that a dose of paracetamol is log-normally distributed
(where we choose the log-normal distribution as p can not take negative values) between
the hepatocytes in the liver. We assumed that a lethal dose for cells (PL) is 5 times the
daily safe dose [37] and we aim to find what fraction of cells have p > PL. We let
PL = 6.6× 10−13 mol/cell,
and use standard deviations of
s = 2, 4, 6, 8, 10× 10−13.
For the lognormal distribution,
p.d.f(x;µ, σ) =
1
xσ
√
2pi
e−(ln(x)−µ)
2/2σ2 ,
where
PL = e
µ+σ2/2,
and,
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σ =
√
ln(s2/P 2L) + 1,
therefore,
µ = ln(PL)− σ2/2.
Figure 2.10 shows the results of plotting the cumulative distribution function, c.d.f(p,σ,µ),
with varying standard deviation, where the horizontal dashed line represents 70% of
cells with p > PL and therefore an expectation that the patient will die [37] and the
vertical dashed line representing our standard 4g dose. As can be observed from the
graph, a lower standard deviation decreases cell death at low doses but leads to a lower
total survival fraction at very high doses. The inverse is true for a high standard de-
viation, whereby more damage is seen at relatively low levels of initial acetaminophen
but less damage is experienced overall at higher levels of acetaminophen intake. This
suggests that variation is a positive property for the population on average, for survival
against a very large, single dose. However this does not necessarily mean that it is a
positive property for the individual.
2.5 Discussion
In this chapter, we have derived a cell scale mathematical model which describes the
metabolism of acetaminophen in hepatocytes. In order to obtain insights into this
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Figure 2.10: Plot showing the fraction of cell death in response to an in-
creasing initial paracetamol dose, lognormally distributed amongst cells.
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system using more advanced mathematical methods, we simplified the full metabolic
pathway to one that still maintains the three major pathways, while reducing overall
complexity.
The simulations demonstrate that the model captures the expected dynamics of
metabolism and, in particular, the distinguishing dynamics between the safe and over-
dose cases. As expected in the safe dose cases, the sulphation pathway does not fall
to negligible levels, leading to less NAPQI being formed. GSH levels also remain at
acceptable levels, binding with NAPQI and forming a safe conjugate, resulting in low
NAPQI levels and therefore protein adduct levels overall. In the overdose cases we see
both sulphation and GSH reaching negligible levels, resulting in much higher levels of
both NAPQI and protein adducts, as we expect from clinical observation and in pa-
tients this would lead to hepatotoxicty and potentially death. The numerical results
show that a four-fold increase in the initial acetaminophen dose can lead to a large
increase in the amount of protein adducts being formed, suggesting that a threshold
dose exists, which will be studied in the next chapter through timescale analysis. We
also explore differing dosing regimens, examining the effect of smaller regular doses as
opposed to single bolus doses. Again, small changes in the dose being taken are shown
to lead to large changes in both NAPQI and protein adduct levels. Of particular note
is the drop in GSH levels even at a ‘safe’ daily intake of acetaminophen.
Our sensitivity analysis has enabled us to identify the most sensitive parameters
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in our model, and we can use these to guide in vitro experiments which could then
potentially provide further insight and help us to refine our model. The analysis in
Section 2.4 showed that the key parameters affecting total toxicity are kG (the rate
constant for glucuronidation) and k450 (the rate of oxidation); the other parameters
have secondary effects on the dynamics and, in particular, the sulphation pathway is less
influential than glucuronidation and oxidation. These results were confirmed by both
sensitivity analysis and variance-based analysis. While the sensitivity analysis revealed
the most sensitive parameters and whether they had a positive or negative effect on
the toxic outcome, the variance based analysis allowed us to quantify numerically how
much of an effect each parameter had on the system and whether it interacts with
other parameters to influence the model outcome. We used this analysis to guide
further numerical work in to the effects of changes in k450 and kG on total toxicity.
Our parameter selection is good but there are gaps in the current literature that
highlight a need for more data on the metabolism of APAP in humans. While litera-
ture is available which has allowed us to begin parameterisation, further experimental
work would benefit the robustness of the model greatly. The parameter values for glu-
curonidation and oxidation pathways are obtainable from the literature, whilst those
relating to sulphation are less well characterised. This model has been used to find
results in human models, but we expect that the model is suitably generic to describe
acetaminophen metabolism in other species with little modification and could poten-
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tially be used to examine other drugs which are metabolically similar. However, to fully
understand the contrast between animal and human models, more data on metabolism
differences and subsequent model reparamaterisation for the different species is essen-
tial.
Although simple, this model successfully captures the dynamics of acetaminophen
metabolism and has improved our understanding of how the different pathways behave
when subjected to different dosing regimens and timings. We have highlighted key
parameters that our system is sensitive to and also found new details on pathway
interactions, and how this affects the production of protein adducts and the potential for
toxicity. In the next chapter we use singular perturbation analysis to further study the
model, identifying threshold levels and other key events in acetaminophen metabolism
and expanding upon the numerical and sensitivity work carried out in this chapter.
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Chapter 3
Timescale Analysis of a Single-Cell
Model
The work of this chapter has been published in the Journal of Theoretical Biology
as “Timescale analysis of a mathematical model of acetaminophen metabolism and
toxicity” [1].
3.1 Timescale Analysis
In the previous chapter we were able to gain insight into how certain parameters af-
fect the predicted toxicological outcome of our model. In this chapter we will employ
singular perturbation theory to get a much better analytical understanding of APAP
metabolism according to the model. Close examination of Figure 2.2 reveals the exis-
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tence of distinct timescales, starting with a rapid decline in PAPS and GSH followed
by longer timescales for recovery. To apply this theory we first non-dimensionalise the
system of equations (2.4.1) - (2.4.5). Using the data values in Table 2.2 we express the
new parameters in terms of a single small parameter ‘’ (i.e.   1), which will be
exploited in the analysis. Singular perturbation analysis allows us to take a far more
detailed view of the dynamics in our model than numerical analysis alone provides. We
can use this analysis to pick out key events over time, as well as build on the numer-
ical analysis we have. We will present the full results, followed by a summary of the
most important timescales. The full derivation of each timescale can be found in the
appendices.
3.1.1 Non-dimensionalisation
To aid the analysis we rescale our variables in order to eliminate units, which allows
comparison of variables and parameters in terms of their magnitude, so that the dom-
inant and negligible mechanisms can be systematically identified. In order to non-
dimensionalise the system we must first rescale our parameters and look for fast and
slow timescales. We rewrite our variables as
t = t0tˆ, P = P0pˆ, S = S0sˆ, N = N0nˆ, G = G0gˆ, C = C0cˆ.
We must then find suitable rescalings for each parameter such that no parameter in
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the model has any units. We start with t0 and since glucuronidation is the dominant
metabolisc pathway for APAP, we rescale time with parameter kG; using the values
in Table 2.2, the dimensionless time tˆ = 1 thus represents about 8 hours. We rescale
PAPS and GSH with their homeostatic levels and rescale APAP, NAPQI and protein
adducts to a reference value P0 which represents the acetaminophen concentration in
a single hepatocyte following a 4g dose i.e. P0 = 1.32× 10−13 mol/cell. The rescalings
are thus,
t =
1
kG
tˆ, P = P0pˆ, S =
bS
dS
sˆ, N = P0nˆ, G =
bG
dG
gˆ, C = P0cˆ.
and we note the standard dose concentration P0 corresponds to pˆ = 1. We then substi-
tute these values into our model and so the dimensionless system of equations is
dpˆ
dtˆ
= −αˆ∗S sˆpˆ− pˆ− pˆ+ 2kˆ∗N nˆ, (3.1.1)
dsˆ
dtˆ
= − αˆ
∗
Sφˆ
∗
S sˆpˆ

+ δˆ∗S(1− sˆ), (3.1.2)
dnˆ
dtˆ
= pˆ− 2kˆ∗N nˆ−
kˆ∗PSH

nˆ− αˆ
∗
G
3
nˆgˆ, (3.1.3)
dgˆ
dtˆ
= − αˆ
∗
Gφˆ
∗
G
4
nˆgˆ + δˆ∗G(1− gˆ), (3.1.4)
dcˆ
dtˆ
=
kˆ∗PSH

nˆ, (3.1.5)
where the rescaled parameters are listed in Table 3.1. The third column of Table 3.1
lists the value of the parameter, and for the purpose of the analysis we will rewrite
them in terms of the small parameter,  = k450/kG ' 0.1, guided by magnitudes
indicated in the 4th column; thus starred values in equations (3.1.1)-(3.1.5) are defined
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Table 3.1: Table of dimensionless parameters, their values and the assumed
value relative to the reference small parameter .
Parameter Definition Value Order in terms of 
kˆ450 k450/kG 0.105 
kˆN kN/kG 0.0105 O(2)
αˆS kSbS/dSkG 1 O(1)
φˆS P0dS/bS 10 O(1 )
δˆS dS/kG 0.668 O(1)
kˆPSH kPSH/kG 36.8 O(1 )
αˆG kGSHbG/dGkG 3680 O( 13 )
φˆG P0dG/bG 19.3 O(1 )
δˆG dG/kG 0.668 O(1)
as kˆN = 
2kˆ∗N , αˆS = αˆ
∗
S etc. These dimensionless variables are subject to the initial
conditions
pˆ(0) = PS , sˆ(0) = 1, nˆ(0) = 0, gˆ(0) = 1, cˆ(0) = 0,
recalling that PS = 1 represents the 4g dose case and PS = 4 would represent our 16g
overdose case. Henceforth, we will drop the hats and the *’s for clarity. In Section 3.2
we provide an overview of the main mathematical results and we then give biological
interpretations in Section 3.5.
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3.2 Application of singular perturbation theory
The system (3.1.1)-(3.1.5) will be analysed in the limit  → 0. Using singular pertur-
bation theory we can perform this analysis systematically and formally reduce the full
system to a sequence of timescales in which the system hopefully reduces to a simpler
solvable one in each timescale. This will enable us to identify when a particular process
is important and determine an approximation to key quantities such as critical dose
in terms of the model parameters. We provide a full explanation of this analysis and
each timescale in the next section. A summary of the results and the most important
timescales and events is provided in Section 3.5.
3.2.1 t = O(3)
On introduction of the APAP bolus in to a hepatocyte there is a rapid adjustment over
t = O(3), the first 30 seconds or so, in which NAPQI is produced and equilibrates at
very low levels. Denoting variables in this timescale with a superscript *, we write
t = 3τ ∗, p = p∗, s = s∗, n = 4n∗, g = g∗, c = 6c∗.
These rescalings are then substituted into our dimensionless equations (3.1.1)-(3.1.5),
subject to the initial conditions p∗ = PS , s∗ = 1, g∗ = 1, n∗ = 0 and c∗ = 0 at t∗ = 0.
In each timescale we seek solutions of the form
p(τ ∗) = p∗0(τ
∗) + p∗1(τ
∗) + 2p∗2(τ
∗) + ...
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This leads to the system
dp∗
dτ ∗
= −3αss∗p∗ − 3p∗ − 4p∗ + 9kˆNn∗,
ds∗
dτ ∗
= −2αsφss∗p∗ + 3δˆS(1− s∗),
dn∗
dτ ∗
= p∗ − (5kˆN + 2kˆPSH)n∗ − αGn∗g∗,
dg∗
dτ ∗
= −3αGφGn∗g∗ + 3δˆG(1− g∗),
dc∗
dτ ∗
= kPSHn
∗,
we expand the variables as follows
p∗ = p∗0 + p
∗
1 + 
2p∗2 + ...,
s∗ = s∗0 + s
∗
1 + 
2s∗2 + ...,
n∗ = n∗0 + n
∗
1 + 
2n∗2 + ...,
g∗ = g∗0 + g
∗
1 + 
2g∗2 + ...,
c∗ = c∗0 + c
∗
1 + 
2c∗2 + ....
Then the leading order ODE system is
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dp∗0
dτ ∗
= 0,
ds∗0
dτ ∗
= 0,
dn∗0
dτ ∗
= p∗0 − αGn∗0,
dg∗0
dτ ∗
= 0,
dc∗0
dτ ∗
= kPSHn
∗
0.
Solving the ODE’s using our initial conditions we arrive at our leading order values
p∗0 = PS,
s∗0 = 1
n∗0 =
PS
αG
(1− e−αGτ∗),
g∗0 = 1,
c∗0 =
kˆPSHPS(αGτ
∗ + e−αGτ
∗
+ 1)
α2G
.
The first non trivial correction terms for the variables that are constant at leading order
satisfy
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dp∗3
dτ ∗
= PS(−1− αS),
ds∗2
dτ ∗
= −αSφSPS,
dg∗3
dτ ∗
= −φGPS(1− e−αGτ∗).
Again solving these ODE’s gives
p∗3 = PS(1− (αS + 1)τ),
s∗2 = −αSφSPSτ,
g∗3 = −
φGPS(αGτ
∗ + e−αGτ
∗ − 1)
αG
.
Hence,
p∗ ∼ PS + 3(PS(1− (αS + 1)τ ∗)),
s∗ ∼ 1 + 2(−αSφSPSτ ∗),
g∗ ∼ 1 + 3(−φGPS(αGτ
∗ + e−αGτ
∗ − 1)
αG
),
n∗ ∼ PS
αG
(1− e−αGτ∗),
c∗ ∼ kˆPSHPS(αGτ
∗ + e−αGτ
∗
+ 1)
α2G
.
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In this short initial timescale, APAP, PAPS and GSH remain relatively unchanged
and NAPQI equilibrates to a negligible O(4) level. As t∗ → ∞, NAPQI settles to
n ∼ 4 (PS /αG) and c ∼ 6 (kPSHPS τ ∗/αG). We note here that as τ ∗ → ∞, n ∼
4PS /αG, this represents the amount of NAPQI formed if PAPS and GSH remain at
their homeostatic levels. There is no change at leading order of p, s and g, however the
correction terms become O(1) at τ ∗ = O(−2) i.e. at t = O().
3.2.2 t = O()
It is in this timescale that the contribution from sulphation begins to decline. We
introduce t = τ¯ and the relevant rescalings are
p = p¯, s = s¯, n = 4n¯, g = g¯, c = 4c¯.
We use these new scalings to rewrite our ODE’s,
dp¯
dτ¯
= −αss¯p¯− p¯− 2p¯+ 6kˆN n¯,
ds¯
dτ¯
= −αsφss¯p¯+ δˆS(1− s¯),
2
dn¯
dτ¯
= p¯− (5kˆN + 2kˆPSH)n¯− αGn¯g¯,
dg¯
dτ¯
= −αGφGn¯g¯ + δˆG(1− g¯),
dc¯
dτ¯
= kPSH n¯.
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We introduce similar expansions as in the previous timescale, thus the leading order
ODE’s for the system become
dp¯0
dτ¯
= 0,
ds¯0
dτ¯
= −αSφS s¯0p¯0,
dg¯0
dτ¯
= 0,
dc¯0
dτ¯
= kPSH n¯0,
n¯0 = p0/αGSH g¯0.
Solving these ODE’s as in the previous section we find
p¯ ∼ PS + 
(
1
φS
(e−αSφSPS τ¯ − 1)− PS τ
)
,
s¯ ∼ e−αSφSPS τ¯ ,
g¯ ∼ 1 + (−φGPS τ¯),
n¯ ∼ PS
αG
,
c¯ ∼ kPSHPS
αG
τ¯ .
68
In this timescale, we see that sulphate levels drop rapidly whilst APAP is relatively
steady. Biologically this is due to the conjugation of APAP and PAPS, leading to
declining PAPS levels in the cell. The parameters used suggest that the pretreated
PAPS concentration is O(PS ) so, at best, sulphates are only able to metabolise an O()
fraction of the drug. There is also an increase in protein adducts, although they are still
only present in very low amounts. We note as τ¯ →∞, p¯ ∼ PS − 
(
φ−1S + PS τ¯
)
, where
/φS represents the amount of APAP being metabolised by the sulphation pathway.
3.2.3 t = O(1)
In this timescale, we have two divergent cases. One in which we have sufficient amounts
of GSH in the system to conjugate NAPQI, the other is characterised by a rapid drop
in GSH and potential toxin build up. As we shall show, the critical dose at which the
two cases diverge is
P ∗S =
δ
δG
δG−1
G
φG
, (3.2.1)
such that, PS < P
∗
S can be classified as “safe” and PS > P
∗
S can be considered a
potential overdose. We note here that we have assumed that δG 6= 1, we will omit
details for the coincidental case of δG = 1 (i.e. dG = kG in dimensional terms).
In both cases, we adopt the following rescaling.
t = τ˜ , p = p˜, s = s˜, n = 4n˜, g = g˜, c = 3c˜.
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Our ODE’s are thus
dp˜
dτ˜
= −αS s˜p˜− p˜− p˜+ 2kˆN n˜,

ds˜
dτ˜
= −αSφS s˜p˜+ δS(1− s˜),
3
dn˜
dτ˜
= p˜− (5kˆN + 2kˆPSH)n˜− αGn˜g˜,
dg˜
dτ˜
= −αGφGn˜g˜ + δG(1− g˜),
dc˜
dτ˜
= kˆPSH n˜.
Expanding the variables in the usual way, and solving the resulting system yields
p˜ ∼ PS e−τ˜ − 
(
e−τ˜ (
δS
φS
− PS τ˜)− δS
φS
)
, (3.2.2)
s˜ ∼ δSe
τ˜
αSφSPS
, (3.2.3)
n˜ ∼ PS e
−τ˜
αG
(
φGPS
δG−1 (e
−δGτ˜ − e−τ˜ ) + 1
) = PS e−τ¯
αGΨ(τ¯)
, (3.2.4)
g˜ ∼ φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ) + 1 = Ψ(τ¯), (3.2.5)
c˜ ∼ kPSH
∫ τ˜
0
n˜(τ˜)dτ˜ . (3.2.6)
Here, APAP is metabolised such that p ∼ PS e−τ˜ (due to glucuronidation at leading
order) and that PAPS is recovering, noting that s = O() and therefore is not contribut-
ing to APAP metabolism at leading order. We also note that, for general parameter
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values, we can only express c˜ in terms of quadratics, but we can deduce behaviour as
τ˜ → τ˜ ∗.
The divergence depends on the function
Ψ(τ˜) = 1 +
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ),∀τ˜ > 0,
where,
g˜ = Ψ(τ˜),
and
n˜ =
PSe
−τ˜
αGΨ(τ˜)
.
Such that if Ψ(τ˜) > 0, ∀τ˜ > 0, then n˜ and g˜ remain positive and O(1), this is our safe
dose case. If at τ˜ = τ˜ ∗, such that Ψ(τ˜ ∗) = 0, then n˜→∞ in finite time τ˜ → τ˜ ∗ whilst
g˜ → 0. The divergence condition (PS = P ∗S) is determined by assuming that Ψ(τ˜ ∗) = 0
is a turning point at τ˜ = τ˜ ∗, i.e. solving Ψ(τ˜ ∗) = 0 and Ψ′(τ˜ ∗) = 0 simultaneously
leading to t∗ = ln(δG)/(δG − 1). We note that the safe and overdose cases can be
connected smoothly by analysis in the region of PS = P
∗
S + θ, where θ ' O(1). The
results are omitted as they are not of biological significance other than it reveals that
the jump region observed in Figure 2.3 is of O() = O(k450/kG) in size.
In the overdose case, when PS > P
∗
S , breakdown occurs when t ∼ µ1(), where
µ1(0) = τ˜
∗ is defined such that Ψ(µ1(0)) = 0; and g˜ = O() and n˜ = O(1/). Here,
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µ1() is the time at which hepatocytes no longer have an effective means of dealing
with NAPQI. It is straightforward to show that µ1() is a decreasing function of PS
and δg, i.e. more drug and less glutathione reduces the time interval, as expected. We
further note that given Ψ(µ1) = 0 and Ψ
′(µ1) < 0 we can show that φGPS e−µ1 > δG.
In the overdose case, breakdown occurs when t ∼ τ˜ ∗ = µ1(), where Ψ (µ1(0)) = 0 and
Ψ(τ˜) = O(), so that g˜ = O() and n˜ = O(1/), this is discussed in Section 3.4.
3.3 Safe dose case (PS < P
∗
S)
The solutions for the previous section are valid throughout the t = O(1) timescale,
namely
p˜ = PSe
−τ˜ − 
(
− δS
φS
+ e−τ˜ (
δS
φS
− PS τ˜)
)
,
s˜ =
δSe
τ˜
αSφSPS
,
n˜ =
PSe
−τ˜
αG(
φGPS
δG−1 (e
−δGτ˜ − e−τ˜ ) + 1) ,
g˜ =
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ) + 1,
c˜∞ =
∫ ∞
0
kPSHPSe
−τ˜
αGΨ(τ˜)
dτ˜ ,
Here, the drug decays exponentially (predominantly by glucuronidation) and g˜ =
O(1) throughout, i.e. GSH is able to handle the NAPQI being produced. Meanwhile
sulphate cofactors are recovering but only at very low levels. Protein adducts attain
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their maximum level i.e. O(3), namely
c∞ ∼ 3kPSHPS
αG
∫ ∞
0
e−τ
Ψ(τ)
dτ
This timescale breaks down as τ˜ → ln(1/).
3.3.1 t = ln
(
1

)
+ τ˘
In the final timescale of the safe dose case we rescale our variables as
t = ln(1/) + τ˘ , p = p˘, s = s˘, n = 5n˘, g = g˘, c = 3c∞ + 4c˘.
Expanding and substituting as before, our leading order system becomes
dp˘0
dτ˘
= −αS s˘0p˘0 − p˘0,
ds˘0
dτ˘
= −αSφS s˘0p˘0 + δS(1− s˘0),
dg˘0
dτ˘
= −αGφGn˘0g˘0 + δG(1− g˘0),
dc˘0
dτ˘
= kˆPSH n˘0,
subject to αGn˘0g˘0 = p˘0 as τ˘ →∞. Unfortunately, the system of ODE’s is not solvable
in terms of an elementary solution. However, there is only one steady-state and it is a
stable attractor for non-negative initial conditions, hence
p˘→ 0, s˘→ 1, n˘→ 0, g˘ → 1,
as τ˘ →∞ and c˘ reaches its maximum concentration of O(3).
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3.4 Overdose Case (PS > P
∗
S)
From our O(1) timescale we reach a point in time, µ1, where the timescale collapses
and we see a divergence from our safe dose case. GSH has dropped to negligible levels,
allowing NAPQI levels and therefore conjugate levels to rise.
3.4.1 t = µ1() + O(1).
GSH and NAPQI continue to drop and rise, respectively, over a series of intermediate
timescales (described fully in the appendices) until the current timescale, which de-
scribes the time period at which GSH is at its minimum level. We rescale our variables
as follows
t = µ1 + τˇ , p = pˇ, s = sˇ, n = 
2nˇ, g = 2gˇ, c = cˇ.
We then expand our variables as before, and our leading order ODE’s are
dpˇ
dτˇ
= −αS sˇpˇ− pˇ− pˇ+ 4kN nˇ,

dsˇ
dτˇ
= −αSφS sˇpˇ+ δS(1− sˇ),

dnˇ
dτˇ
= pˇ− (3kN + kPSH)nˇ− αGnˇgˇ,
2
dgˇ
dτˇ
= −αGφGnˇgˇ + δG(1− 2gˇ),
dcˇ
dτˇ
= kPSH nˇ.
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Solving these we find
pˇ ∼ PS e(−µ1−τˇ),
sˇ ∼ δSe
µ1
αSφSPS
,
nˇ ∼ φGPS e
−µ1−τˇ − δG
kPSHφG
,
gˇ ∼ δGkPSH
αG(φGPS e−µ1−τˇ − δG) ,
cˇ ∼ PS e−µ1(1− e−τˇ )− δG
φG
τˇ
In this timescale APAP levels continue to drop while sulphates remain constant. Pro-
tein adducts approach their maximum level while NAPQI production begins to slow
and GSH levels begin to rise as APAP levels decline. The solutions in this timescale
breakdown as τˇ → µ2()−, with µ2(0) = ln(φGPS /δG) − µ1(0), where gˇ = O(1/) and
nˇ = O(). After this timescale, NAPQI levels begin to decline. As τˇ → µ−2 , c attains
its maximum value to leading order, i.e. c∞ ∼ (PS e−µ1(1− e−µ2)−µ2δG/φG). We can
show that the amount of protein adducts increases with PS (i.e. higher initial dose)
and φG (less GSH present) as would be expected.
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3.4.2 t = µ1() + µ2() + O(1) (overdose).
This timescale follows a series of intermediate timescales in which GSH rapidly recovers
and NAPQI diminishes. Here, the rescalings are
t = µ1 + µ2 + τ
◦, p = p◦, s = s◦, n = 4n◦, g = g◦, c = c◦
and proceeding as before we find the following ODE’s
dp◦
dτ ◦
= −αSs◦p◦ − p◦ − p◦ − 6kNn◦,

ds◦
dτ ◦
= −αsφSs◦p◦ + δS(1− s◦),
3
dn◦
dτ ◦
= p◦ − (5kN + 2kPSH)n◦ − αGn◦g◦,
dg◦
dτ ◦
= −αGφGn◦g◦ + δG(1− g◦).
dc◦
dτ ◦
= kPSHn
◦.
Which can be solved to find the following solutions,
p◦ ∼ PS e−µ1−µ2−τ◦
s◦ ∼ δSe
µ1+µ2+τ◦
αSφSPS
n◦ ∼ PS e
−µ1−µ2−τ◦
αG(
φGPS e
−µ1−µ2
δG−1 (e
−δGτ◦ − e−τ◦) + 1)
g◦ ∼ φGPS e
−µ1−µ2
δG − 1 (e
−δGτ◦ − e−τ◦) + 1
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c◦ ∼ PS e−µ1(1− e−µ2)− δG
kG
µ2
Here we see that APAP levels continue to drop exponentially, allowing PAPS levels to
rise exponentially. GSH levels are now O(1) and will soon recover to its pretreated
level, whilst the tiny amounts of NAPQI that remain rapidly decrease. We now have
GSH returning to pretreated levels as NAPQI diminishes.
After this, the only timescale of significance is τ ◦ = ln(1/)+O(1), whereby p→ O()
and s→ O(1), i.e. their pretreated levels.
3.4.3 Comparison with numerics
Figure 3.1 shows the evolution of the dimensionless APAP, PAPS and GSH concentra-
tions against dimensionless time in an overdose case. The plots show the evolution of
the different species in the model against time, and the dashed lines are our estimates
of exhaustion/recovery timescales as discussed in the next section. We expect that as
→ 0, our analytical values and simulated values will converge. As can be seen in the
plot, as  becomes smaller, the analytical estimates for the various timescales become
more accurate. This indicates that our analytical results provide a good approximation
of the numerical system. Similarly in Figure 3.2 we compare the model solution for
GSH against our analytical solutions from our different timescales. We see that they
provide a good fit, and converge well as → 0.
77
Figure 3.1: Plots of APAP, Sulphates, Drug-Protein Adducts and GSH
against dimensionless time in an overdose case, the left hand graph when
 = 0.105 and the right hand graph when  = 0.1052. The horizontal dashed
line shows our analytical estimate for C∞, the vertical dashed lines show the estimates
for GSH collapse and recovery as discussed in section 3.5.1, 3.5.4 and 3.5.5.
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Figure 3.2: Plot of GSH and the solutions from the various timescales in
this chapter against dimensionless time in an overdose case. The left hand
graph when  = 0.105 and the right hand graph when  = 0.1052.
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3.5 Timescale Analysis Summary
Here we summarise the important events and timescales from the previous section,
expressing the key dimensionless quantities in their dimensional form.
3.5.1 Critical acetaminophen concentration
In Section 3.2.3, where t = O(1) we observe a divergence between our safe and overdose
cases. This divergence occurs at a critical concentration
P ∗S ∼
(
dG
kG
)kG/(dG−kG) bG
kG
, (3.5.1)
where P ∗S = 1.47 × 10−13mol/cell using the data available in Table 2.2. We note 4g
translates to a concentration of 1.32× 10−13 mol/cell and our divergence happens at a
point 11% above this dose. This highlights the relatively low tolerance the liver has in
response to large bolus doses of paracetamol.
3.5.2 Exhaustion of sulphate
Our analysis shows that sulphate is exhausted in the intermediate timescale between
Section 3.2.2 and Section 3.2.3. The approximate timescale for exhaustion of sulphate
is
t ∼ k450
kGkSPS
ln(kG/k450),
which using the data is t ∼ 12 minutes for a 4g dose. After this point the pathway
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saturates and we observe a greater proportion of APAP being metabolised into NAPQI,
impacting GSH levels. We note that the estimate is only logarithmically accurate and
will not be as precise as those in Section 3.5.1, 3.5.4 and 3.5.5 are; nevertheless it makes
explicit how much faster PAPS is exhausted in response to an increased drug dose.
3.5.3 Sulphate recovery
In both safe and overdose cases, we see sulphate recover at t = ln(1/), in dimensional
parameters this is
t ∼ 1
kG
ln
(
kS PS kG
dS k450
)
.
Using the data this equates to about 40 hours after ingestion for a 4g dose; though we
note, like that of Section 3.5.2, this estimate is only logarithmically accurate. Sulphate
recovery is a long term process and the liver takes an extended time to recover from a
high paracetamol dose. In the case where a person uses paracetamol chronically to deal
with pain then this long recovery time could impact how well the liver can deal with
multiple doses. We note, as expected, that the recovery time is extended with dose,
but in a sublinear fashion.
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3.5.4 GSH depletion
In our overdose case, when PS > P
∗
S we observe a collapse in GSH levels at t ∼ µ1
(Section 3.2.3), where µ1 satisfies the implicit equation
1 +
kGdGPS
bG(dG − kG)
(
e−dGµ1 − e−kGµ1) = 0.
This equation cannot be solved directly to find µ1 but given values of the parameters,
the equation can be solved using the Newton-Raphson method. Using the data in
Table 2.2 gives µ1 ≈ 0.046 for the overdose case, which using dimensionless parameters is
µ1 ≈ 0.138 which is in good agreement with the numeric values shown in Figure 3.1. We
then show that mathematically we can improve our estimate by reducing the size of .
Similarly, we find t ∼ µ2 ≈ 2.358 in the overdose case, again providing good agreement
with the numeric values shown in Figure 3.1. In terms of dimensional parameters this
gives us µ2 ≈ 0.79, which is discussed further in Section 3.5.5.
3.5.5 GSH Recovery
Again looking at the case where PS > P
∗
S , the time for GSH recovery is given by
t ∼ 1
kG
ln
(
kGPS
bG
)
.
Which is approximately 8.9 hours for a 4g dose and 20 hours for a 16g dose. People
regularly taking high doses of APAP can cause damage by not allowing time for GSH
recovery and subsequently protein adduct formation could be high. Again, the plot
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in Figure 3.1 shows how this estimate of GSH recovery is accurate for our model and
how smaller values of  (i.e. a decreasing k450/kG ratio) increase the accuracy of our
estimate.
3.5.6 Total protein conjugate formation, C∞
The total concentration of drug-protein adducts in the overdose case, PS > P
∗
S , is
C∞ ∼ k450PS e
−kgµ1
kG
− bGk450
k2G
(1 + kGµ2)
We note that the accumulated drug-protein adducts total is unaffected (to leading order)
by parameters associated with PAPS. Moreover, we can show that C∞ increases with
an increasing initial APAP dose and CYP reaction rate, and decreases in response to an
increasing GSH production rate and glucuronidation reaction, as expected. Figure 3.1
shows that this offers a fair prediction of maximum drug-protein adduct levels. We note
that no parameters associated with sulphation have an affect on the final accumulation
of protein conjugate formation and suggest that the sulphation pathway is unlikely to
be a suitable target for an effective new treatment against the toxicological effects of an
APAP overdose. However, we should note that even though sulphates are “exhausted”
by time t ∼ ln(kG/k450)/kGPS it is still removing APAP at around the same rate as
the oxidative pathway between timescales 4-10 (see appendices).
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3.6 Discussion
In this chapter we have used singular perturbation analysis to further investigate our cell
scale model, investigating how the processes affecting metabolism vary over time and the
differences between safe and overdose cases. We have observed that the system operates
over a number of distinct timescales and explained which metabolic processes dominate
in each timescale. The most important metabolic pathways initially in acetaminophen
metabolism are sulphation, glucuroniodation and oxidation. At t = O() ∼ 45 minutes
we see sulphate levels begin to decline in response to the APAP present, as sulphate
levels drop we expect that more acetaminophen will be metabolised through the glu-
curonidation and oxidation pathways, leading to an increase in GSH consumption. As
time progresses, we observe that sulphates continue to decline, and by t = O(1) ∼ 8
hours we see that sulphates have become exhausted as they drop by an order of magni-
tude (i.e. S = O()). Once we observe sulphation saturate completely, we see a critical
divergence between the safe dose and overdose cases,
P ∗S ∼
(
dG
kG
)kG/(dG−kG) bG
kG
.
Using data from Table 2.2 we find this to be an initial paracetamol dose of 4.54g, this
dose is very close to the recommended daily dose for acetaminophen consumption. This
divergence was found numerically by Remien et al. [39] via steady state analysis, and
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this work provides an analytical proof of the existence of a safe/overdose case divergence.
In our overdose case we are able to identify the timescale for GSH depletion, and we
verify the accuracy of this by direct comparison with numerical data. GSH depletion
directly leads to an increase in NAPQI, which as explained earlier will results in higher
protein adduct formation as NAPQI binds with proteins in hepatocytes and leads to
liver injury. Following this, we are also able to identify the recovery timescales of
sulphates and GSH levels. In the previous chapter, our sensitivity analysis enabled us
to deduce that changes in kG and k450 have the largest impact on the dynamics of the
system. Further to this, the asymptotic analysis of this chapter has allowed us to express
key quantities (critical concentrations, timescales etc.) in terms of relatively simple
formula (Section 3.3), so the effect of varying parameters can be explicitly observed.
Such methods have broad application and are somewhat underused in the study of
mathematical models in pharmacology. The cell-scale model presented in these two
chapters will be used as a framework to build further models. We have created a
simple and easy to analyse model, which we know behaves correctly from a biological
perspective, and understand the underlying mechanisms involved through our analysis.
The next chapter uses this model and adds an adaptive mechanism which cells use to
cope with high acetaminophen doses.
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Chapter 4
Nrf2 and GSSG Adaptation Model
4.1 Introduction
In the previous chapters we presented a basic cell scale model involving the major
metabolic pathways of acetaminophen metabolism. In this chapter we extend this
model to include adaptation via the Nrf2 transcription factor, and expand the GSH
pathway to include GSH/GSSG metabolism.
4.1.1 Nrf2 Transcription Factor
Starting with a simple model provides a framework that can be built upon, and so we
look to involve more complex processes in further models. While the previous model
captured acetaminophen metabolism well, more advanced features of metabolism were
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left out. One such feature is the up-regulation of anti oxidative genes by Nrf2 in re-
sponse to oxidative stress and its influences on the regulation of GSH and an associated
compound Glutathione Disulphate (GSSG). To our knowledge, no other mathemati-
cal models of Nrf2 and its relationship with acetaminophen metabolism exist, however
there is research into the effects of Nrf2 on different metabolic processes associated with
acetaminophen metabolism, as well as mathematical models of the Nrf2 pathway, which
we will discuss later in Section 4.1.3.
Figure 4.1: Basic pathway of Nrf2-Keap1-ARE pathway.
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Nuclear factor erythroid 2-related factor 2 or Nrf2 is a transcription factor that,
in response to oxidative stress such as NAPQI binding to cellular proteins as well as
the presence NAPQI itself [62], up regulates various cellular processes in an attempt
to protect the cell against damage. Reactive oxygen species (ROS), such as hydrogen
peroxide can be formed normally through cellular metabolism. However, high levels of
these ROS damage cellular components such as proteins, lipids and DNA [63]. In order
to combat this damage, antioxidants such as GSH can inactivate ROS as discussed in
the previous chapter. In steady state conditions Nrf2 is bound to Keap1 (Kelch ECH
associating protein 1) in the cytoplasm of the cell. In response to oxidative stress, Nrf2
is liberated from its binding with Keap1 and translocates to the nucleus where it acts
as a transcriptional activator, binding to antioxidant response elements (AREs) and
upregulating gene transcriptions associated with antioxidants [64], these elements can
be seen in Figure 4.1.
4.1.2 Glutathione Regulation
Glutathione disulphide (GSSG) is derived from two GSH molecules. When GSH binds
with an oxidative species, such as NAPQI, it donates an electron, becoming reactive
itself and will then readily bond with another reactive GSH molecule to form GSSG [65].
Glutathione reductase (GSR) can reduce GSSG back to GSH [66] and it has been shown
that in times of high oxidative stress, Nrf2 increases GSR activity and therefore increases
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the pool of available GSH [67]. This process is shown visually in Figure 4.2.
Figure 4.2: The relationship between GSH and GSSG.
4.1.3 Biological Overview
The role of Nrf2 in the detoxification of acetaminophen metabolism by comparing Nrf2
knockout mice (that is, mice with the Nrf2 pathway blocked) and wild type mice was
examined by Chan et al. [68]. They tested multiple doses of 100, 200 and 300 mg/kg
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bodyweight, approximately 7-21g for an average human, and measured the affects on
GSH levels. They found that Nrf2 null mice would die sooner and at lower doses of
acetaminophen and also found that Nrf2 null mice experienced a much higher drop in
GSH levels in response to acetaminophen ingestion, in fact at the 100mg/kg treatment
level GSH levels declined by 10% in the wild type mice but declined 57% in the Nrf2
null mice. The study also found that Glutamate-cysteine ligase catalytic subunit (GCL-
C) expression levels were increased. GCL-C is the first and rate-limiting step in GSH
synthesis [69], this means that the up regulation of this gene directly affects the synthesis
rate of GSH. As we have shown in the previous chapter, GSH is needed to prevent
toxicity in response to high acetaminophen doses and so, at least in mice, we see that
Nrf2 provides a protective mechanism in response to oxidative stress.
In a similar study, Enomoto et al. [70] also found that Nrf2 null mice were more
likely to die in response to acetaminophen overdose than their wild type counterparts.
They also studied the expression levels of P450 and found that while more NAPQI
wasn’t necessarily being produced, the reduced synthesis of GSH and other protective
enzymes meant that Nrf2 null mice were much more susceptible to liver damage at
lower doses of acetaminophen.
In 2004, Goldring et al. [71] studied the effects of Nrf2 activation by acetaminophen
in mice. They found that Nrf2 plays a critical role in cellular defence against oxidative
stress. Using male CD-1 mice, they administered doses of 50, 100, 300, 520, 700 and
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1000mg/kg and observed the changes in gene expression. It should be noted that
these doses translate to approximately 3.5-70g for an average human. They found that
acetaminophen overdose lead to Nrf2 activated up regulation of 3 genes, HO-1, GCL-C
and mEH at overdose levels of acetaminophen, although at a dose of 1000mg/kg this
was no longer observed, which the authors attributed to the hepatocytes being too
damaged to carry on normal function. HO-1 does not appear to have any affect on
APAP metabolism and mEH is part of the GSH pathway; in the modelling to follow it
will be bundled in to the synthesis and degradation of GSH in order to avoid unnecessary
complexity.
Okawa et al., 2006 [72], examined the effect of Keap1 depletion on resistance to
drug toxicity. They bred mice with a hepatocyte-specific disruption of the Keap1 gene,
meaning that Nrf2 would no longer remain bound in the cytoplasm, leading to increased
nuclear accumulation of Nrf2 and examined the effects on gene expression and response
to acetaminophen toxicity. They found that a lack of Keap1 expression did not cause
any adverse affects to the animals. Following a dose of 600 to 700 mg APAP/kg
bodyweight, the majority of the wild type mice died. However all of the Keap1 deficient
mice survived, they also found very little necrosis of hepatocytes in these mice compared
to wild type species. It was also observed that drug-protein adducts were not produced
in the Keap1 deficient mice at sub lethal doses, but were elevated in the wild type mice.
This study shows the effect of Nrf2 on acetaminophen toxicity, without examining the
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underlying reasons behind these responses (i.e. which particular genes were leading
to this outcome). An artificially increased level of Nrf2 leads to protection of the
hepatocytes from high doses of acetaminophen, presumably through an up regulation
of the antioxidant pathways and therefore, more efficient detoxification of ROS.
In 2008, Harvey et al. [67] studied how Nrf2 regulates GSH homeostasis in response
to oxidative stress. Specifically, they exposed wild type and Nrf2-null mice to cigarette
smoke, and measured the effects on GSR, which is a cofactor involved with converting
GSSG back to GSH in the cell (see Figure 4.2). They found that when exposed to
oxidative stress, wild type mice showed elevated levels of GSR expression while Nrf2-
null mice showed no change from their basal levels. It was observed that both the
wild type and Nrf2-null mice showed no differences in basal levels of GSR. GSR-specific
activity was also observed to be elevated in the wild type mice, and no such induction
occurred in the Nrf2-null mice. Wild type mice were found to have a greater ability to
detoxify GSSG compared to the knockout mice, leading to less apoptosis in response
to the oxidative stress. In mice treated with an inhibitor of GSR, GSH:GSSG levels
were found to be approximately 1:4, whereas in the wild type mice it was found to be
approximately 20:1, proving that GSR helps maintain GSH homeostasis. This study
examines the effect of Nrf2 on the GSH/GSSG system which will be important in our
upcoming model, it provides a thorough review of how exactly Nrf2 helps maintain cell
viability in response to oxidative stress.
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Copple et al., 2008 [62], used an in vitro model to examine how acetaminophen
activates the Nrf2 pathway. They directly exposed a hepatic cell line to NAPQI and
found that in response, nuclear Nrf2 increased within one hour of exposure indicating
that NAPQI directly activates Nrf2. The study found that when exposed to NAPQI,
cellular GSH synthesis was increased via Nrf2-dependant adaptive response, with an
increase in GCL-C expression leading to higher synthesis rates. They also found that
NAPQI modifies cysteine residues in Keap1, which reduces Keap1-Nrf2 binding and
increases nuclear Nrf2 accumulation. In conclusion, the study found that NAPQI, the
main ROS produced in acetaminophen overdose, directly activates the Keap1-Nrf2 cell
defence system through both the depletion of GSH and through modification of Keap1
resulting in higher nuclear Nrf2 levels. Nrf2 then increases GSH synthesis through
up-regulation of GCL-C expression, leading to increased GSH synthesis.
A 2014 article by Xue et al. [73] aimed to examine how Nrf2 signals adaptation to
stress. In order to examine this they examined response signalling in the cell and found
that Nrf2 is activated in cells without changing the total Nrf2 protein concentration.
In order to validate their findings, they created a number of mathematical models
with the aim of reproducing these oscillations in activated Nrf2 levels. They began
with a one-variable delay differential equation (DDE) and extended the model to a 9
variable ODE model which captures the various binding and activations of Nrf2 in the
cytoplasm and nucleus. Although these models are more complex than required for
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our needs, they provide a starting point for the basic actions involved in Nrf2/Keap1
binding. Unfortunately, all parameters in the model are non-dimensional and have no
units and it is not explained how they are scaled so we can not use them directly in our
model. However, we can compare them to each other to find differences in the order of
magnitudes of various rates in Nrf2 metabolism.
Kahlil et al. [74], 2014, used mathematical modelling alongside experiments to ex-
amine the change in Nrf2 levels in response to ROS in ovarian cancer cells. They found
that general cellular ROS levels, for example hydrogen peroxide turnover in cells, mod-
ulate basal cellular Nrf2 and Keap1 protein levels. They found differences in cellular
responses depending on the cell lines but found that Nrf2 basal levels were correlated
with total ROS and that perturbation of this balance increased levels of Nrf2 in the
nucleus as a protective response. To validate this data, they produced a 15 variable
mass action ODE model, which included hydrogen peroxide and other cellular proteins.
Again, this model is more complex than ours but provides a good framework for us
to build on as it is well parameterised and thorough in its reproduction of total Nrf2
metabolism.
4.1.4 Summary of Biological Overview
Although mathematical modelling of the Nrf2/Keap1 system is limited, there is a lot
of literature available on the biological processes involved in Nrf2 gene regulation and
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how this affects acetaminophen metabolism. The literature shows a need for there
to be an adaptive response in our model to high levels of Nrf2 nuclear translocation,
specifically in GSH synthesis as well as changes in the GSH/GSSG system. The current
mathematical models are highly complex and seek solely to model the Nrf2 system and
how it changes in response to basal ROS as well as changes in ROS levels. However,
these models are more complex than required for modelling alongside acetaminophen
metabolism; instead we focus on the relationship between NAPQI (the main ROS that
is produced as a byproduct of acetaminophen overdose), the GSH/GSSG system and
GSH synthesis as targets of Nrf2-mediated regulation. It is expected that in response to
high levels of NAPQI, Nrf2 will increase both GSH synthesis as well as increasing GSR
activity, lowering total GSSG and increasing cellular GSH as a method of combating
the destructive affects of NAPQI accumulation.
4.2 Modelling Background
In our previous model, we did not include the Nrf2 system and instead focused solely
on the main metabolic pathways of acetaminophen metabolism. In this chapter we will
expand our model to include adaptation in response to high levels of ROS. As explained
in the previous chapter, when acetaminophen is metabolised, approximately 10% is
oxidised creating NAPQI, a reactive oxygen species. In low dose cases, GSH binds with
NAPQI and it is excreted as a harmless metabolite and when GSH is depleted, NAPQI
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binds with cellular proteins causing damage to hepatocytes. However, in response to
high levels of NAPQI, Nrf2 unbinds from Keap1 in the cytoplasm and accumulates
in the nucleus. This has a number of effects on different gene expressions which help
protect the cells against oxidative stress. In the case of NAPQI and acetaminophen,
the genes we are most interested in are Gcl, which increased the basal synthesis rate of
GSH and GSR, subsequently increasing the rate at which GSSG becomes GSH. In short,
Nrf2 adaptation increases the amount of antioxidants available in the cell which assists
in nullifying ROS and helping reduce the amount of cell damage from acetaminophen
overdose. A full pathway diagram can be found in Figure 4.3.
4.3 Derivation of the Model
In this section we derive the model to be studied in this chapter. We will start by
presenting simple models of the GSH/GSSG system (Section 4.3.1) and Nrf2 adaptation
(Section 4.3.2) and then in Section 4.3.3 we will incorporate these in to a full model to
be studied in the remainder of this chapter.
4.3.1 GSH/GSSG Model
As explained earlier, GSSG is the reduced form of GSH, formed when GSH binds with
NAPQI; GSH can be reconstituted from GSSG through the enzyme GSR. For this
model we assume that dG in the previous model included GSSG metabolism without
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Figure 4.3: Schematic of the metabolic pathways and adaptive responses
of acetaminophen metabolism and Nrf2. Coloured boxes represent mod-
elled variables. Light green boxes denote that the variable was also mod-
elled in the cell-scale model. GSSG can be considered a part of the ‘GSH
Metabolism’ box in Figure 1.2 and as such is the same colour. Blue boxes
denote that these variables were not included in Figure 1.2 as they are
signalling mechanisms and not part of APAP metabolism.
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explicitly modelling it’s affects on the system. We also assume that the rate at which
GSH binds with background oxidative species is much higher than the natural decay
rate of GSH. Very simply, we can explain GSH/GSSG metabolism as
GSH + ROS→ GSH−,
2 GSH− → GSSG,
and
GSSG + GSR→ 2 GSH.
We can describe this process with a 2 variable ODE model,
dG
dt
= bG − d¯GG+ 2dRH, (4.3.1)
dH
dt
=
1
2
d¯G − dHH − dRH. (4.3.2)
Where bG is the natural production rate of GSH, d¯G is the rate at which GSH binds
with oxidative species to become GSSG, dR is the rate at which GSR and GSSG bind
to create GSH and dH is the natural decay rate of GSSG. We assume that formation
of GSSG occurs very quickly and so do not explicitly model GSH−. Data suggests that
the normal ratio of GSH:GSSG is 20:1 in the cell at homeostasis [75]. By adding (4.3.1)
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and (4.3.2) together we find that the steady state for H is
H∗ =
bG
2dH
.
We know that in the previous model, G∗ = bG/dG (the steady state for GSH from our
previous model, where dG denotes the decay rate of GSH from our previous model and
d¯G denotes the rate at which GSH binds with oxidative species to form GSSG) and
H∗ = 0.05G∗ (as the GSH:GSSG ratio is 20:1) and so can use this to find dH .
dH ∼ bG
2H∗
∼ 10dG = 20.
We also note that
H∗
G∗
=
d¯G
2(dH + dR)
,
so we can now find dR if we have values for d¯G and dH . After running simulations
and looking at GSH behaviour, we choose d¯G = 6 as this provides the best agreement
both with the previous model and biological consensus of GSH behaviour in overdose
situations, therefore dR = 40. The parameters and their units for this model are listed
in Table 4.1.
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Table 4.1: Parameter values for the GSH/GSSG system model.
Parameter Value Units
bG 1.375× 10−14 mol · cell−1day−1
dH 20 day
−1
dR 40 day
−1
d¯G 6 day
−1
4.3.2 Nrf2 Model
In non-oxidative stress conditions, Nrf2 is bound to Keap1 in the cytoplasm which un-
bind in response to the presence of ROS. Unbound Nrf2 migrates into and accumulates
in the nucleus where it up regulates expression of some genes as a protective response.
In our model, NAPQI is the ROS of interest and is included in the Nrf2 model. For
simplicity, we assume that there is a constant pool of Keap1 which binds to Nrf2 when
NAPQI levels are low [64], and therefore model free (N) and bound (B) Nrf2 using a
2 ODE model:
dF
dt
= bF − gFBF + dNBNB − dFF + dFBB, (4.3.3)
dB
dt
= gFBF − (dB + dNBN + dFB)B, (4.3.4)
where bF is the production rate of Nrf2, gFB is the binding rate of Nrf2, dNB is the rate
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at which Nrf2 unbinds in response to rising NAPQI levels, dF and dB are decay rates
for F and B respectively and dFB is a constant background unbinding rate in response
to basal cellular ROS levels. From Kahlil, 2014 [74] and Xue, 2014 [73] we find the
parameters in Table 4.2. In the upcoming work, we take one of two values for dNB,
dNB = 0.2 min
−1 which is chosen by us to provide realistic simulations, or dNB = 0,
which we choose if we want to produce simulations with no Nrf2 adaptation. Kahlil et
al. modelled Keap1 explicitly and we deduce a value of gFB from the steady states of
(4.3.4) and (4.3.5) using the formula
bF
K∗gFB1 + dF
= F ∗,
where gFB1 = 0.2 µM
−1· min−1 [74] and at basal levels K∗ = 2F ∗ [76] and by substitut-
ing in these values we find gFB = 0.26 min
−1. They also estimate that bF = 288× 10−6
mol L−1 day−1 over the whole liver [74], there are 1.6× 1011 cells in 1.4 L of the human
liver [37], from which we deduce that bF = 2.5 × 10−15 mol cell−1 day−1. The final
values for these parameters are listed in Table 4.4.
4.3.3 Full Model
In experiments in rats, our collaborators found that chronically infusing acetaminophen
did not lead to steady state APAP levels in the plasma, but instead to the results shown
in Figure 4.4. It was hypothesised that this increase and subsequent decrease in plasma
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Table 4.2: Parameters for the Nrf2 system from the literature.
Parameter Value Units
bF 0.2 µM · min−1
gFB1 0.2 µM
−1 ·min−1
dF 0.05 min
−1
dB 0.05 min
−1
APAP was due to an adaptive response in Nrf2 transcription. To test this hypothesis, we
include a parameter φ in our model, which acts as a chronic infusion term. We use this
to investigate the affects of Nrf2 adaptation on steady-state acetaminophen metabolism
and whether we can qualitatively reproduce the results of these experiments.
We now combine the models presented in Section 4.3.1 and 4.3.2 with our previous
cell scale model, describing acetaminophen (P ), PAPS (the cofactor for sulphation of
acetaminophen) (S), NAPQI (N) and conjugate levels (C) in the same way as the
previous model. Our model variables and their units can be found in Table 4.4.
An additional change to the original model is the GSH synthesis rate where bG is
rewritten as bG0 +
bG1F
F/Fc+1
so that the production of GSH is up-regulated by higher Nrf2
levels. Here, GSH is produced at a background rate, bG0 and is enhanced by Nrf2 at
a rate described by a Michaelis-Menten term, Fc being the Michaelis constant. The
parameters are chosen such that at homeostasis, the levels of F lead to bG0 +
bG1F
F/Fc+1
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Figure 4.4: Plot of Time vs Serum APAP Levels for a chronic infusion of
acetaminophen over 2 days in a rat.
being approximately equal to our GSH synthesis rate in our previous model. Similarly,
to model changes in GSR, dR is replaced by
dRFH
F/Fc+1
so that it is also up-regulated by Nrf2
in a similar way to GSH production. Finally, the parameter value for dNB is divided
through by the steady state NAPQI level for a 16g overdose with no Nrf2 adaptation.
Our full model is then,
dP
dt
= φ− kSSP − kGP − k450P + kNN, (4.3.5)
dS
dt
= − kSSP + bS − dSS, (4.3.6)
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Table 4.3: Model variables and their units.
Variable Interpretation Units
P Paracetamol (APAP) mol/cell
S Sulphate (PAPS) mol/cell
N NAPQI mol/cell
G GSH mol/cell
H GSSG mol/cell
F Nuclear Nrf2 mol/cell
B Bound Nrf2 mol/cell
dN
dt
= k450P − kNN − kGSHNG− kPSHN, (4.3.7)
dG
dt
= bG0 +
bG1F
F/Fc + 1
− d¯GG− kGSHNG+ 2dRFH
F/Fc + 1
, (4.3.8)
dH
dt
=
1
2
d¯GG+
1
2
kGSHNG− dHH − dRFH
F/Fc + 1
, (4.3.9)
dC
dt
= kPSHN, (4.3.10)
dF
dt
= bF − gFBF + dNBNB − dFF + dFBB, (4.3.11)
dB
dt
= gFBF − (dB +NdNB + dFB)B. (4.3.12)
For our initial simulations in Section 4.4., we assume in this study that the drug is
introduced into cells as a single bolus dose at t = 0 at a concentration PS (φ = 0).
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The cells at this point are assumed to be at pretreatment steady-state level. The initial
conditions for this system are thus
P (0) = PS , S(0) =
bS
dS
, H(0) =
1
2
(
F (0)bG1Fc + bG0(F (0) + Fc)
dh(F (0) + Fc)
)
, (4.3.13)
G(0) = 2
(
F (0)H(0)dRFc + F (0)bG1Fc + bG0(F (0) + Fc)
d¯G(F (0) + Fc)
)
, N0 = 0, C(0) = 0,
F (0) =
bF (dB + dFB)
dBdF + dBgFB + dFdFB
, B(0) =
gFBbF
dBdF + dBgFB + dFdFB
.
The parameters for this model can be found in Table 4.4.
In Section 4.5, where APAP is infused into the system at a rate φ > 0, the initial
conditions are as above, but with P (0) = 0.
4.4 Results, φ = 0
4.4.1 Simulations
Our aim using this model is to understand how Nrf2 adaptation influences acetaminophen
metabolism and the effect this has on total toxicity in overdose cases. We solve the
system of equations (4.3.6)-(4.3.13) with φ = 0, using the MATLAB routine ode15s [56]
and use the parameter values listed in Table 4.4 unless otherwise stated.
We first examine the 4g dose case. As before we would expect GSH and PAPS
levels to remain non-negligible and NAPQI and conjugate levels should remain low.
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Table 4.4: Parameter values and their units for the Nrf2 adaptation model
Parameter Value Units
kS 2.26× 1014 cell · mol−1 · day−1
kG 2.99 day
−1
k450 0.315 day
−1
kN 0.0315 day
−1
bS 2.65× 10−14 mol · cell−1 · day−1
dS 2 day
−1
kGSH 1.6× 1018 cell · mol−1 · day−1
kPSH 110 day
−1
bG0 4.125× 10−15 mol · cell−1 · day−1
bG1 2.234× 103 day−1
dH 20 day
−1
dR 1.06× 1019 cell · mol−1 · day−1
d¯G 6 day
−1
bF 2.5× 10−15 mol · cell−1 · day−1
gFB 374 day
−1
dNB 1.73× 1018 cell · mol−1 · day−1
dF 72 day
−1
dB 72 day
−1
dFB 7.2 day
−1
Fc 1× 1017 day−1
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We would also expect very little change in our Nrf2 as there will not be a significant
amount of oxidative species present in the hepatocytes. In Figure 4.5 we observe all of
these features. PAPS and GSH both stay at non-negligible levels and GSSG levels climb
due to some GSH binding with NAPQI, these then drop again as GSH and GSSG return
to their steady states. Both NAPQI and Conjugates stay at negligible levels and Nrf2
increases just 7% and its bound complex stays at approximately steady state levels due
to very little oxidative stress on the hepatocyte. We also note that we do not see any
significant disagreement with the simulations from our previous model in Figure 2.2.
We expect that in response to an overdose, we will see both PAPS and GSH drop to
negligible levels, and in the new model an associated rise in GSSG levels. As in our
previous model, we would expect much higher levels of both NAPQI and drug-protein
conjugates. Most importantly in this new model, we would expect a rise in Nrf2 levels
and a corresponding drop in the amount of our bound Nrf2:Keap1 complex.
In Figure 4.6 we plot the effects of a 16g overdose on our modelled hepatocyte.
As expected, PAPS levels drop to near zero before recovering at a later time. A 70%
reduction in GSH is required for acetaminophen induced hepatotoxicity [77], and we see
GSH levels drop to well below this in our simulations, although due to Nrf2 adaptation
and the inclusion of GSSG redux GSH levels no longer stay at near-zero levels for the
same length of time observed in Figure 2.2. NAPQI and drug-protein conjugates are an
order of magnitude above their safe dose levels and we see that the amount of Nrf2 in
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the nucleus increases by 70% of its steady state level in response to these higher levels
of NAPQI.
In order to ensure that the Nrf2 adaptation in our model is working as expected, we
must look at the overdose case when Nrf2 levels remain unchanged in the nucleus. In
the case where Nrf2 does not increase in response to oxidative stress, we would expect
our minimum GSH levels to be lower, as well as our maximum NAPQI and Conjugate
levels to be higher.
Figure 4.7 shows the results of our simulations when dNB = 0 leading to Nrf2
remaining at steady state levels while ROS levels are increased in the cell. We observe
that GSH levels are lower and NAPQI and Conjugate levels are higher as we expected.
Numerically we find that Cmax is approximately 220% higher, Nmax is 400% higher and
GSH levels are 87% lower in our Nrf2-null simulations. All of these markers indicate
that in our model, Nrf2 adaptation is reducing the total damage being done to the
hepatocytes when high levels of acetaminophen are ingested by a substantial amount.
Before carrying out full steady state analysis, we examined how multiple daily doses
affect the model now that Nrf2 adaptation is included. Figure 4.8 shows a dose of 1g
being taken 4 times a day, 4 hours apart. We observe that while conjugates and NAPQI
do increase slightly over time, their levels are relatively low. GSH levels remain high,
indicating that the hepatocytes are still well protected from further doses if this dosing
scheme was continued. In Chapter 2 we looked at the case where 1.5g was taken 4 times
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Figure 4.5: Plot of the evolution of APAP, PAPS, GSH, GSSG, NAPQI,
Conjugates, Nrf2 and Nrf2:Keap1 Complex in response to a 4g dose. The
units in each graph are mol/cell
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Figure 4.6: Plot of the evolution of APAP, PAPS, GSH, GSSG, NAPQI,
Conjugates, Nrf2 and Nrf2:Keap1 Complex in response to a 16g dose. The
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per day, however with Nrf2 adaptation we find that this is not sufficient for depletion
of GSH. Figure 4.9 shows a 5g dose taken 4 times per day, as you can see, conjugate
and NAPQI levels are approximately 100 times higher and GSH has reduced near zero
levels. PAPS has reduced to very low levels and Nrf2 increases and drops in response
to each dose. Compared to similar simulations in Section 2.4, we see that in the Nrf2
adapted system, hepatocytes can cope with much higher transient doses.
4.4.2 Parameter Sensitivity Analysis
As in Section 2.4.2, we will examine the sensitivity of our model solution to changes in
our parameter values. We again use the Latin Hypercube method as described earlier
and run 1000 iterations of the parameters between 10× and 1
10
× their original values
and examine the effect on the total accumulated adducts, C∞, note this is a greater
range than the one used in Section 2.4.2.
We run both the 4g safe dose case and 16g overdose case as described in the previous
chapter. As you can see in Figure 4.10 and 4.11, there is very little sensitivity in the
system. Where before k450 and kG had large effect on the total amount of conjugates
being produced, in this new model they do not. There is a slight positive trend in dG
however it is not as pronounced as the results in the previous chapter, and variance-
based analysis shows it has no effect on other parameters. We also run Sobol sensitivity
tests and find similar results, with no parameters with statistically high Sobol indices.
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Figure 4.8: Plot of the evolution of modelled variables against time for 4x1g
doses taken throughout the day over the course of 5 days.
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Figure 4.9: Plot of the evolution of modelled variables against time for 4x5g
doses taken throughout the day over the course of 5 days.
This suggests that the addition of the Nrf2 system provides a stabilising influence on the
processes described in our model, increasing k450 in the previous model increased the
amount of NAPQI and therefore increased the total amount of conjugates. However, in
response to increased NAPQI, we now see an increase in Nrf2 and therefore an increase
in GSH synthesis so the effect is less pronounced.
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Figure 4.10: Sensitivity analysis for a 4g dose in our Nrf2 Model.
4.5 Steady State Analysis, φ > 0
Recall from Section 4.3.3, the experiments investigating adaptation using chronic infu-
sion studies, to model these effects we now use φ > 0 in equation (4.3.6). In order to
further explore the model dynamics in normal and overdose cases, we will analyse the
model at steady state for different dosing regimes. We must first non-dimensionalise
the model as before, and subsequently we analyse leading order solutions of each of our
ODE’s after rescaling them with respect to a small parameter  1, which we exploit
to find leading order terms in our system. We can then use these rescaled equations
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Figure 4.11: Sensitivity analysis for a 16g dose in our Nrf2 Model.
to find our steady states, analyse their stability and explore the effects the different
variables in our model have on each other.
4.5.1 Non-dimensionalisation
As in Section 3.1.1 we rescale our variables so that their units are eliminated in order
to directly compare our parameters and variables based on their size and then precede
to identify dominant mechanisms in the model. We rewrite our parameters such that
t = t0tˆ, P = P0pˆ, S = S0sˆ, N = N0nˆ, G = G0gˆ, F = F0fˆ , B = B0bˆ, C = C0cˆ.
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Proceeding as before we rescale t0, our time parameter such that t0 = 1/kG so that
our dimensionless time tˆ = 1 represents approximately 8 hours. We rescale our other
variables similarly and our rescaled variables are thus,
t =
1
kG
tˆ, P = P0pˆ, S =
bS
dS
sˆ, N = P0nˆ, G =
bG0
d¯G
gˆ, H =
1
2
bG0
dH
hˆ, C = P0cˆ,
F =
bF
dF
fˆ , B =
bF
dF
bˆ.
Substituting these into our equations and grouping and rewriting our parameters we
find our rescaled system is
dpˆ
dtˆ
= φ− α∗Ssp− p− p+ 2k∗Nn, (4.5.1)
dsˆ
dtˆ
= − αˆ
∗
Sφˆ
∗
S sˆpˆ

+ δˆ∗S(1− sˆ), (4.5.2)
dnˆ
dtˆ
= pˆ− 2kˆ∗N nˆ−
kˆ∗PSH

nˆ− αˆ
∗
G
2
nˆgˆ, (4.5.3)
dgˆ
dtˆ
= − αˆ
∗
Gφˆ
∗
G
4
nˆgˆ + δˆ∗G(1 +
α∗Ff
f/f ∗c + 
− gˆ) + α
∗
Hφ
∗
Hfh
f/f ∗c + 
, (4.5.4)
dhˆ
dtˆ
=
αˆ∗Gφˆ
∗
G
5φ∗H
nˆgˆ +
δˆ∗H

(gˆ − hˆ)− αˆ
∗
H fˆ hˆ
(fˆ/f ∗c + )
, (4.5.5)
dcˆ
dtˆ
=
kˆ∗PSH

nˆ, (4.5.6)
dfˆ
dtˆ
=
αˆ∗NB
5
nˆbˆ+ δˆ∗FB bˆ+
δˆ∗F

(1− fˆ)− γˆ
∗
FB
2
fˆ , (4.5.7)
dbˆ
dtˆ
= − αˆ
∗
NB
5
nˆbˆ+
γˆ∗FB
2
fˆ − ( δˆ
∗
B

+ δˆ∗FB)bˆ. (4.5.8)
The parameters in equations (4.5.1)-(4.5.8) and their orders in terms of  can be found
in Table 4.5, in these equations our parameters are defined as kˆN = 
2kˆ∗N , αˆS = αˆ
∗
S
etc. such that they are O(1). We now use an initial condition of p(0) = 0 and instead
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acetaminophen is chronically infused governed by the φ term in p˙, which we define in
our different steady state cases, as discussed at the beginning of this section. In the
next section we utilise these rescaled equations to find leading order solutions for the
steady states. Our other initial scalings when APAP is infused at φ ∼ O() are O(1)
with the exceptions of
nˆ(0) = 4n, fˆ(0) = f.
We now continue with our analysis, dropping the hats and ∗’s for clarity.
4.5.2 Steady State Solutions: Safe dose regime φ < φc
We first seek steady-states in a safe chronic dose regime, i.e. φ < φc, where φc will be
given later in this section (see equation 4.5.25). We find that the correct scaling for
this critical concentration is φ = O(), for φ < φc, and find that g = O(1). Using this
scaling we can rescale our variables in terms of , for example by substituting φ = φ¯
into equations (4.5.1) and (4.5.2) we see
φ¯− αSsp− p− p+ 2kNn = 0, (4.5.9)
αSφSsp

+ δS(1− s) = 0. (4.5.10)
Our leading order terms must match, therefore from equation (4.5.10) we see that
sp ∼ O(), as this term must have the same order as dS, and substituting this into
equation (4.5.9) we see that in order for our terms to match, p ∼ O() and s ∼ O(1).
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Table 4.5: Table of dimensionless parameters, their values and the assumed
value relative to the reference small parameter .
Parameter Definition Value Order in terms of 
φ φ/kGP0 N/A N/A
kˆ450 k450/kG 0.105 
kˆN kN/kG 0.0105 O(2)
αˆS kSbS/dSkG 1 O(1)
φˆS P0dS/bS 10 O(1/)
δˆS dS/kG 0.668 O(1)
kˆPSH kPSH/kG 36.8 O(1/)
αˆG kGSHbG0/d¯GkG 368 O(1/2)
αˆF bG1bF/bG0dF 18.84 O(1/)
φˆG P0d¯G/bG0 192 O(1/2)
αH dRbF/kGdf 123 O(1/2)
fc Fcdf/bf 0.288 O()
δˆG d¯G/kG 2 O(1)
δˆH dH/kG 6.68 O(1/)
φH d¯G/dH 0.3 O()
αNB P0dNB/kG 76286 O(1/5)
γˆFB γFB/kG 125 O(1/2)
δˆF dF/kG 24.1 O(1/)
δˆB dB/kG 24.1 O(1/)
δˆFB dFB/kG 2.41 O(1)
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Proceeding similarly for the rest of the model we find our complete initial scalings are
p ∼ O(), s ∼ O(1), n ∼ O(4), g ∼ O(1), h ∼ O(1), f ∼ O(), b ∼ O(1).
Here we ignore our equation for c as it does not have a steady state, (4.5.6) implies
that c ∼ kPSHn∗t/ as t→∞, where n∗ is the steady-state NAPQI concentration. By
substituting these scalings into our system and collecting leading order terms, we find
our leading order steady state equations are
φ¯− αSsp− p ∼ 0, (4.5.11)
−αSφSsp+ δS(1− s) ∼ 0, (4.5.12)
−αGng + p ∼ 0, (4.5.13)
−αGφGng + δG
(
1 +
αFf
(f/fc) + 1
− g
)
+
αHφHfh
(f/fc) + 1
∼ 0, (4.5.14)
αGφGng
φH
+ δH(g − h)− αHfh
(f/fc) + 1
∼ 0, (4.5.15)
αNBnb− γFBf + δF ∼ 0, (4.5.16)
− αNBnb− δBb+ γFBf ∼ 0. (4.5.17)
By eliminating s between equations (4.5.11) and (4.5.12) we find that the only positive
solution is
pss ∼ 1
2
φ¯αSφS + δS(1 + αS)±
√
φ¯2α2Sφ
2
S − 2δSφα2SφS + δ2Sα2S + 2δSφ¯αSφS + 2δ2SαS + δ2S
αSφS
.
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Which can be rewritten as
pss ∼ 1
2
c1 +
√
c21 + 4c2
αSφS
,
Where c1 = φ¯αSφS− δS(1 +αS), and c2 = δSφ¯αSφS, and as we know p ≥ 0 we conclude
that
pss =
1
2
φαSφS − δS(1 + αS) +
√
φ2α2Sφ
2
S − 2δSφα2SφS + δ2Sα2S + 2δSφαSφS + 2δ2SαS + δ2S
αSφS
.
Proceeding this way we find the rest of our steady states
sss ∼ δS
pssαSφS + δS
, (4.5.18)
nss ∼ pss
gssαG
, (4.5.19)
hss ∼ (αFfc + 1)(gssαGδB + pssαNB)δF + gssfcαGδBγFB
(gssαGδB + pssαNB)δF + gssfcαGδBγFB
, (4.5.20)
fss ∼ δF (δBαGgss + pssαNB)
gssαGδBγFB
, (4.5.21)
bss ∼ δF
δB
, (4.5.22)
where,
gss ∼−pssδHf
2
ssφG − 2pssδHfssfcφG − pssδHf 2c φH + δGf 2ssf 2c αFαH + δGδhf 2ssfcαF + δGδHff 2c αF
(fss + fc)2δHφG
(4.5.23)
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+
δGf
2
ssfcαH + δGfssf
2
c αH + δGδHf
2
ss + δGδHfssfc + δGδHf
2
c
(fss + fc)2δHφG
We leave gss and pss ‘as is’ in our other steady states for readability.
We assume that damage to the liver occurs when gss ceases to be O(1). Solving (4.5.23)
for gss = 0 leads to a critical pss value namely
pc =
δG(fssfcαF + fss + fc)(fssfcαH + δHfss + δHfc)
δH(fss + fc)2φG
, (4.5.24)
such that gss = O(1) for pss < pc and gss << 1 for pss > pc. This suggests that at
low doses of acetaminophen, i.e. φ = O() it is still possible to deplete GSH levels to
below the initial levels of g = O(1). We also note that pc is dependant on f , and so
higher NRF2 levels maintain high GSH levels and therefore have a protective effect on
the cell. Substituting fss into (4.5.24) leads to the simple formula for pc
pc ∼ δG(αFfc + 1)(αHfc + δH)
δHφG
.
Furthermore, from (4.5.11) and (4.5.12) we obtain the critical dose rate,
φ¯c ∼ pc
(
1 +
αSδS
αSφSpss
)
(4.5.25)
whereby φc ∼ φ¯c.
Therefore in this initial analysis of the steady states we find another critical point
at which we see a bifurcation and a change in stability of our steady states. As pss → pc
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and gss → 0 we observe
sss → δS
pcritαSφS + δS
, (4.5.26)
nss, fss →∞, (4.5.27)
hss → αFfc + 1. (4.5.28)
We note that as pss → p+c all variables are O(1) except nss, fss →∞ and gss → 0.
We proceed to investigate the stability of our leading order solutions found in equa-
tions (4.5.18) - (4.5.23). We have expanded our variables such that
p ∼ pss +O() etc.
Linear stability analysis assumes that
p ∼ pss + δP0eλt where δ >> O(),
where the sign of λ indicates the stability of the given solution.
We find the Jacobian matrix and seek solutions for eigenvalues λ1..7. The resulting
characteristic polynomial is of the form
(λ2+(αSφSp+αSs+δS+1)λ+δS(1+αSs)+αSφSp)(a5λ
5+a4λ
4+a3λ
3+a2λ
2+a1λ+a0),
where a0..a5 are coefficients involving the model parameters and the full characteristic
polynomial and its coefficients are given in the appendices.
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The quadratic polynomial here has solely positive coefficients, indicating that they
are real and negative or complex with negative real part. Therefore we conclude that
λ1,2 < 0.
As these eigenvalues are negative, we can say that these two solutions are stable in
the direction of their eigenvectors. Unfortunately, we are unable to solve the quintic
portion of our characteristic polynomial and so cannot prove the remaining eigenvalues
are negative analytically. However, if we substitute our parameter values from Table 4.5
in to our quintic equation, we can show that in this case our eigenvalues are negative.
Figure 4.12 shows the plot of this quintic equation.
4.5.3 Intermediate dose regime, φ ∼ φc
Here we investigate the steady-states in the intermediate region between φ < φc and
φ > φc. We find that the size of the intermediate region is O(
3/2).
We identified an intermediate scaling as g → O() from O(1), in which g ∼ O(√).
In this scaling we see p, s, h and b, stay constant while the other variables increase or
decrease by O(
√
). We rescale our variables such that
φ ∼ φ¯c + 3/2φ1, p ∼ pc + 3/2p1, s ∼ sc +
√
s1, n ∼ 7/2n0 + 4n1,
g ∼ √g0 + g1, h ∼ hc +
√
h1, f ∼
√
f0 + f1, b ∼ bc +
√
b1,
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Figure 4.12: Plot of the quintic equation for the stability analysis of Section
4.5.2. Numerically we find the roots of f(λ) to be -1.53, -21.7, -27.5, -141.1
and -732.2
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where φc, pc etc. are the leading order solutions from the previous scaling, as these
variables do not change order between the two timescales, and g0, n0 etc. are leading
order variables that need to be solved for this scaling of g. By looking at our O(1)
solutions from the previous scaling as p→ pc, we can say that
φc =
((φS(αFfc + 1)(fcαH + δH)δG + δHδSφG)αS + δHδSφG)δG(fcαH + δH)(αFfc + 1)
(φS(αFfc + 1)(fcαH + δH)δGαS + δHδSφG)φGδH
,
(4.5.29)
pc =
δG(αFfc + 1)(αHfc + δH)
δHφG
, (4.5.30)
sc =
δS
pcαSφS + δS
, (4.5.31)
hc = αFfc + 1, (4.5.32)
bc =
δF
δB
. (4.5.33)
Proceeding as in the previous section we find the following leading order solutions for
our variables,
f0 =
αNBpcδF
g0αGδBγFB
,
n0 =
pc
g0αG
,
h1 =
f 2c αFg0αGδBγFB
αNBpcδF
,
p1 =
φ1(pcαSφS + δS)
2
p2cα
2
Sφ
2
S + (2pcδSφS + δ
2
S)αS + δ
2
S
.
We can then use these to solve for g0. We find that
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−e1
g0
+ e2φ1 + e3g0 = 0
where,
φ1 =
φ− φc√

,
e1 =
pckPSHφG
αG
,
e2 =
φG(p
2
cα
2
Sφ
2
S + 2pcαSφsδS + δ
2
S)
p2cα
2
Sφ
2
S + 2pcαSδSφS + αSδ
2
S + δ
2
s
,
e3 =
2f 3c αFαGαHδBγFBφH + f
2
c αFαGδBδGγFB + f
2
c αGαHδBγFBφH + pcαNBδF δG
pcαNBδF
.
As φ1 → +∞ we find that −e1g0 + e2φ1 ∼ 0 and so
g ∼ e1
e2φ1
,
implying that g0 → 0 as φ1 → +∞.
Figure 4.13 plots g0 against φ with all parameters equal to 1, as can be seen from the
graph, our steady state solution is in good agreement with our model solution.
4.5.4 Unsafe doses, φ > φc
Staying in the φ = O() regime, we seek steady-state solutions for φ > φc, whereby the
scalings of the variables are
p ∼ O(), s ∼ O(1), n ∼ O(3), g ∼ O(), h ∼ O(1), f ∼ O(1), b ∼ O(1).
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Here we note that g has dropped from O(1) to O() and we see a corresponding rise in
n to O(3), while our acetaminophen levels remain at O(). Nrf2 levels have also now
increased to O(1), this means our Michaelis-Menten term can be expanded such that
f
f/fc + 
∼ fc +O().
Substituting these scalings into our model, we find our leading order steady state
equations
φ− αSsp− p ∼ 0, (4.5.34)
−αSφSsp+ δS(1− s) ∼ 0, (4.5.35)
−αGng + p− kPSHn ∼ 0, (4.5.36)
−αGφGng + δG(1 + fcαF ) + αHφHfch ∼ 0, (4.5.37)
αGφGng
φH
− δHh− αHfch ∼ 0, (4.5.38)
αNBnb− γFBf ∼ 0, (4.5.39)
−αNBnb+ γFBf ∼ 0. (4.5.40)
Our steady states for s and p are the same as in the previous section and we solve for
the rest of our variables as we did previously, finding
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pss =
1
2
φαSφS − δS(1 + αS) +
√
φ2α2Sφ
2
S − 2δSφα2SφS + δ2Sα2S + 2δSφαSφS + 2δ2SαS + δ2S
αSφS
,
(4.5.41)
sss =
δS
pssαSφS + δS
, (4.5.42)
nss =
pss
gssαG + kPSH
, (4.5.43)
hss =
pssαGφGgss
φH(αGgss + kPSH)(fcαH + δH)
, (4.5.44)
fss =
pssαNBδF
δBγFBαGgss + δFαNBpss + δBγFBkPSH
, (4.5.45)
bss =
γFBδF (αGgss + kPSH)
δBγFBαGgss + δFαNBpss + δBγFBkPSH
. (4.5.46)
In this scaling we find that
gss =
δGkPSH(fcαF + 1)(fcαH + δH)
αG(pssδHφG − δGf 2c αFαH − δGδHfcαF − δGfcαH − δGδH)
Solving the Jacobian for equations (4.5.34)-(4.5.40) we find the characteristic poly-
nomial
(λ+δB)(λ+δF )(λ
2+λ(αSφSpss+αSsss+δS+1)+αSφSp+δS(1+αSs))(λ
3+a1λ
2+a2λ+a3)
Where a1..a3 are coefficients involving the model parameters and the full character-
istic polynomial and its coefficients are given in the appendices. We immediately see
that two eigenvalues are −δF and −δB. For the quadratic part, we have all coefficients
being positive, which means that they are real and negative or complex with negative
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real part. For the cubic part we have a1 < 0, a2 < 0 and that a1a2 > a3, which by using
the Routh-Hurwitz condition means that all 3 roots have negative real parts. Hence,
the steady states in this system are stable. We find that as φ¯ → ∞, pss ∼ φ¯ and
g ∼ 1/φ so gss → 0 as φ¯→∞. We also see that nss →∞, bss, sss → 0.
4.5.5 Very Unsafe Dose, φ >> φc
In this section we investigate steady states in the case of φ = O(1), which represents liver
cells being continuously dosed at concentrations which are only experienced temporarily
in the bolus case. We rescale our ODE’s such that φ = O(1) and rescale our variables
as described in the previous sections. We find our new variable scalings are thus
p ∼ O(1), s ∼ O(), n ∼ O(2), g ∼ O(2), h ∼ O(1), f ∼ O(1), b ∼ O().
In comparison to the previous sections, we see that PAPS levels have now dropped
such that s ∼ O(), NAPQI has risen and GSH has dropped and so n, g ∼ O(2), we
note this is the scaling when p0 > p
∗
0 in the analysis of Section 3.4. We also note that
we have high levels of Nrf2, f ∼ O(1) but low levels of the bound complex remaining,
suggesting that in high dose cases, the complex is depleted as Nrf2 levels stay high for
a prolonged period. We again rescale our ODE’s so that
f
f/fc + 
∼ fc +O(),
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and find that at leading order, our steady state equations are
φ− p ∼ 0, (4.5.47)
δS − αSφSp ∼ 0, (4.5.48)
p− kPSHn ∼ 0, (4.5.49)
−αGφGng + δG(1 + fcαF ) + αHφHfch ∼ 0, (4.5.50)
αGφGng
φH
− δHh− αHfch ∼ 0, (4.5.51)
αNBnb− γFBf ∼ 0, (4.5.52)
−αNBnb+ γFBf ∼ 0. (4.5.53)
Proceeding as before it is clear that pss = φ and so using this in subsequent equations
the steady states are,
pss ∼ φ, (4.5.54)
sss ∼ δS
φαSφS
, (4.5.55)
nss ∼ φ
kPSH
, (4.5.56)
gss ∼ δGkPSH(αFfc + 1)(αHfc + δH)
δHαGφGφ
, (4.5.57)
hss ∼ δG(1 + αFfc)
φHδH
, (4.5.58)
fss ∼ 1, (4.5.59)
bss ∼ kPSHγFB
αNBφ
. (4.5.60)
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Solving the Jacobian for equations (4.5.47)-(4.5.53) we find our characteristic equation
(λ+1)(λ+φαSφS)(λ+kPSH)(λ+δF )(λ+δB)(λ
2+λ
(
δH + fcαH +
φαGφG
kPSH
)
+
φαGφGδH
kPSH
).
Clearly,
λ1 = −δF , λ2 = −1, λ3 = −αsφSφ, λ4 = −kPSH and λ5 = −δB.
All the coefficients of the polynomial are again positive and so we conclude that
λ6,7 < 0
Therefore all of our eigenvalues are negative and the system is stable.
4.5.6 Comparison with Numerics
Figure 4.13 shows our steady state approximations plotted alongside our model output
for different sizes of . Decreasing the size of  improves the agreement between our
numerical and analytical results, suggesting that the analytical results offer a good
approximation of the model. We see that even with the Nrf2 system in place, sustaining
acetaminophen levels in cells at levels relevant to prescription doses, will lead to liver
damage due to an inadequate supply of GSH.
4.6 Summary of Results
Here we will summarise the most important results from the numerical and steady state
analysis of our APAP-Nrf2 Model.
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Figure 4.13: Comparison of our model simulations and our steady state
approximations for  = 0.105 (left) and  = 0.1052 (right). The black dashed
line represents Φcrit, the critical dose at which g → O().
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4.6.1 Nrf2 adaptation decreases toxicity
In our simulations we demonstrate the difference between an Nrf2-null model and a wild
type model in a bolus dosing regime. In Section 4.4.1 we found that when exposed to a
16g overdose, the Nrf2-null model results in 220% higher conjugate levels, 400% higher
NAPQI levels and a corresponding 80% drop in minimum GSH levels. The difference
in toxicity between these two cases will therefore be very large, with less GSH to bind
with the increased levels of NAPQI, more NAPQI will bind with hepatocytes causing
extensive liver damage. In Figure 4.14 we plot Fc against φc (4.5.25) to test the effects
of increased Nrf2 on the threshold critical value of our infused drug. Recall that Fc
acts as a Michaelis-Menten term and increasing this will increase our maximum Nrf2
steady state. We use values of 1/100× to 100× the value of Fc found in Table 4.4 and
observe that increasing Fc increases φc and therefore has a positive affect on the ability
of GSH to remain at O(1), where it can effectively deal with NAPQI. In Figure 4.15
we plot dNB, the parameter related to NAPQI’s up regulation of the Nrf2 pathway,
against C∞, our max conjugates for a 16g overdose case. We increase dNB from 0 to
100× the values found in Table 4.4. We see that increasing dNB in this fashion reduces
C∞ by almost an order of magnitude, showing the positive effect of Nrf2 adaptation in
response to increased NAPQI on acetaminophen toxicity.
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Figure 4.14: A plot of Fc against φc. An increase in φc allows larger infused
doses before GSH drops an order of magnitude.
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Figure 4.15: A plot of dNB against C∞ for the 16g dose case.
4.6.2 Nrf2 adaptation decreases model sensitivity
In our previous model, our sensitivity testing revealed that our model was sensitive to
kG and k450, indicating that decreased glucuronidation or increased oxidation would
lead to more conjugates being produced. This analysis was also performed on this
model and we found that no parameters significantly affected conjugate production in
a global sense. This analysis reveals that Nrf2 upregulation and its affects on GSH
synthesis act as a counter measure against changes in these two pathways and therefore
lead to a more stable system overall.
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4.6.3 Low chronic doses of APAP can lead to order of magni-
tude decreases in GSH
Our steady state analysis on the model revealed that even at chronic doses of φ = O(),
GSH could be depleted from O(1) to O() levels. The precise dosage at which this
depletion occurs is based on Nrf2 concentration in the nucleus. As a result we have two
separate scales for the φ = O() case in our steady state analysis. Although stability
analysis reveals that O() is as low as GSH can potentially fall with low chronic doses,
this could have potentially lethal consequences if dosage was increased. If a healthy
dose has the potential to lower GSH levels then the body has less protection against
any acetaminophen taken on top of this dosage, which would lead to a much faster
crash in GSH levels and a subsequent rise in NAPQI levels and conjugates. This effect
can be seen numerically in our previous model in Figure 2.4 and we now have proved
the existence of this critical point analytically.
4.6.4 Large chronic doses deplete bound Nrf2 complex
Our analysis of the φ = O(1) case shows that in this regime our bound complex, b, falls
to O() levels in response to the large chronic dose of acetaminophen. This leads to Nrf2
reaching its maximum concentration, f ∼ 1, which dimensionally can be interpreted as
F ∼ bF/dF . This depletion indicates that at high doses, Nrf2 translocation is saturated
and the effect it can have on GSH synthesis is limited. This suggests that Nrf2 acts
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as a useful regulator at low and medium doses, but at a very high concentration of
acetaminophen, can not prevent damage to hepatocytes.
4.7 Discussion
In this chapter we have created a new model, building upon the previous model of
Chapter 2, that includes Nrf2 adaptation, a regulatory mechanism that acts as a defence
against increased reactive oxygen species in cells. Using our reduced acetaminophen
model of the previous chapters, we have added ODE’s describing the GSH:GSSG system
as well as the Nrf2 system and its effects on GSH synthesis as a means of protecting
cells from oxidative damage.
Our simulations capture the same dynamics in our system as the previous model,
as before we find a large difference in PAPS, GSH, NAPQI and conjugate levels be-
tween our safe and overdose cases. Increased NAPQI leads to an increase in Nrf2 levels,
which in our model causes GSSG to be converted to GSH faster as well as increasing
the production rate of GSH. These adaptations act as a defence against acetaminophen
overdose and, in particular, the increased numbers of ROS that this results in. How-
ever, if we turn off Nrf2 adaptation we find that using our parameter set, NAPQI and
conjugate levels increase by up to 400%, which we would expect to cause extensive hep-
atocyte damage in comparison to a wild type model where Nrf2 adaptation increases
GSH synthesis.
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Our sensitivity analysis has revealed that Nrf2 decreases the overall sensitivity of
our model to parameter changes when compared to the previous model. Where, in the
previous model, an increase in NAPQI would directly lead to an increase in conjugates,
in this model it instead leads to an increase in Nrf2. This in turn up-regulates GSH
production which binds with the NAPQI and prevents its binding with hepatocytes.
Our model has the same problems with parameterisation as our previous model,
that is, a lack of human toxicity data in comparison to rat and mice. Differences in
Nrf2 adaptation between species has not been extensively studied and therefore to make
this model applicable to multiple species, more experimental work would need to be
undertaken across a variety of animal models or at least using appropriate cell lines in
in vitro studies.
Steady state analysis of the system reveals that in a chronic dosing regimen, GSH can
be depleted at relatively low doses of acetaminophen. Although the dose at which this
happens is dependent on Nrf2 levels in the system. This suggests that chronic dosing can
leave the body susceptible to increased damage from further doses of acetaminophen. If
a bolus dose of acetaminophen was taken after GSH was already depleted, much more
damage would be done comparatively than if the same dose was taken whilst GSH was
still O(1). We also find that for high dose regimens, the Nrf2:Keap1 bound complex is
reduced to low levels and so Nrf2 can no longer increase GSH production, and we find
it reaches a saturation point, governed by its basal synthesis rate.
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Overall, the model captures the difference between Nrf2-null and wild type cases in
our numerical simulations. Our steady state analysis has revealed interesting low-dose
effects that we did not find in the previous model and we see that Nrf2 decreases the
sensitivity of the model to increased oxidation or decreased glucuronidation, factors
that in the previous model increased toxicity. However, even with Nrf2 adaptation, we
were unable to reproduce the results of the experiments of our collaborators shown in
Figure 4.4.
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Chapter 5
PBPK Model
5.1 Introduction
Physiologically based pharmacokinetic modelling or PBPK modelling is a technique
for modelling the absorption of drugs over the entire body of an animal. Such models
generally involve modelling organs as compartments, which correspond to the organs
involved in the metabolism of the drug being studied. PBPK models include different
parameters for volumes of tissues, organs and blood, depending on the animal used. As
such it is a useful platform to model the metabolic differences between species without
the need for large scale alteration of the metabolism model. In the introduction to
this thesis we mentioned the fact that scaling experimental results from rats or mice to
humans is not as simple as assuming a human is just a 70kg rat, differences in blood and
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organ volume, as well as differences in metabolism mean that scaling between species is
a complex problem. PBPK models allow for these differences in species to be modelled
in an in silico environment.
Many PBPK models do not specifically include metabolism in their design. Instead
they opt to simply use absorption and clearance in a specific organ, the liver in the
case of acetaminophen, and are used to study the plasma concentration of a drug
over time. One such example is Jiang et al. [78], who created a PBPK model to
predict acetaminophen metabolism in children. They model excretion via the GSH,
glucuronidation and sulphation pathways as clearance rates from the liver, and fit this
to in vitro data. While this approach is suitable to explore plasma concentrations
and clearance profiles of a drug, it does not provide deeper insight in to the effects of
metabolism in a full body model.
In Figure 4.4 of the previous chapter, we detailed the results of an experiment in
a rat, where the acetaminophen concentration in the plasma from an infused dose did
not reach steady state as one might expect, but instead reached a maximum and then
decreased over time. The previous model was unable to reproduce these dynamics. As
the previous model was a single cell model, we decided to create a new model which
would examine the metabolism over the whole body of the rat. We reason that perhaps
the results of the experiment were due to the effects of transport between the blood
and liver, or other organs and the liver, and how Nrf2 adaptation affects toxicity in a
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full body model. The work presented in this chapter is a preliminary study of a full
body PBPK model of acetaminophen metabolism.
5.2 Mathematical Modelling
5.2.1 PBPK Rat Model
As the experiments we are trying to reproduce were performed in a rat model, we use a
rat as the basis for the parameterisation of the mathematical model. We model the rat
as three separate compartments; blood (B), liver (P ) and rest (R). The blood and liver
compartments are self-explanatory, and the ‘rest’ compartment refers to bloodflow in to
the other organs of the body, where acetaminophen might reach but is not metabolised.
Figure 5.1 provides a visual representation of how we model the rat. Acetaminophen is
introduced in to the blood either in a bolus dose or via infusion, it is then transported
either to the ‘rest’ compartment or the liver compartment, where it is metabolised as
in previous chapters.
We arrive at a ten ODE model describing the transport between these compartments
as well as metabolism in the liver compartment
d(VBB)
dt
= φ− αQR(B − µRR)− βQL(B − µLνP ), (5.2.1)
d(VRR)
dt
= αQR(B − µRR), (5.2.2)
d(νVLP )
dt
= βQL(B − µLνP )− νVL(kSSP + kGP + k450P − kNN), (5.2.3)
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Figure 5.1: A diagram of the PBPK model used in this chapter. We model
three compartments; blood, liver and ‘rest’. Acetaminophen is metabolised
in the liver as in previous chapters.
dS
dt
= − kSSP + bS − dSS, (5.2.4)
dN
dt
= k∗450P − kNN − kGSHNG− kPSHN, (5.2.5)
dG
dt
= bG0 +
bG1F
F/Fc + 1
− d¯GG− kGSHNG+ 2dRFH
F/Fc + 1
, (5.2.6)
dH
dt
=
1
2
d¯GG+
1
2
kGSHNG− dHH − dRFH
F/Fc + 1
, (5.2.7)
dC
dt
= kPSHN, (5.2.8)
dF
dt
= bF − gFBF + dNBNBo− dFF + dFBBo, (5.2.9)
dBo
dt
= gFBF − (dB +NdNB + dFB)Bo. (5.2.10)
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Table 5.1: Model parameters for Rats. Parameters marked with a ∗ ex-
plained in Section 4.3.3. Parameters marked with † are from Brown et
al. [80]
Parameter Interpretation Rat Unit
QC†total Total Cardiac Output 120 L·day−1
Qha† Hepatic Artery Flow 2.52 L·day−1
Qpv† Portal Vein Flow 18.36 L·day−1
V †L Total Volume of Liver 0.009 L
V †B Volume of Blood Plasma 0.011 L
V †R Remaining Volume (Total-Liver-Blood) 0.224 L
ν Cells per Volume Scaling 1.23× 1011 cells/L
µL Blood to Liver Partitioning 0.03 non-dim
µR Blood to Rest Partitioning 1 non-dim
α Mass Transfer Coefficient 0.005 non-dim
β Mass Transfer Coefficient 100 non-dim
dG GSH Decay Rate 2 day
−1
kGSH GSH/NAPQI binding rate 1.6× 1018 cell · mol−1· day−1
kG Glucuronidation Rate 2.99 day
−1
kS Sulphation Rate 2.26× 1014 cell · mol−1· day−1
bS PAPS Production rate 2.65× 10−13 mol · cell−1 · day−1
dS PAPS Decay Rate 2 day
−1
k450 Oxidation Rate 0.315 day
−1
kN Reverse Reaction 0.0315 day
−1
kPSH NAPQI/Protein binding 110 day
−1
bG0 GSH Production Rate
∗ 4.125× 10−15 mol · cell−1 · day−1
bG1 GSH Production Rate
∗ 2.234× 103 day−1
dH GSSG Death Rate 20 day
−1
dR GSSG to GSH Conversion Rate 1.06× 1019 cell · mol−1· day−1
d¯G GSH Decay Rate 6 day
−1
bF Nrf2 Production Rate 2.5× 10−15 mol · cell−1 · day−1
gFB Nrf2 Binding Rate 374 day
−1
dNB NAPQI-Driven Bound Complex → Nrf2 Rate 1.73× 1018 cell · mol−1· day−1
dF Nrf2 Decay Rate 72 day
−1
dB Bound Complex Decay Rate 72 day
−1
dFB Bound Complex to Nrf2 Natural Decay Rate 7.2 day
−1
Fc Michaelis-Menten term 1× 1017 day−1
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Where the mass transfer coefficients are
QR = QCtotal −Qha−Qpv,
QL = Qha+Qpv,
and our initial conditions are
B(0) = 0, P (0) = 0, R(0) = 0, S(0) = bS/dS, N(0) = 0,
G(0) = 2
(
F (0)H(0)dRFc + F (0)bG1Fc + bG0(F (0) + Fc)
d¯G(F (0) + Fc)
)
,
H(0) =
1
2
(
F (0)bG1Fc + bG0(F (0) + Fc)
dh(F (0) + Fc)
)
,
F (0) =
bF (dB + dFB)
dBdF + dBgFB + dFdFB
, Bo(0) =
gFBbF
dBdF + dBgFB + dFdFB
.
Equations (5.2.4)-(5.2.10) are the same as the metabolism equations in our previous
chapter, with the exception of the bound Nrf2 complex, which is now referred to as
Bo to differentiate it from our blood compartment. We note that no cell death is as-
sumed. When modelling a chronic dose scenario in this model, we use φ = 1.43× 10−3
mol/day, the value used in our collaborators experiments detailed in the previous chap-
ter. As mentioned in the introduction, rats are significantly more resistant to ac-
etaminophen overdose than humans; to account for this we increase bS to 10× the
value used previously. We increase bS because rats experience a delayed depletion in
hepatic GSH [28], suggesting that more acetaminophen is metabolised before it can
be converted to NAPQI and deplete GSH. ν is used to scale the total acetaminophen
concentration in the liver to a per-cell concentration for our metabolism equations [79].
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Qha, Qpv and QCtotal are blood flow rates for the hepatic artery, portal vein, and total
cardiac output respectively, and VL, VB and VR are volumes of the liver, blood plasma
and total remaining volume respectively. µL, µR, α and β are non-dimensional param-
eters chosen by us to describe the partitioning between the different compartments and
to achieve the expected results seen in Section 5.3. All physiological parameters are
found in Brown et al. [80]. Full parameter values, their physiological interpretation and
units can be found in Table 5.1. The liver is now modelled as a separate compartment,
in which we see the same ODE for single cell metabolism as in previous models.
5.2.2 Non-Dimensionalisation
We non-dimensionalise as in Section 3.1.1, scaling time with the rate constant for glu-
curonidation and write
t =
1
kG
tˆ, , P = P0pˆ, S =
bS
dS
sˆ, N = P0nˆ, G =
bG0
d¯G
gˆ, H =
1
2
bG0
dH
hˆ, C = P0cˆ,
F =
bF
dF
f, Bo =
bF
dF
bo.
We introduce non-dimensional variables for the blood and rest compartments
B = b0bˆ, R = r0rˆ.
We then write our non-dimensional system as
dbˆ
dtˆ
= φˆ∗ − α
∗
BRφ
∗
BR

(bˆ− µRrˆ)− α
∗
BLφ
∗
BL
4
(bˆ− µLpˆ), (5.2.11)
147
drˆ
dtˆ
= α∗BR(bˆ− µRrˆ), (5.2.12)
dpˆ
dtˆ
=
α∗BL
4
(bˆ− µLpˆ)− α∗S sˆpˆ− pˆ− pˆ+ 2k∗N nˆ, (5.2.13)
dsˆ
dtˆ
= −α
∗
Sφ
∗
S sˆpˆ

+ δ∗S(1− sˆ), (5.2.14)
dnˆ
dtˆ
= pˆ− 2k∗N nˆ−
k∗PSH

nˆ− α
∗
G
2
nˆgˆ, (5.2.15)
dgˆ
dtˆ
= −α
∗
Gφ
∗
G
4
nˆgˆ + δG(1 +
α∗F fˆ
fˆ/f ∗c + 
− gˆ) + α
∗
Hφ
∗
H fˆ hˆ
fˆ/f ∗c + 
, (5.2.16)
dhˆ
dtˆ
=
α∗Gφ
∗
G
5φ∗H
nˆgˆ +
δ∗H

(gˆ − hˆ)− α
∗
H fˆ hˆ
(fˆ/f ∗c + )
, (5.2.17)
dcˆ
dtˆ
=
k∗PSH

nˆ, (5.2.18)
dfˆ
dtˆ
=
α∗NB
5
nˆbˆo+ δ∗FB bˆo+
δ∗F

(1− fˆ)− γ
∗
FB
2
fˆ , (5.2.19)
dbˆo
dtˆ
= −α
∗
NB
5
nˆbˆo+
γ∗FB
2
fˆ − (δ
∗
B

+ δ∗FB)bˆo. (5.2.20)
Here, we write b0 = r0 = νP0 and denote αBL = α
∗
BL/
4 etc. so that the parameters
in equations (5.2.11)-(5.2.20) are O(1). The new non-dimensional parameters, including
new values for αS and φS which have changed due to the increase in bS, can be found
in Table 5.2 while the other non-dimensional parameters used in past models can be
found in Table 4.5. Henceforth in this chapter we will drop the hats and ∗’s for clarity.
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Table 5.2: Non-dimensional Model parameters for PBPK Model.
Parameter Definition Value Order in terms of 
φˆ φ/kGVBνP0 2.68 O(1)
αBR αQR/VRkG 0.74 O(1)
φBR VR/VB 20.36 O(1/)
αBL QLβ/VLkG 77600 O(1/4)
φBL VL/VB 0.82 O(1)
αS kSbS/dSkG 10 O(1/)
φS P0dS/bS 1 O(1)
5.3 Results
5.3.1 Effects of Nrf2 Adaptation
To initially verify the model, we run chronic dose simulations with φ = 2.68, with Nrf2
adaptation in response to NAPQI either on or off. The bioavailability of acetaminophen
is 80−90% [81] and so we expect that the majority of the drug will be found in the liver
compartment. Acetaminophen is administered at t = 0.5 until t = 6 (note that in the
experiments, acetaminophen is infused over 2 days, equal to t = 6 in non-dimensional
time) and the simulations are then run until t = 15.
Figure 5.2 shows the results of these simulations. As expected, the majority of the
acetaminophen is found in the liver compartment, we also observe that there is similar
amounts of acetaminophen in the blood plasma vs. the other organs in the body. With
Nrf2 adaptation being modelled, we see that GSH drops to approximately 20% of its
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Figure 5.2: Plots of B, L, R, S, N , G, H, C, N and Bo against time, with
Nrf2 adaptation in response to NAPQI on (black) or off (orange).
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steady state levels, however when adaptation is not present, it falls to negligible levels.
This leads to an associated rise in NAPQI and conjugates of approximately an order of
magnitude. As in the previous model, we see that Nrf2 adaptation provides protection
against high levels of acetaminophen and we would expect less necrosis to occur than
if Nrf2 adaptation is not present. We note however that we are still unable to replicate
the results of the experimental work in the blood compartment (B).
5.3.2 Differential Delay Equations (DDEs)
To attempt to replicate the results of the experimental work, whereby acetaminophen
concentration in the plasma does not reach a steady state but instead reaches a maxi-
mum and then decreases again we introduce delay terms in our model. We hypothesise
that if Nrf2 adaptation in the GSH/GSSG pathway is delayed then we may be able to
reproduce the experimental results. To investigate this, we introduce delays into our
GSH and GSSG equations,
dg
dt
= −αGφG
4
ng + δˆ∗G(1 +
αFf(t− τ)
f(t− τ)/fc +  − g) +
αHφHf(t− τ)h
f(t− τ)/fc +  , (5.3.1)
dh
dt
=
αGφG
5φH
ng +
δH

(g − h)− αHfh
(f(t− τ)/fc + ) , (5.3.2)
such that increased Nrf2 does not immediately increase GSH synthesis and GSSG re-
duction via GSR, but instead this increase is delayed by a time τ , chosen by us. The
model was solved using the ‘dde23’ [82] solver in Matlab.
151
Figure 5.3 shows the results of simulations with τ = 1.5 (approximately 12 hours),
we see that in comparison to Figure 5.2, GSH decreases at an increased rate, and
reaches a lower minimum. At t ' 2, GSSG levels reach a maximum, at which point
they begin to fall again as Nrf2 mediated GSR reduction increases and so GSH begins
to rise again. Maximum NAPQI and conjugate levels are approximately double the
maximums observed in Figure 5.2, as the delay in Nrf2 adaptation means that less
GSH is present to bind with NAPQI and be safely excreted. We do however note that
the acetaminophen levels in the blood, liver and other organs remain the same. From
this we conclude that delays due to DNA transcription time do not seem to have an
effect on the absorption of acetaminophen from the bloodstream.
During the course of this work we realised that in order to replicate the results
of our collaborators within this framework, our model parameters must be rescaled.
As it stands, Nrf2 does not affect the metabolism of acetaminophen in the liver at
leading order. In order to try and replicate these results we have to rescale a number
of parameters to levels that are much higher than we have assumed in the previous
models, however we use them to try and show that we can qualitatively reproduce the
results of our collaborators. In order for Nrf2 to have an effect at leading order, we
have to increase both k450 and kN so that the oxidation pathway metabolises more
acetaminophen than in our original model and the return rate is much higher than the
forward rate of metabolism. We also increase the reduction rate of GSSG to GSH, dR,
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Figure 5.3: Plots of b, p, r, s, n, g, h, c, f and bo against time, using DDEs
with τ = 1.5.
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Table 5.3: New and old parameter values for new simulations.
Parameter Previous Value New Value
kN 0.0315 3000
k450 0.315 31.5
dR 1.06×1019 8.5×1019
bF 2.5×10−15 2×10−14
and the rate at which NAPQI up-regulates the Nrf2 pathway, dNB. Table 5.3 shows
the new parameters in our model compared to the previously used values.
Figure 5.4 plots our variables against non-dimensional time using these new param-
eters and a delay term, τ = 2. We observe that the results now qualitatively match
those from our collaborators experiments, where blood APAP (B) reaches a maximum
before falling again while acetaminophen is infused. GSH falls initially but recovers
to levels much higher than its steady state due to the increased rate at which GSSG
is reduced to GSH, as well as the increased unbinding of the bound complex bo due
to dNB being higher, which leads to more Nrf2 available in the system to increase the
production rate of GSH. Due to the delay in Nrf2 adaptation, we see that conjugates
and NAPQI reach a maximum of approximately twice that seen in Figure 5.2 when
Nrf2 is enabled.
Figure 5.5 plots the experimental data of our collaborators on the same axes as our
model output for Blood APAP (B) whilst acetaminophen is being infused. Although
the data is not an exact quantitative match, we see that the model is now providing a
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similar response to the experiments. It is possible that further fitting of the parameters
could provide results closer to those seen in the experiments, however as we have had
to alter the parameters so much from the initial set that gave us biologically relevant
results in the previous models, we may affect how predictive our results are of an in
vivo system.
5.4 Discussion
In this chapter we have presented a PBPK model, parameterised using the physiological
parameters of a rat. It was hoped that this model would be able to better explain the
affects found in our collaborators experiments seen in Figure 4.4 in the previous chapter.
Although the model was unable to capture these dynamics with the initial parameter-
isation, it has provided interesting results of how acetaminophen is distributed across
the whole body and the affects that delayed adaptation from Nrf2 in the GSH/GSSG
pathway has on total ROS in the system.
We created a three compartment model, consisting of a compartment for the blood
plasma, liver and other organs (‘rest’). We parameterised this model using rat physio-
logical parameters as the experiments we were trying to reproduce were performed in a
rat model. We found that Nrf2 adaptation in the model had a large effect on total tox-
icity experienced from the chronically infused dose. In the absence of Nrf2 adaptation
we saw 10× as many conjugates being formed due to lower minimum GSH levels. We
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Figure 5.4: Plots of b, p, r, s, n, g, h, c, f and bo against time, using DDEs
with τ = 2 and the new parameters found in Table 5.3.
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Figure 5.5: Plot of the experimental data of our collaborators (black) and
our model data from the new simulations (orange).
expect that this would lead to increased damage to hepatocytes in an in vivo setting.
As our initial simulations did not capture the experimental data from Figure 4.4,
we tested a new hypothesis that a delay in Nrf2 adaptation in the GSH/GSSG pathway
would perhaps have an effect on acetaminophen concentration in the blood plasma. In
order to test this, we used differential delay equations, and experimented with whether
this delay had an effect on the model. Delayed adaptation in the GSH/GSSG system
led to the formation of more NAPQI and conjugates, which would lead to higher hep-
atotoxicity and therefore a worse outcome in an in vivo setting. We have not found
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any discussion in the literature of whether this delay exists and so this could provide
motivation for new in vitro experiments.
We then tested a new set of parameters in the model, increasing the rate of oxida-
tion of acetaminophen as well as the rate at which NAPQI is metabolised back in to
acetaminophen. We also increased the rate at which GSSG is reduced back to GSH
and the rate at which NAPQI up-regulates the Nrf2 pathway. These new parameters,
combined with the DDE model, produced results qualitatively similar to those seen in
the experiments. We conclude that in the confines of our model, either Nrf2 adaptation
was not the cause of these experimental results, or that we do not fully understand the
oxidation pathway of acetaminophen metabolism and its associated parameters.
PBPK models can be paramaterised for different species, providing a framework to
study inter-species differences in metabolism, providing differences in cofactors such as
PAPS and GSH is known. In future this model could be used to compare the effects of
acetaminophen overdoses in different species and be fitted to in vitro data to improve
the predictive value of the results.
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Chapter 6
Spheroid Modelling
6.1 Introduction
Thus far in this thesis, all the models that have been presented have been ODE-based
models that do not include any sort of spatial component. While this is adequate for
modelling metabolism in a single cell, as well as cells in a compartmental model, to
model multiple cell systems with spatial heterogeneity and have more applicability to
in vitro work, such as for multi-cell spheroids, we need to introduce more dimensions
in our model.
Multi- cell spheroids are groups of cells which are grown in an environment where
they can grow and move in all three dimensions, similar to how we would expect cells to
grow in vivo. Spheroids can be grown in a variety of different containers. For example,
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Glicklis et al. [83] used three different bioreactors to grow hepatocyte spheroids. Isolated
hepatocytes from rats were seeded on to either alginate scaffolds; a series of small
cylindrical scaffolds that spheroids would grow upon, spinner flasks; where cells were
added to the vessel and constantly stirred at 110rpm; or T-Flasks, which were placed
onto an orbital incubator, spinning the flasks and causing the hepatocytes to form in to
spheroids. These spheroids can then be used for in vitro experiments, but potentially
provide results closer to those achieved in vivo, when compared to something like 2D
cultured hepatocytes on a petri dish.
From a mathematical perspective, while the growth and oxygen consumption ki-
netics of a spheroid have been modelled [84, 85, 86], not much work has been done on
the metabolism of drugs within a spheroid, and whether that can be used to further
experimental work. Glicklis et al. [83] use a series of first and second order differential
equations to describe both the size of the spheroid, as well as the oxygen consumption
and cell viability as a function of the spheroid radius. Their model provides a good fit
to their data, however some of the spheroid growth rates seem biologically unfeasible.
Leedale et al. [87] , modelled hypoxia across a spheroid. Due to the size of spheroids, as
they continue to grow the cells in the middle begin to suffer from oxygen deprivation due
to oxygen from the media being unable to diffuse adequately through the cells. They
found that in the centre of spheroids, O2 concentration dropped rapidly and could lead
to a group of dead cells, called a necrotic core, forming in the centre due to a lack of
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oxygen. Curcio et al. [88] also found similar results and produced a basic 3D model to
measure the gradients in oxygen concentration across the radius of the spheroid. This
work is of particular interest to our modelling as intracellular hypoxia impairs oxidative
drug metabolism, and so we would expect a lower oxygen concentration to lead to less
NAPQI being formed [89].
There are currently no models in the literature that look specifically at mathematical
models of acetaminophen metabolism in a spheroid. In this chapter we present an in
silico model and study the effects of acetaminophen metabolism on spheroid growth, the
effects of NAPQI on cell death, and test hypotheses of how the oxygen gradient across
the spheroid affects the oxidative pathway. In future we hope that these results can be
tested against in vitro models to gain quantative insight on metabolism in spheroids.
6.2 Mathematical Modelling
6.2.1 Spheroid Growth Equations
This model is based upon the model found in Ward and King [86] for avascular tumour
growth. We assume that the spheroid is radially symmetric and defined in the domain
0 ≤ r ≤ R(t), where R(t) is the coordinate of the moving boundary representing the
outer edge of the spheroid. The growth, division and death of our volume fraction for
cells φ, is dependant on a nutrient c. We assume that the nutrient diffuses through the
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spheroid and transports rapidly across cell membranes and adopt a quasi-steady limit.
The growth and death of cells leads to local volume changes which moves cells and is
described here as a velocity field. The equations for the spheroid structure are thus,
∂φ
∂t
+∇ · (vφ) = (km(c)− kd(c))φ = a(c)φ, (6.2.1)
0 = Dc∇2c− βkm(c)φ, (6.2.2)
∇ · v = (km(c)− (1− δ)kd(c))φ = b(c)φ, (6.2.3)
where dimensionless δ is constant equal to “deal cell volume / live cell volume” and use
shorthand for the differential operators such that ∇ is the 1-D radially symmetric grad
operator, so ∇Z = ∂Z
∂r
and ∇ · Z = 1
r2
∂ r2Z
∂r
.
The boundary conditions are
t = 0 R = R0, φ = φ0, (6.2.4)
r = 0 v = 0,
∂c
∂r
= 0,
r = R(t)
dR
dt
= v, c = C0,
where φ0, C0 and R0 are constants. The birth km(c) and death kd(c) rate functions are
assumed to be
km(c) = A
cm1
cm1m + cm1
, kd(c) = B
(
1− φ c
m1
cm1d + c
m1
)
+ αˆcn,
where A,B, cm, cd,m1,m2, αˆc and φ are all constants.
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6.2.2 Acetaminophen Metabolism Equations
For acetaminophen metabolism we return to the model of Chapters 2 and 3. The molec-
ular mass of acetaminophen is approximately 151g/mol and has a diffusion coefficient
of Dp ' 5×10−5 m2/day [90]. This is comparable to the diffusion coefficients of oxygen
(' 2× 10−4m2/day [91]) and glucose (' 6× 10−6 m2/day [92]). Therefore we can treat
acetaminophen diffusion similarly to that of the nutrients in our model (i.e. diffusion
and reaction are in balance), while the rest of the acetaminophen metabolites are locked
inside cells, changing on longer timescales, and therefore will not be quasi-steady. The
equations are thus,
0 = Dp∇2p− φ(kGp+ kSsp+ k450p− kNn), (6.2.5)
∂(φs)
∂t
+∇ · (vφs) = φ(bS − dSs− kSsp)− φkd(c)s, (6.2.6)
∂(φg)
∂t
+∇ · (vφg) = φ(bG − dGg − kGSHng)− φkd(c)g, (6.2.7)
∂(φn)
∂t
+∇ · (vφn) = φ(k450p− kNn− kGSHng − kPSHn)− φkd(c)n, (6.2.8)
∂(φna)
∂t
+∇ · (vφna) = φkPSHn− φkd(c)na, (6.2.9)
subject to the initial conditions
t = 0 p = 0, s = bS/dS, g = bG/dG, n = 0, na = 0, (6.2.10)
r = 0,
∂p
∂r
= 0,
r = R(t), p = Pe(t).
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Variable Description Variable Description
φ(r, t) Live cell fraction p(r, t) Cellular APAP concentration
c(r, t) Cellular nutrient concentration s(r, t) Cellular PAPS concentration
v(r, t) Solid phase velocity g(r, t) Cellular GSH concentration
R(t) Spheroid radius n(r, t) Cellular NAPQI concentration
na(r, t) Cellular protein adducts
Table 6.1: Model Variables
Here, Pe(t) is the external concentration of acetaminophen in the media, which depletes
through uptake and metabolism in the spheroid. The reaction terms are the same as
those found in Chapter 2, with additional loss as cells die. An explanation of the model
variables can be found in Table 6.1.
If we assume that the media containing the spheroid has a constant volume Ve then,
d
dt
((
Ve − 4
3
piR3
)
Pe
)
= − 4piR2Dp ∂p
∂r
∣∣∣∣
r=R
, (6.2.11)
where the right-hand side is the mass flux of APAP into the spheroid. We can then use
this to find an ODE for Pe,
dPe
dt
=
12piR2
3Ve − 4piR3
(
Pe
dR
dt
−Dp ∂p
∂r
∣∣∣∣
r=R
)
. (6.2.12)
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6.2.3 Non-dimensionalisation
We non-dimensionalise as we did in Section 3.1.1, scaling time with the glucuronodation
timescale, and write
t =
tˆ
kG
, r = r0rˆ, c = C0cˆ, v = r0Avˆ, (6.2.13)
p = P ∗0 pˆ, Pe = P
∗
0 Pˆe, s =
bS
dS
sˆ, g =
bG
dG
gˆ, n = P ∗0 nˆ, na = P
∗
0 nˆa, (6.2.14)
where r0 is the radius of a single cell (as opposed to R0) and P
∗
0 is the “normal” dose
concentration, and define the new constants
ε =
k450
kg
, Λ =
A
kG
, Bˆ =
B
A
, βˆ =
r20βA
DcC0
, cˆm =
cm
C0
, cˆd =
cd
C0
, Rˆ0 =
R0
r0
, (6.2.15)
Pˆ0 =
P0
P ∗0
, γˆ =
kGr
2
0
Da
, kˆN =
kN
kG
, αS =
kSbS
dSkG
, φS =
P ∗0 dS
bS
, δS =
dS
kG
, kˆPSH =
kPSH
kG
,
αG =
kGSHbG
dGkG
, φG =
P ∗0 dG
bG
, δG =
dG
kG
, Re = r0
(
3Ve
4pi
)1/3
,
and let km(c) = A kˆm(cˆ) and kd(c) = A kˆd(cˆ). The rescaled equations are, upon dropping
the hats,
∂φ
∂t
+ Λ∇ · (vφ) = Λ(km(c) − kd(c))φ, (6.2.16)
0 = ∇2c − βkm(c)φ, (6.2.17)
∇ · v = (km(c) − (1− δ)kd(c))φ, (6.2.18)
0 = ∇2p − γ φ(p + αSsp + εp − kNn), (6.2.19)
∂(φ s)
∂t
+ Λ∇ · (vφ s) = φ(δS(1− s) − αSφSsp) − Λφkd(c) s, (6.2.20)
∂(φ g)
∂t
+ Λ∇ · (vφ g) = φ(δG(1− g) − αGφG n g) − Λφkd(c) g, (6.2.21)
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∂(φn)
∂t
+ Λ∇ · (vφn) = φ(εp− kNn− αGng − kPSHn)− Λφkd(c)n,(6.2.22)
∂(φna)
∂t
+ Λ∇ · (vφ na) = φ kPSHn − Λφkd(c)na, (6.2.23)
and
km(c) =
cm1
cm1m + cm1
, kd(c) = B
(
1 − σ c
m1
cm1d + c
m1
)
+ αcn. (6.2.24)
The complete initial and boundary conditions are
t = 0 R = R0, φ = φ0, p = 0, s = 1, g = 1, n = 0, na = 0,
r = 0 v = 0,
∂c
∂r
= 0,
∂p
∂r
= 0,
r = R(t)
dR
dt
= Λ v, c = 1, p = Pe,
dPe
dt
=
3R2
R3e −R3
(
Pev − 1
γ
∂p
∂r
)
.
(6.2.25)
For the numerics we note,
∂(φZ)
∂t
+ Λ∇ · (vφZ) = φFZ − Λφkd(c)Z
⇒ φ
(
∂Z
∂t
+ Λv∇Z
)
+ Z
(
∂φ
∂t
+ Λ∇ · (vφ)
)
= φFZ − Λφkd(c)Z,
and from (6.2.1),
∂Z
∂t
+ Λ v∇Z = Fz − Λ km(c)Z, (6.2.26)
for Z = s, g, n, na.
6.2.4 Reformulation for Numerical Solution
We map the equations onto the unit domain r = R(t)ρ, ρ ∈ [0, 1], such that the moving
boundary coordinate corresponds to the fixed position ρ = 1. This leads to the modified
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system
∂φ
∂t
+ Λ
(v − ρR˙)
R
∂φ
∂ρ
= Λφ (km(c) − kd(c)− φ (km(c) − (1− δ)kd(c))),(6.2.27)
0 =
1
ρ2
∂
∂ρ
(
ρ2
∂c
∂ρ
)
− R2 βkm(c)φ, (6.2.28)
1
ρ2
∂(ρ2v)
∂ρ
= R (km(c) − (1− δ)kd(c))φ, (6.2.29)
0 =
1
ρ2
∂
∂ρ
(
ρ2
∂p
∂ρ
)
− R2 γ φFp, (6.2.30)
∂Z
∂t
+ Λ
(v − ρR˙)
R
∂Z
∂ρ
= Fz − Λ km(c)Z, (6.2.31)
where Z = s, g, n, na and Fp = p+αSsp+εp−kNn. The initial and boundary conditions
are
t = 0 R = R0, φ = φ0, p = 0, s = 1, g = 1, n = 0, na = 0,
ρ = 0 v = 0,
∂c
∂ρ
= 0,
∂p
∂ρ
= 0,
ρ = 1
dR
dt
= Λ v, c = 1, p = Pe,
dPe
dt
=
3R2
R3e −R3
(
Pev − 1
γ R
∂p
∂ρ
)
.
(6.2.32)
The complete system consists of 8 PDEs (5 quasi-linear first-order, (6.2.27),(6.2.31); 2
elliptic (6.2.28),(6.2.30); 1 first order spatial, (6.2.29)) and 2 ODEs (for R and Pe).
The program was supplied by the supervisor, being written in Fortran 77 using a
hybrid characteristic method for the first-order PDEs, Numerical Algorithm Group
(NAG) routine D02RAF for the second-order PDE’s and the trapezium method for
the equations for v,R and Pe. The solver uses a predictor corrector type, variable
time-stepping algorithm, whereby the time-step was chosen to satisfy the Courant-
Friedrichs-Lewy (CFL) condition for the first-order PDEs.
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6.2.5 Parameterisation
Spheroid Growth and Decay Rates
Initially, we use the parameters of Ward and King [86] in our model. However, this
model was based upon a cancer cell line, rather than hepatocytes. In order to model
the growth rates of a hepatocyte spheroid, we fit to the data of Curcio et al. [88].
Figure 6.1 plots the non-dimensional spheroid size against survival fraction, we allowed
the spheroid to grow from R(0) = 2 with no external acetaminophen. The green error
bars are the results of experimental data found in the paper and the black line is
the result of our simulations. We obtained a good fit to the data and so will use these
parameters in our upcoming simulations. We note that larger spheroids have less viable
hepatocytes due to nutrients being unable to reach the centre of the spheroid. The set
of new parameters can be found in Table 6.2, all non dimensional constants for the
metabolism equations remain the same as in previous chapters.
Oxygen Zonation
Recall from Figure 1.1 that blood flows into a lobule from the portal field and leaves
via the central vein. As the blood passes through the lobule, the oxygen concentration
changes and as such an oxygen gradient is present. We consider the lobule as three
distinct zones; the periportal, midlobular and centrilobular. The average oxygen con-
centration for each of these zones is 2.95, 2.4 and 1.9 g/cm3 [93] respectively, which in
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Figure 6.1: A plot of non-dimensional spheroid size against cell survival
fraction. The green bars represent the data being fit to, and the black line
is the result of our simulations.
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Parameter Value Parameter Value
φ(r, 0) 1 c(r, 0) 1
s(r, 0) 1 g(r, 0) 1
n(r, 0) 0 na(r, 0) 0
A 0.8 B 1.2
cm 0.37 cd 0.37
σ 0.9 β 0.08
δ 0.5 Re 200
Λ 0.05 αc 10
Table 6.2: Dimensionless Model Parameters and their values, for the stan-
dard simulation.
non-dimensional terms is .37, .3 and .24. In the model, c = c0cc and using our different
oxygen concentrations we scale our parameters such that cc = cd = .37 and then rescale
c0 such that c0 = 1 represents the oxygen concentration in the periportal, c0 = 0.81
represents the oxygen concentration in the midlobular and c0 = 0.65 represents the
oxygen concentration in the centrilobular region.
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6.3 Results
6.3.1 Acetaminophen and Nutrient Distribution
The results presented here model a spheroid of an initial size R(0) in media with fixed
nutrient and drug concentrations. The nutrients and drug diffuse from the media into
the spheroid and then diffuse across the spheroid.
We first investigate how oxygen and acetaminophen distribute themselves across
the spheroid. We expect to see much higher nutrient concentrations at the edge of the
spheroid near our modelled media, and much lower concentrations in the centre where it
is more difficult for oxygen and other nutrients to diffuse. Figure 6.2 plots the nutrient
and acetaminophen concentration against the distance from the spheroid centre, x at
time t = 30. We see that oxygen concentration is distributed as we expected, with
much higher concentrations at the edge of the spheroid than at the centre. We also
see that acetaminophen is uniformly distributed across the spheroid due to its rapid
diffusion, as such we would not expect any one area of the spheroid to see higher doses
of acetaminophen, but damage to hepatocytes will not be evenly distributed due to the
effects of oxygen concentration on NAPQI formation. Figure 6.2 also plots the live cell
fraction against the distance from our spheroid centre. We see that at the centre of the
spheroid, approximately 30% of hepatocytes are viable, increasing as we move towards
the outer edge of the spheroid. Due to the low nutrient concentrations at the centre
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of the spheroid, less cells are viable compared to at the edge of the spheroid where
nutrient concentrations are much higher.
Figure 6.3 plots time against radius and time against survival fraction in the case
where there is no added acetaminophen. We observe that while the radius increases
linearly, the survival fraction decreases over time. This suggests that while the spheroids
keep growing, the number of viable cells decreases with time. We also note that higher
oxygen concentrations lead to higher growth rates and a higher number of viable cells
at the end of our simulations.
Figure 6.4 plots time against the spheroid radius and the necrotic core radius with
no external acetaminophen dose, in our model we parameterise such that a necrotic
core forms when φ = 0.1. We see that the necrotic core is not present until the radius
of the spheroid is approximately R = 35, which is 175 µm in dimensional terms. The
average spheroid radius Glicklis et al. [83] presented in their paper was approximately
100 µm. In our model, a necrotic core only forms at very large spheroid radii, in the
simulations presented, our spheroids do not reach this size and therefore we do not
expect a necrotic core to be present.
6.3.2 Acetaminophen Simulations
We now simulate the spheroids with differing doses of acetaminophen in the external
media. The simulations were run with an initial spheroid size R(0) = 15 (approx-
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Figure 6.2: Plot of nutrient, APAP concentration and live cell fraction vs
distance from spheroid centre x at t = 30.
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Figure 6.3: Plot of time vs. spheroid radius (top) and survival fraction
(bottom) for Pe = 0, R(0) = 15. Oxygen concentrations were c0 = 1 (black),
c0 = 0.86 (red) and c0 = 0.65 (green).
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Figure 6.4: Plot of time vs. spheroid radius (black) and necrotic core radius
(red) for Pe = 0, R(0) = 20. In our model we parameterise such that a necrotic
core forms when φ = 0.1
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imately 75µm in dimensional terms), and our three differing oxygen concentrations;
the spheroids were then allowed to grow until t = 10, at which point the simulated
spheroids were treated with acetaminophen. We first plot time against P (0, t), S(0, t),
G(0, t), N(0, t) and C(0, t) as in previous chapters, for Pe = 1 and Pe = 4 with c = 1.
As Pe is maintained at its initial level we expect high levels of conjugates and NAPQI
as well as low levels of PAPS and GSH. We observe this in Figure 6.5, and as expected
from a dose like this maintained over a long time period, we see PAPS and GSH fall
to low levels upon introduction of APAP to the external media. NAPQI reaches high
steady state levels and conjugates grow linearly as expected from the model design.
The left hand graphs of Figure 6.6 show the results of the introduction of a dose
of Pe = 1 at t = 10, we note that this is the same “safe dose” that we have used in
previous chapters. We see that the introduction of acetaminophen has little effect on
the growth of the spheroid over time, or the survival fractions for the different oxygen
concentrations are slightly lower at t = 30. From these simulations it appears that at
a safe dose, acetaminophen has little effect on the growth of the spheroid.
The right hand graphs of Figure 6.6 simulates a treatment of Pe = 4 at t = 10,
which would represent a 16g dose in the non-dimensional case, as modelled in the
previous chapters. We again see that acetaminophen has little effect on the radius
of the spheroid, although the radius is slightly lower at t = 30 in these simulations.
However, we now see a more pronounced effect on the survival fraction of the cells. At
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t = 10 when acetaminophen is introduced to the spheroid we see the rate at which cells
die increase and see lower numbers of surviving cells at the end of our simulations.
Figure 6.7 plots the live cell fraction, φ, against the distance from the spheroid
centre x for our two different dosing regimens at t = 30. We observe little difference
between the two graphs, indicating that in our model the dose has little effect on the
distribution of live cells through the spheroid. We note that these two graphs are almost
identical to the case with no dose shown in Figure 6.2.
6.3.3 NAPQI Related Effects
We now modify the model to include the fact that NAPQI production has a depen-
dance on oxygen concentration in the spheroid. Yan et al. [89] suggests that NAPQI
production is reduced in low oxygen conditions, reaching approximately 30% of normal
levels in low oxygen environments. To model this we rewrite our equations for PAPS
and NAPQI as
0 = ∇2p − γ φ(p + αSsp + γc(c)εp − kNn), (6.3.1)
∂(φn)
∂t
+ Λ∇ · (vφ n) = φ (γc(c)εp − kNn − αG n g − kPSHn) − Λφkd(c)n.
Here, γc(c) = 0.3 + 0.7c(r, t), so that at low oxygen concentrations, the rate constant is
approximately 30% of , our rate constant for NAPQI formation in past models. We use
Pe = 4, R(0) = 15 as before, introducing acetaminophen at t = 10 and simulating until
t = 30. In Figure 6.8 we see the results of this simulation. Compared to the right hand
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Figure 6.5: Plot of time vs. variable concentrations for Pe = 1, R(0) = 15
(left) and Pe = 4, R(0) = 15 (right) with oxygen concentration c0 = 1 at the
spheroid edge.
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Figure 6.6: Plot of time vs. spheroid radius (top) and survival fraction
(bottom) for Pe = 1, R(0) = 15 (left) and Pe = 4, R(0) = 15 (right). Oxygen
concentrations were c0 = 1 (black), c0 = 0.86 (red) and c0 = 0.65 (green). The
dashed line indicates the time at which APAP is introduced.
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Figure 6.7: Plot of distance from spheroid centre, x vs the live cell fraction
φ for Pe = 1 (left) and Pe = 4 (right) at t = 30.
side of Figure 6.6 we see little effect on the growth of the spheroid over time, however
we see that the survival fraction does not decrease as quickly when acetaminophen
is introduced. As expected, if NAPQI is dependent on oxygen concentration, then
less NAPQI is produced in total due to low oxygen environments in the centre of the
spheroid. As NAPQI binds with proteins and leads to hepatocyte death, it is important
that this effect is included in the model and in vitro experiments quantifying exactly
how much of an effect this has in a spheroid would be important for the model to have
predictive value.
In Figure 6.9, αc, the rate at which NAPQI kills cells has been increased from 10 to
100. As in the previous simulation, we use Pe = 4 and R(0) = 15. We observe that the
introduction of acetaminophen at t = 10 now has a large effect on the growth of the
180
spheroid, decreasing the growth rate substantially. In the high oxygen concentration
case (black line) we see that the survival fraction at t = 30 has fallen from ∼ 65%
to ∼ 40% and the rate at which cells become non-viable after the introduction of ac-
etaminophen has increased. This result suggests that NAPQI has an important role to
play in spheroid growth and associated cell survival in spheroid experiments, and quan-
tifying the rates at which NAPQI kills hepatocytes in these experiments is important to
ensure physiologically relevant results from the model. We also observe that the live cell
fraction is lower throughout the spheroid compared to previous simulations, and due
to the modelling of oxygen dependence in the oxidation of acetaminophen, we see more
NAPQI accumulating towards the spheroid edge due to higher oxygen concentration.
6.4 Discussion
In this chapter we have presented preliminary results from an in silico model of ac-
etaminophen metabolism in a spheroid. Spheroids can be used to give more phys-
iologically relevant results in vitro versus a 2D cell culture, due to more accurately
representing the physical properties of organs and tissue within the body. As such, a
mathematical model that can describe a spheroid in silico could provide insights in to
potential experiments and data gaps in the literature. We presented a multivariable
PDE model which describes both the growth of the spheroid and the metabolism of
acetaminophen as it diffuses through the cells.
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Figure 6.8: Plot of time vs. spheroid radius (top) and survival fraction
(bottom) for Pe = 4, R(0) = 15 and including the new γ(c) term. Oxygen
concentrations were c0 = 1 (black), c0 = 0.86 (red) and c0 = 0.65 (green). The
dashed line indicates the time at which APAP is introduced.
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Figure 6.9: Plot of time vs. spheroid radius (top left), survival fraction (top
right) for Pe = 4, R(0) = 15, αc = 100 and live cell fraction (φ) and NAPQI
against distance from spheroid centre x at t = 30. Oxygen concentrations
were c0 = 1 (black), c0 = 0.86 (red) and c0 = 0.65 (green). The dashed line
indicates the time at which APAP is introduced.
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We parameterised the model to obtain a good fit with data from the literature,
and then used differing oxygen concentrations to capture the zonation present in a liver
lobule. We found that the oxygen distribution behaved as expected, with a much higher
oxygen concentration towards the outside of the spheroid, and a low concentration
towards the centre. We also found that due to its quick diffusion rate, acetaminophen
distributes uniformly through the spheroid, therefore we would expect all hepatocytes
in the spheroid to have similar concentrations of acetaminophen and damage from high
doses would be spread throughout the culture.
Our simulations of acetaminophen metabolism in the spheroid show that even at
high doses, with the initial parameter set used, the effect on the growth rate on the
spheroid was minimal. In all the simulations, we found that although the radius of the
spheroid was not affected, the survival fraction was, indicating that while the spheroid
may continue growing, the number of viable cells decreases over time and that higher
doses of acetaminophen lead to lower survival fractions. We found that the dependence
on oxygen for cells to grow and survive meant that lower oxygen concentrations led to
less growth and a lower total survival fraction.
The effect of oxygen concentration on NAPQI production was investigated and we
found that if NAPQI production is significantly affected by low oxygen environments,
then the number of surviving hepatocytes at the end of our simulations is higher. We
also found the rate at which NAPQI contributes to cell death to be very important in
184
our model. Increasing αc, the constant which dictates how quickly NAPQI kills cells in
the spheroid, led to much slower overall growth as well as far lower numbers of surviving
cells at the end of the simulations. This highlights potential experiments which could
be followed up in vitro to improve the accuracy and predictive value of our model.
In future we hope that this work can be paired with in vitro experiments with
spheroid cultures, so that the conclusions of this section can be tested in actual hepa-
tocytes. Of particular interest is how much NAPQI contributes to cell death in an in
vitro culture. We note that in this preliminary model, we predict too little difference
in growth and survival fraction between the different regions of the liver lobule to be
discerned in experiments. Furthermore, with the kinetics presented in this chapter,
we find that damage in the liver is likely to be fairly uniform, and not dependent on
position in the lobule. However, more data is needed on oxygen dependence of the
kinetics to be certain of this conclusion. Experiments of this nature could help better
parameterise the model, which would in turn lead to the model being able to provide
more accurate predictive results for future experimental work.
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Chapter 7
In Vitro to In Vivo extrapolation
7.1 Introduction
As the need to reduce the number of animals in animal testing increases, whilst the
need for more compounds to be tested increases alongside it, physiologically relevant
in vitro methods are becoming more necessary. In vitro methods not only reduce
the number of animals being used in experiments, but also reduce the amount of time
taken per experiment. All of the models presented throughout this thesis have a similar
problem in parameterisation, in part because some parameters simply are not tested
for in the literature, and some because the parameters come from other species and so
their applicability to human models must be questioned.
Most mathematicians are not trained to work in labs and perform experimental
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work, and biologists do not possess the training to create mathematical models that
they can parameterise and use to further their experimental work. In order to improve
efficiency in drug discovery, more researchers from both sides of the mathematical bi-
ology field need to take a multidisciplinary, collaborative approach to their research.
The following section is the first step towards this multidisciplinary approach in our
modelling.
In our initial model, presented in Chapter 2, we found that the sulphation pathway
of acetaminophen metabolism was not well paramterised in the literature, and therefore
parameterisation of this pathway in the model was difficult. In this chapter we present
the results of a short two week experiment which aimed to quantify the parameter
kS, the rate constant for sulphation in our model, in human liver cytosol. Cytosol is
a sub cellular fraction, derived from the liver, which contains metabolic enzymes and
can therefore be used to assess in vitro metabolism of drugs. These experiments could
also be performed on similar cellular fractions from rats or mice. Most importantly,
studying metabolism in this way forgoes the need for animal models. The aim of the
study is to assess the sulphation pathway of acetaminophen metabolism, through use of
liquid chromatography-mass spectrometry (LC-MS), a method of separating, analysing
and identifying chemicals. We intend for this to provide us with a usable parameter for
kS in human models which can be used in future mathematical work.
In this chapter we present our experimental methods and discuss the results of these
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experiments in the context of mathematical modelling.
(N.B. To provide a more detailed description of the experimental process for those
unfamiliar with these types of experiments, we have included a glossary for a number
of the terms used in this chapter, found in Appendix D.)
7.2 Materials and Methods
7.2.1 Materials
Human liver cytosol was obtained from Corning (Amsterdam, Netherlands). Acetoni-
trile, methanol and LC-MS grade water were purchased from Fisher Scientific (Lough-
borough, UK). Unless otherwise stated, all reagents were obtained from Sigma-Aldrich
Chemical Co. (Poole, U.K).
7.2.2 Cytosol incubation: APAP sulphation in human cytosol
We used Corning UltraPoolTM Human Cytosol 150 cytosols, which were tested with a
coumarin substrate assay and expressed an activity of 470 pmole product/(mg protein x
minute). The cytosolic fraction was stored at -80◦C and quickly thawed just prior to use.
Incubations were performed in triplicate and on three separate occasions and contained
APAP (50µM), PAPS (50µM) or both. Cytosol (1mg/ml in 1.8ml) incubations were
carried out in a final volume of 1.8ml with 5 mM stock concentration of APAP in 0.08M
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phosphate buffer (13.08mM potassium di-hydrogen orthophosphate and 67.27mM di-
sodium hydrogen orthophosphate at pH 7.4) for a final concentration of 50µM. Control
incubations contained either only PAPS or only APAP, with the remaining volume
made up by the phosphate buffer and cytosol. After 0, 5, 10, 15, 30, 45, 60 and 80
minutes of incubation at 37◦C in a shaking water bath, the reaction was terminated by
the addition of an equal volume of ice cold acetonitrile and stored at -20◦C.
7.2.3 Sample preparation for LC-MS
Following incubation, all samples were stored at -20◦C for at least 30 minutes. After
this, the samples were centrifuged at 2200RPM for 10 minutes. The supernatant was
then removed and evaporated to dryness under nitrogen in a water bath at 37◦C. The
samples were then reconstituted with 200µL of 5% methanol and returned to the freezer
at -20◦C for a further 20 minutes. All samples were then centrifuged at 13900RPM for
10 minutes at 4C. Our standards contained 12µL APAP-S, 12µL AMAP and made up
to a final volume 120µL with 5% MeOH for a final concentration of of 0, 2, 5, 10, 20,
50, 100 and 250nM APAP, the samples from 60 and 80 minutes were prepared at a 1
in 2 dilution.
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7.2.4 LC/MS/MRM Analysis
In order to characterize the products of metabolic sulphation of APAP in human liver
cytosol (1 mg/ml) the drug was incubated and prepared as per the above sections.
Samples were analysed using a 4000 Q-Trap (AB Sciex, Framingham, MA). Chromato-
graphic separation was performed on a Gemini C-18 (4.6 mm x 250 mm x 5 µm) column
(Phenomenex, Macclesfield, UK). Mobile phase A was 5mM ammonium formate and
0.05% formic acid (FA); mobile phase B was 100% acetonitrile. The analytes were
eluted from the column using a gradient of acetonitrile (described in Table 7.1) with
a flow rate of 1ml/min split to 200 µL/min. The mass spectrometer was operated in
negative-ion mode. Nitrogen was used as the nebulizing gas and the source was oper-
ated at 400◦C. Quantification of APAP-S was based on the ratio of analyte to internal
standard peak areas against a calibration curve from our standard samples described
in the previous section. All data was processed using Analyst 1.5.2 software.
7.3 Results
7.3.1 Rate constant for Sulphation
The experiment was run 3 times with 7 samples per time point per experiment. Fig-
ure 7.1 plots the average results of the experiments. We find that the results of APAP-S
accumulation vs. time is linear and the gradient of the resulting graph gives us a pro-
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Table 7.1: Buffer gradient for LC-MS analysis
Time (mins) A. 5mM Ammonium Formate 0.05% FA B. Acetonitrile
0 95% 5%
1 95% 5%
6 55% 45%
8 48% 52%
8.5 48% 52%
10 95% 5%
14 95% 5%
duction rate for APAP-S of 1.63 nmol ·L−1·min−1.
Assuming abundant APAP and PAPS in the experiment, so only a tiny fraction is
used; we can write this as
A˙ = kSP0S0,
where
P0 = S0 = 5× 10−5 mol · L−1, A˙ = 1.63 nmol · L−1 ·min−1.
Using this we can find a value for kS in terms of the given units,
kS = 0.65 L ·mol−1 ·min−1,
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and given that there are 8.9× 1010 cells/L in humans [80] we find
kS = 8.3× 1013 cell ·mol−1day−1.
In Section 2, we used
kS = 2.26× 1014 cell ·mol−1day−1.
which we arrived at through assumptions and simulations. We see that this initial
parameter is pleasingly close to the results we have achieved through our experiments.
7.3.2 Comparison of simulations with new kS
In Figure 7.2 we compare the affects of the new kS parameter on our model. Due
to kS not being involved in the major timescales, as discussed in Section 3.5, we do
not expect a change in this parameter to have a large influence on our model output.
However, as we see in Figure 7.2, the new value for kS leads to higher minimum levels
of PAPS in response to a 4g bolus dose. We also observe that the minimum PAPS
levels are higher in the 16g case, although it is less pronounced. A slightly slower
rate of binding between PAPS and acetaminophen leads to less depletion of PAPS,
as expected. Figure 7.3 plots conjugate vs time simulations for the different values of
kS, we find that for a 4g bolus dose, kS being lower increases the total amounts of
conjugates being produced (2.3 × 10−16 vs. 2.6 × 10−16) however the conjugate levels
still remain low and as discussed in Section 3.5, doses of this level can not deplete GSH
stores even with lower kS. We see in the overdose case that the differences between the
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Figure 7.1: Average results of experiments plotting APAP-S concentration
against time.
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maximum conjugate levels for our two kS parameters is negligible, as expected as kS
does not feature in our analytical solution for maximum conjugates discussed in Section
3.5.6.
7.4 Discussion
In order to improve the efficiency and accuracy of mathematical models of drug metabolism,
a multi-disciplinary approach needs to be taken. Models can inform experiments and
experiments improve models, creating a positive feedback loop and leading to better
results. Working in larger groups and projects where mathematicians and biologists
can communicate ideas freely is a step on the ladder towards this, but having mathe-
maticians trained to carry out simple lab work, and biologists with an understanding of
basic modelling will allow researchers from both sides of mathematical biology to work
more closely together, and understand their collaborators’ disciplines more deeply.
Although acetaminophen is a popular and widespread drug, metabolic parameters
for humans are not necessarily available in the literature and as such the gaps in models
have to be filled in through assumptions and simulation, which could affect the ability
of the model to make accurate predictions. The sulphation pathway was identified to
be one of the gaps in the parameterisation of acetaminophen metabolism through our
early work and as such we decided to focus on parameterising this pathway first.
The rate constant for sulphation was explored through experiments using human
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Figure 7.2: Comparison of PAPS simulations for safe and overdose cases
with kS = 2.26× 1014 (top) and kS = 8.3× 1013 (bottom).
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Figure 7.3: Comparison of Conjugate simulations for safe and overdose cases
with kS = 2.26× 1014 (top) and kS = 8.3× 1013 (bottom).
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cytosol, utilising various concentrations of PAPS and APAP, and tested against a stan-
dard curve to find the rate at which APAP-S was produced. LC-MS analysis was used
to assess the change in concentration of APAP-S in the medium and we then used these
results to find a value for kS.
The results of the experiments were promising, we achieved the goal of identifying
the rate constant for Sulphation in our model and laid the groundwork for further
experimentation. Unfortunately, due to limited lab time and supervision, we were only
able to spend two weeks in the lab and so were unable to run further experiments.
In conclusion, we were able to further parameterise our model through non-animal
experiments, by combining mathematical modelling with experimental work. This work
provides the framework for further experimentation for mathematical models, improv-
ing the value of their predictions. The work highlights a need for multi-disciplinary
researchers who can design both models and experiments in order to produce models
with good parameterisation that provide valuable real world results.
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Chapter 8
Conclusions and Further Work
8.1 Conclusions
This thesis has been focused on a variety of mathematical models for acetaminophen
metabolism. Starting from relatively simple single cell models, we have introduced more
complex metabolic effects and studied how these affect the outcomes of the model. We
have used a variety of mathematical techniques to analyse these models in order to
gain new insights into acetaminophen metabolism through in silico modelling. The
motivation for this work was a need for more advanced methods of drug testing and
development, to be used in conjunction with in vitro and in vivo models with the aim of
providing a framework which can be built upon for testing other drugs and chemicals.
In Chapter 1 we presented a brief background on drug development in the phar-
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maceutical industry, highlighting the vast amount of effort that goes in to bringing a
drug to market, as well as explaining the drawbacks of the current methodology. We
discussed the reliability of animal models as a predictor of adverse drug reactions in
humans and went on to outline the need for new approaches to the modelling of hepa-
totoxicity. We also introduced the 3R’s, a vision that seeks to reduce, refine or replace
animals being used in testing for research. We then went on to present a basic overview
of acetaminophen metabolism.
Chapter 2 contained discussion on past models of acetaminophen metabolism, high-
lighting the drawbacks of certain methodologies with respect to more advanced analyt-
ical techniques, and explaining how our model differs from those currently available in
the literature. We then present the first of the mathematical models in this thesis, a
single cell model of acetaminophen metabolism and toxicity. While this model was rel-
atively simple, the simulations captured the various biological dynamics that we would
expect to see in vivo. We explored a number of different dosing regimens, beginning
with bolus doses and then examining how these differ to multiple smaller doses, which
more accurately reflect how people generally self-administer acetaminophen. We found
that doses that exceeded what we classed as a ‘safe’ dose by as little as 10% could begin
to lead to a large accumulation of toxic conjugates which would indicate that the liver
is being damaged. We then went on to analyse the sensitivity of the model through
latin hypercube tests as well as Sobol sensitivity testing, which revealed that oxidation
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and glucuronidation were the pathways which had the largest affect on conjugate ac-
cumulation. This model also highlighted gaps in the parameter set, which can be used
to inform future in vitro tests.
In Chapter 3 we use the same model, however this time we apply singular pertur-
bation analysis with the intention of identifying critical timescales in acetaminophen
metabolism. This analysis provided a number of key insights, including the identifi-
cation of a critical acetaminophen concentration, above which we find GSH depletes
leading to high levels of NAPQI which can then bind with cellular protein, damaging
hepatocytes. We also derived expressions for the timescales of sulphate and GSH ex-
haustion and recovery as well as total protein conjugates, C∞. The work in Chapters
2 and 3 was published in the Journal of Theoretical Biology as “Timescale analysis of
a mathematical model of acetaminophen metabolism and toxicity” [1].
In Chapter 4 we introduced Nrf2 adaptation to our model, and expanded the model
to include the GSH/GSSG system. Nrf2 adaptation increases both the production of
GSH as well as the reduction of GSSG to GSH in response to oxidative species such as
NAPQI. This adaptation was hypothesised to be responsible for the experimental results
seen in Figure 4.4. We verified that Nrf2 adaptation reduced NAPQI and conjugate
levels in the model and then proceeded to examine a chronic infusion scenario, where
acetaminophen is introduced to the cell at a constant rate over time. We found a steady
state solutions to the model and identified a critical infused dose; when acetaminophen
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is infused at a rate below this dose we found that GSH levels did not deplete and
therefore we would expect liver damage to be negligible. However above this dose we
found that GSH levels dropped an order of magnitude, increasing the amount of NAPQI
present in the system. We concluded that Nrf2 adaptation does in fact decrease toxicity
as well as also decreasing the sensitivity of the model to the parameters identified in
the previous chapter. We also found that relatively low chronic doses of approximately
O() could deplete GSH.
In Chapter 5 we presented a full-body PBPK model, parameterised for a rat. PBPK
models give further insight into the distribution of drugs across the whole body of an
animal, rather than a specific organ such as the liver. We built upon the model presented
in Chapter 4, adding three compartments; the blood, liver and a ‘rest’ compartment,
intended to describe the absorption across the other organs in the body. We used DDE’s
to test whether a delay in Nrf2 adaptation in the GSH/GSSG system affected the model
and found that this caused greater buildup of NAPQI and conjugates, leading to higher
levels of hepatotoxicity. We then altered the model parameters, increasing k450, kN , dNB
and dR, and found that we could qualitatively reproduce the experimental results of
our collaborators. We concluded that within the confines of our model, this meant that
either Nrf2 adaptation was not the cause of the increase and subsequent decrease in
blood acetaminophen levels, or that the parameters we originally used in our model
need to be reexamined. In the future this model could be reparameterised for different
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species, to look at the differences in metabolism between rodents and humans, or any
other animal as mentioned in the next section.
In Chapter 6 we presented a model of acetaminophen metabolism in a spheroid.
Spheroids can be used in vitro as a more accurate analogue to organs than a 2D cell
line. We achieved a good fit with the data from the literature and proceeded to examine
how oxygen distribution affects metabolism. We found that lower oxygen environments
slowed the growth of the spheroid and decreased the survival fraction over time. We also
investigated the effects that NAPQI has on cell death and how low oxygen environments
decrease NAPQI production. The work in this chapter was preliminary, but identified
a number of factors that would be important if further modelling was to be undertaken.
If we intended to combine this work with in vitro spheroid experimentation, it would
be important to explore both how much NAPQI contributes to cell death, as well as
how different oxygen concentrations affect NAPQI production.
Finally in Chapter 7 we presented an overview of experimental work performed on
human liver cytosol. The aim of this experiment was to find new parameters for our
model using human hepatocytes. Although the work was brief due to the amount of
time available to us in the lab, we were able to find a value for kS, which can be used
in future models. Combining in silico and in vitro models is an important step in
improving the reliability of non-animal models in drug testing and development, and
this work provided a first step towards this goal.
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8.1.1 Further Work
The models presented in this thesis are designed to be simple enough that more ad-
vanced analytical techniques such as singular perturbation analysis can be performed,
while still capturing the dynamics we expect to be present in an in vivo environment.
The advantage of starting simple is that the models can be built upon to include new
effects while knowing that the foundations upon which these models are built are math-
ematically sound. In this section we present a number of possible areas where these
models could be expanded to give new results and interesting insights.
• As mentioned in Chapter 1, phenol related drugs are metabolised via sulphation
and glucuronidation. As such, the model presented in Chapter 2 could be adapted
to a number of different drugs. The model would have to account for whether
the drug is oxidised or metabolised in a different way alongside sulphation and
glucuronidation.
• The model presented in Chapters 2 and 3 examines metabolism in a single hep-
atocyte. However, this could be expanded to model the whole liver, explicitly
modelling hepatocyte numbers and linking NAPQI-protein binding to cell death.
This model could then be combined with any of the other models here, to examine
the affects of Nrf2 adaptation for example.
• The Nrf2 adaptation model presented in Chapter 4 can also be analysed with
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singular perturbation theory in a similar way to the model in Chapter 3. This
could give further insight in to how exactly Nrf2 reduces the total number of
conjugates.
• Our PBPK model can be used to model a number of different species, providing
the differences in how they metabolise acetaminophen are well known. Pharma-
cokinetic parameters are known for most species used in testing. This can be used
to examine the differences in acetaminophen metabolism between species, and,
given the right parameters, be used to extrapolate in vitro data from one species
to in vivo results in another.
• The work presented in Chapter 6 on our spheroid model was only preliminary,
and much more work could be done examining the differences spatial factors have
on acetaminophen metabolism.
• Parameterisation of a model is generally one of the biggest challenges in providing
biologically relevant results. More in vitro work with the aim of better param-
eterising these models, carried out collaboratively by both mathematicians and
biologists ensures that models are both biologically relevant and mathematically
sound. For example, the parameters k450 and kN are presumed to be relatively
small compared to those describing glucurodination and sulphation, this may not
be the case as the work presented in Section 5.3.2 shows. When we increased these
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parameters we found that we were able to reproduce the results of our collabo-
rators experiments, and so this presents potential experimental work that could
improve our models.
In conclusion, we have presented a number of different models of acetaminophen
metabolism which can be used to assess toxicity across a variety of species. It is hoped
this work can be used as a framework for further improvement of in silico modelling
of drug metabolism, which can then can be combined with in vitro experimentation
to produce results similar to those in vivo, reducing the use of animal models in drug
development.
Appendices
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Appendix A
Sobol Sensitivity Indices
Sobol indices describe the impact a given parameter Xi has on a given model output. In
this appendix we first explain how these indices are found mathematically, and then how
we compute them for our model. We view the model as a function Y = f(X), where
we define X as a vector of p parameters randomly selected from the given parameter
space, and Y as our model output, C∞ or maximum conjugate levels, in our analysis.
It is then possible to decompose our function as
f(X) = f0 +
p∑
i=1
fi(Xi) +
p∑
i<j
fij(Xi, Xj) + ...+ f1,2,...,p(X1, ..., Xp).
Here, f0 is a constant, fi is a function of Xi, fij is a function of Xi and Xj and so on.
We note that a condition of this decomposition is
∫ 1
0
fi1...in(Xi1 , ..., Xin)dXk = 0, for k = i1, ..., in,
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such that all terms in the decomposition are orthogonal. We can then define the terms
of this decomposition as conditional expected values,
f0 = E(Y ),
fi(Xi) = E(Y |Xi)− f0,
fij(Xi, Xj) = E(Y |Xi, Xj)− f0 − fi − fj.
We see that fi is the effect of only varying Xi, known as the main effect, and fij is
the effect of varying both Xi and Xj at the same time in addition to the effect of their
individual variations. Assuming that∫ ∞
−∞
|f(X)|2dx 6=∞,
We can square and integrate our decomposition to find,∫ 1
0
f 2(X)dX − f 20 =
p∑
n=1
p∑
i1<...<in
∫
f 2i1,...,indXi1 ...dXin .
The left hand side of this equation is equal to Var(Y) and the terms on the right hand
side are variance terms which are decomposed with respect to the sets of Xi. We can
write this as
V ar(Y ) =
p∑
i=1
Vi +
p∑
i<j
Vij + ...+ V12...n,
where,
Vi = V arXi(EX∼i(Y |Xi)),
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Vij = V arXij(EX∼ij(Y |Xi, Xj))− Vi − Vj.
Here, X∼i indicates the set of parameters not including Xi. This decomposition shows
that the variance of a given output, Y , can be decomposed into terms related to each
input and the interaction between them. We then define our main effect index as
Si =
Vi
V ar(Y )
,
which gives the contribution of the parameter Xi, averaged over variations in other
input parameters (i.e. X∼i) and standardised by dividing through by total variance to
give a fractional contribution. Our total effect index is then
STi = 1−
V arX∼i(EXi(Y |X∼i))
V ar(Y )
,
which gives the contribution of variations in Xi, including variance caused by its inter-
actions with other parameters.
In order to compute the indices, two M × p (where p is the number of parameters
and M is the total number of parameter sets) matrices are generated, each containing
parameter values selected randomly and uniformly from a defined distribution. These
two matrices are defined as A and B. Further matrices are then formed by all columns
of B except the ith column, which is taken from matrix A, we call these matrices Ci.
Each row of these matrices contains a full parameter set for our model, and the output
for maximum conjugates, C∞, from these parameter sets is then collected in three vec-
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tors; yA = f(A), yB = f(B), yCi = f(Ci).
First order sensitivity indices are found as follows:
Si =
Vi
V (Y )
=
yA · yCi − f 20
yA · yA − f 20
=
(1/N)
∑N
j=1 y
(j)
A y
(j)
Ci
− f 20
(1/N)
∑N
j=1(y
(j)
A )
2 − f 20
,
where
f 20 =
(
1
N
N∑
j=1
y
(i)
A
)2
is the mean, and · denotes the scalar product of two vectors. We calculate STi similarly:
STi = 1−
V [E(Y |X∼i)]
V (Y )
= 1− yB · yCi − f
2
0
yA · yA − f 20
= 1− (1/N)
∑N
j=1 y
(j)
B y
(j)
Ci
− f 20
(1/N)
∑N
j=1(y
(j)
A )
2 − f 20
.
These formulae work to find our indices because in the scalar product yA ·yCi , values
of Y that are an output from matrix A, are multiplied by values of Y where all factors
except Xi are resampled, while values of Xi remain the same. Therefore, if Xi has
little influence on the output, then small and large values of yA and yCi are randomly
associated. However, if Xi is influential, large or small values of yA will be multiplied
by large or small values of yCi , increasing the value of the scalar product. Similarly, the
scalar product for yB · yCi gives the first order index of non-Xi.
Appendix B
Full Timescale Analysis
B.1 A Primer on Matching Timescales
The perturbation analysis we present here is used to examine individual ‘slices’ of time
in a model simulation. However, these timescales are only valid when the leading order
term of our solutions is of a different size to its correction term. For example if we have
a variable X, and are looking at an initial timescale where t = O(2), such that time is
rescaled as t = 2τ we might have a solution for X of the form
X(τ) ∼ 1 + (f(τ))
Where f(τ) ∼ cτ as τ → ∞, where c is a constant in terms of the model parameters.
Here, as τ → 1/ we see that the correction term will become O(1) and this timescale
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will break down. As such, we see that our next timescale will occur when τ = 1/ and
therefore where t = O() = τˆ .
In our next timescale, when we solve for X we will be left with a constant of integration,
which is found by matching with the previous timescale. This matching takes one of
two cases.
B.1.1 Case 1: Order of magnitude increase
In our example, we see that we match between t = 2τ and t = τˆ . We rewrite our time
variables as
τ = −βT,
τˆ = (1−β)T.
Here, β is an arbitrary constant where 0 ≤ β ≤ 1. Our outer solution, Xˆ, must match
with our inner solution X where X(T ) ∼ 1 + (1−β)cτ as → 0. For example, if
X = 1 + cτ,
Xˆ = 1 + (a1dτˆ),
where a1 is a constant of integration and d is a constant in terms of parameters, we can
use our substations to write
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X = 1 + (1−β)cT,
Xˆ = 1 + (a1
(1−β)dTˆ ).
It is then obvious by matching like powers of  that a1 = c/d.
B.1.2 Case 2: Translation
Another possible scenario occurs when our next timescale is of the same order as the
previous one, but time has moved on by some function, f(τ), and consider the case
where f(τ) ∼ Aebτ as τ → ∞, b > 0, and A and b are both constants in terms of the
model parameters. In this case we see a break down when τ ∼ ln(1/)/b+O(1) and so
we match between t = 2τ and t = 2(ln(1/)/b+ τˆ). We then let
τ = β ln(1/)/b+ T,
τˆ = −(1− β) ln(1/)/b+ T.
Here, β is an arbitrary constant such that 0 ≤ β ≤ 1. This implies that if β = 0, τ = T
and τˆ = T − ln(1/)/b, and that if β = 1 that τ = T + ln(1/)/b and τˆ = T . Here, our
inner solution is of the form
X(T ) ∼ 1 + Aebτ = 1 + Aeb(β ln(1/)/b+T ) = 1 + (1−β)AebT ,
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and our outer solution Xˆ must match with this as  → 0. An example of this can be
found in Timescale 3 of our analysis.
B.2 Full Timescale Analysis
To analyse the full system we express our parameters in terms of a small parameter 
which in our analysis is equal to kˆ450/kˆG = 0.105 such that all parameters other than 
are O(1). Using these rescalings our system of equations becomes
dpˆ
dtˆ
= −αˆS sˆpˆ− pˆ− pˆ+ 2kˆN nˆ, (B.2.1)
dsˆ
dtˆ
= − αˆSφˆS sˆpˆ

+ δˆS(1− sˆ), (B.2.2)
dnˆ
dtˆ
= pˆ− 2kˆN nˆ− kˆPSH

nˆ− αˆG
3
nˆgˆ, (B.2.3)
dgˆ
dtˆ
= − αˆGφˆG
4
nˆgˆ + δˆG(1− gˆ), (B.2.4)
dcˆ
dtˆ
=
kˆPSH

nˆ, (B.2.5)
we then look at each timescale individually, identifying key events and changes in
the system. From this point we will drop the hats on our variables to keep things clear.
The drug is introduced into cells as a single bolus dose at t = 0 at a concentration PS.
The cells at this point are assumed to be at pretreatment steady-state level. The initial
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conditions for this system are thus
P (0) = PS, S(0) = 1, G(0) = 1, N0 = 0, C(0) = 0. (B.2.6)
Timescale 1. O(3)
We write
t = 3τ ∗,
p = p∗,
s = s∗,
n = 4n∗,
g = g∗,
c = 6c∗,
with initial conditions p∗(0) = PS, s∗(0) = g∗(0) = 1, n∗(0) = c∗(0) = 0.
This leads to the system
dp∗
dτ ∗
= −3αss∗p∗ − 3p∗ − 4p∗ + 9kˆNn∗,
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ds∗
dτ ∗
= −2αsφss∗p∗ + 3δˆS(1− s∗),
dn∗
dτ ∗
= p∗ − (5kˆN + 2kˆPSH)n∗ − αGn∗g∗,
dg∗
dτ ∗
= −3αGφGn∗g∗ + 3δˆG(1− g∗),
dc∗
dτ ∗
= kPSHn
∗,
we expand the variables as follows
p∗ = p∗0 + p
∗
1 + 
2p∗2 + ...,
s∗ = s∗0 + s
∗
1 + 
2s∗2 + ...,
n∗ = n∗0 + n
∗
1 + 
2n∗2 + ...,
g∗ = g∗0 + g
∗
1 + 
2g∗2 + ...,
c∗ = c∗0 + c
∗
1 + 
2c∗2 + ....
Then the leading order ODE system is
dp∗0
dτ ∗
= 0,
ds∗0
dτ ∗
= 0,
dn∗0
dτ ∗
= p∗0 − αGn∗0,
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dg∗0
dτ ∗
= 0,
dc∗0
dτ ∗
= kPSHn
∗
0.
Solving the ODE’s using our initial conditions we arrive at our leading order values
p∗0 = PS,
s∗0 = 1
n∗0 =
PS
αG
(1− e−αGτ∗),
g∗0 = 1,
c∗0 =
kˆPSHPS(αGτ
∗ + e−αGτ
∗
+ 1)
α2G
.
The first non trivial correction terms for the variables that are constant at leading
order satisfy
dp∗3
dτ ∗
= PS(−1− αS),
ds∗2
dτ ∗
= −αSφSPS,
dg∗3
dτ ∗
= −φGPS(1− e−αGτ∗).
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Again solving these ODE’s gives
p∗3 = PS(1− (αS + 1)τ),
s∗2 = −αSφSPSτ,
g∗3 = −
φGPS(αGτ
∗ + e−αGτ
∗ − 1)
αG
.
Hence,
p∗ ∼ PS + 3(PS(1− (αS + 1)τ ∗)),
s∗ ∼ 1 + 2(−αSφSPSτ ∗),
g∗ ∼ 1 + 3(−φGPS(αGτ
∗ + e−αGτ
∗ − 1)
αG
),
n∗ ∼ PS
αG
(1− e−αGτ∗),
c∗ ∼ kˆPSHPS(αGτ
∗ + e−αGτ
∗
+ 1)
α2G
.
When τ ∗ becomes O(1/2), i.e. t = O(), we see that the correction term for s∗
becomes the same order as its leading term and the solutions for this timescale break
down.
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Timescale 2. O()
For this timescale we write
t = τ¯ ,
p = p¯,
s = s¯,
n = 4n¯,
g = g¯,
c = 4c¯,
and use these new scalings to rewrite our ODE’s
dp¯
dτ¯
= −αss¯p¯− p¯− 2p¯+ 6kˆN n¯,
ds¯
dτ¯
= −αsφss¯p¯+ δˆS(1− s¯),
2
dn¯
dτ¯
= p¯− (5kˆN + 2kˆPSH)n¯− αGn¯g¯,
dg¯
dτ¯
= −αGφGn¯g¯ + δˆG(1− g¯),
dc¯
dτ¯
= kPSH n¯.
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We introduce similar expansions as in the previous timescale, thus the leading order
ODE’s for the system become
dp¯0
dτ¯
= 0,
ds¯0
dτ¯
= −αSφS s¯0p¯0,
dg¯0
dτ¯
= 0,
dc¯0
dτ¯
= kPSH n¯0,
n¯0 = p0/αGSH g¯0.
To match with the previous timescale we seek solutions as τ ∗ → ∞ and τ¯ → 0,
integration of s¯0 leads to s¯0(τ¯) = a1e
−αSφSPS τ¯ , where a1 is the constant of integration
determined by matching s¯0 on τ¯ → 0 and s∗0 → 1. So s¯0 → a1 and s∗0 → 1, therefore
a1 = 1.
For p¯0 we see
p∗0(τ
∗) = PS =⇒ p¯0(τ¯) = PS
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likewise, g¯0 = 1 at leading order. As c has increased 2 orders of magnitude, c¯0(0) = 0,
then we arrive at leading order values for our variables
p¯0 = PS,
s¯0 = e
−αSφSPS τ¯ ,
g¯0 = 1,
c¯0 =
kˆPSHPS
αG
τ¯ .
The ODE’s for the correction terms are as follows
dp¯1
dτ¯
= −αS s¯0p¯0 − p¯0,
ds¯1
dτ¯
= −αSφS s¯0p¯1 + δS(1− s¯0)− αsφS s¯1p¯0,
dg¯1
dτ¯
= −φGSHPS,
and can be solved to give
p¯1 =
1
φS
(e−αSφSPS τ¯ − 1)− PSτ,
s¯1 = e
−αSφSPS τ¯
(
e−αSφSPS τ¯ − 1
φSPS
+
1
2
αSφSPS τ¯ 2 + (αs − δs)τ¯ − δS(1 + e
αSφSPS τ¯ )
αSφSPS
)
,
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g¯1 = −φGPS τ¯ .
The leading order terms are then
p¯ ∼ PS + ( 1
φS
(e−αSφSPS τ¯ − 1)− PSτ),
s¯ ∼ e−αSφSPS τ¯ + 
(
e−αSφSPS τ¯
(
e−αSφSPS τ¯ − 1
φSPS
+
1
2
αSφSPS τ¯ 2 + (αs − δs)τ¯ − δS(1 + e
αSφSPS τ¯ )
αSφSPS
))
,
g¯ ∼ 1 + (−φGPS τ¯),
n¯ ∼ PS
αG
,
c¯ ∼ kˆPSHPS
αG
τ.
The breakdown in this timescale occurs when the leading order term for s¯ becomes
the same order as its correction term, i.e. τ¯ = ln(1/)/αSφSPS +O(1).
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Timescale 3. t = 
(
1
αSφSPS
ln(1

) + τˆ
)
Our new scalings in this intermediate timescale are
t = 
(
1
αSφSPS
ln(1/) + τˆ
)
,
p = pˆ,
s = sˆ,
n = 4nˆ,
g = gˆ,
c = 4
kPSH
αGαSφS
ln(1/) + 4cˆ,
leading to the new system of ODE’s
dpˆ
dτˆ
= −2αssˆpˆ− pˆ− 2pˆ+ 7kˆN nˆ,
dsˆ
dτˆ
= −αsφssˆpˆ+ δˆS(1− sˆ),
2
dn¯
dτ¯
= p¯− (5kˆN + 2kˆPSH)n¯− αGn¯g¯,
dg¯
dτ¯
= −αGφGn¯g¯ + δˆG(1− g¯),
dc¯
dτ¯
= kPSH n¯.
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We expand the variables as before
pˆ = pˆ0 + 
(
1
αSφS
ln(1/) + pˆ1
)
+ ...,
sˆ = sˆ0 + sˆ1 + ...,
nˆ = nˆ0 + 
(
1
αSφSPS
ln(1/) + nˆ1
)
+ ...,
gˆ = gˆ0 + 
(
φG
αSφS
ln(1/) + gˆ1
)
+ ...,
cˆ = cˆ0 + 
(
kPSH
αGαSφS
ln(1/) + cˆ1
)
+ ...
At leading order our ODE’s are
dpˆ0
dτˆ
= 0,
dsˆ0
dτˆ
= −αSφS sˆ0pˆ0 + δS,
dgˆ0
dτ¯
= 0,
dcˆ0
dτ¯
= kPSH nˆ0,
and αGn¯0g¯0 = p¯0. These solve to give
pˆ0 = PS,
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sˆ0 =
δS
αSφS pˆ0
+ a1
βe−αSφSPS τˆ ,
gˆ0 = 1,
cˆ0 =
kˆPSHPS
αG
τˆ + a2.
Where the values of pˆ0 and gˆ0 can be obtained by directly matching with the solu-
tion of the previous timescale.
To match with the solution of the previous timescale, we use an intermediate
timescale T defined as
τ¯ =
β
αSφSPS
ln(1/) + T,
τˆ = − (1− β)
αSφSPS
ln(1/) + T,
where 0 ≤ β ≤ 1. So
sˆ0(T ) =
δS
αSφSPS
+ a1
βe−αSφSPST ,
s¯0(T ) = 
βe−αSφSPST .
Hence a1 = 1 and
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sˆ0 =
δS
αSφSPS
+ e−αSφSPS τˆ ,
and for cˆ0
c¯0(T ) =
kˆPSHPS
αG
(
β
αSφSPS
ln(1/) + T
)
,
cˆ0(T ) =
kˆPSHPS
αG
(
− (1− β)
αSφSPS
ln(1/) + T
)
+ a2 +
kˆPSH
αSαGφS
ln(1/),
so a2 = 0 and
cˆ0 =
kˆPSHPS
αG
τˆ .
The corresponding correction terms for pˆ and gˆ are
dpˆ1
dτˆ
= −PS,
dgˆ1
dτ¯
= −φGPS,
so
pˆ1 = −PS τˆ + a3,
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gˆ1 = −φGPS τˆ + a4.
Matching the outer and inner solutions for p1, we have
p¯1(T ) =
βe−αsφSPST − 1
φS
− PS
(
β
αSφSPS
ln(1/) + T
)
,
pˆ1(T ) = a3 − PS
(
−(1− β)
αSφS
ln(1/) + T
)
+
PS
αSφS
ln(1/),
so a3 = 0 and
pˆ1 = −PS τˆ .
Now for g,
g¯1(T ) = −φGPS
(
β
αSφSPS
ln(1/) + T
)
,
gˆ1(T ) = −φGPS
(−(1− β)
αSφSPS
ln(1/) + T
)
+ a4,
again a4 = 0, hence
gˆ1 = −φGPS τˆ .
So at this order our system is
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pˆ ∼ PS −  1
αSφS
ln(1/)− PS τˆ ,
sˆ ∼ δS
αSφSPS
+ e−αSφSPS τˆ ,
nˆ ∼ PS
αG
,
gˆ ∼ 1−  φG
αSφS
ln(1/)− φGPS τˆ ,
cˆ ∼ kˆPSH
αGαSφS
ln(1/) +
kˆPSHPS
αG
τˆ .
When τˆ becomes O(1/) i.e. t = O(1) the correction terms of pˆ and gˆ become the
same order as their leading order and so it is then the solution for this timescale breaks
down.
Timescale 4. t = O(1)
Our new scalings are
t = τ˜ ,
p = p˜,
s = s˜,
n = 4n˜,
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g = g˜,
c = 3c˜,
leading to the system
dp˜
dτ˜
= −αS s˜p˜− p˜− p˜+ 2kˆN n˜,

ds˜
dτ˜
= −αSφS s˜p˜+ δS(1− s˜),
3
dn˜
dτ˜
= p˜− (5kˆN + 2kˆPSH)n˜− αGn˜g˜,
dg˜
dτ˜
= −αGφGn˜g˜ + δG(1− g˜),
dc˜
dτ˜
= kˆPSH n˜.
We expand as before and find the leading order terms
dp˜0
dτ˜
= −p˜0,
dg˜0
dτ˜
= −αGφGn˜0g˜0 + δG(1− g˜0).
To match with the previous timescale we use,
τˆ = β−1
(
T − 
αSφSpS
ln(1/)
)
,
229
τ˜ = βT.
Solving our leading order differential equations we have
p˜0(T ) = b1e
−βT ,
and
pˆ0(T ) = PS.
Hence, as → 0, b1 = PS and so
p˜0 = PSe
−τ˜ .
The quasi-steady equation for s˜0 yields
s˜0 =
δSe
τ˜
αSφSPS
.
For g˜0 we use that
n˜0 =
PSe
−τ˜
αGg˜0
,
and so
g˜0 = − φGPS
(δG − 1)eτ¯ +
b2
eδGτ¯
+ 1.
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Expressing in terms of the intermediate variable T
g˜0(T ) = − φGPS
(δG − 1)eβT +
b2
eδGβT
+ 1,
gˆ0(T ) = 1,
and as → 0 we find b2 = φGPS/(δG − 1), hence
g˜0 =
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ) + 1.
The corresponding term for p˜ satisfies
dp˜1
dτ˜
= −αSs0p0 − p1 − p0,
and matching with the previous timescale gives us
p˜1 = − δS
φS
+ e−τ˜
(
δS
φS
− PS τ˜
)
.
Divergence between safe and overdose cases
The above solution for g˜0 has a “U”-shaped profile in which g˜0 → 1 as τ˜ →∞. For the
solutions to remain valid for all τ˜ > 0 then g˜0 > 0 (this is “safe dose case”), however, if
g˜0 < 0 then GSH levels has collapsed and the solutions breakdown in finite time (this is
presented as the “overdose case”); an equivalent argument can be made for n˜0. Define
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Ψ(τ˜) = 1 +
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ), ∀τ˜ > 0,
so that
g˜0 = Ψ(τ˜), n˜0 =
PSe
−τ˜
αGΨ(τ˜)
,
then Ψ(τ˜) > 0,∀τ˜ , in the safe dose, whilst for the overdose case there exists 0 <
µ1 < µ˜1 such that Ψ(τ˜) < 0 for τ˜ ∈ (µ1, µ˜1), where Ψ(µ1) = Ψ(µ˜1) = 0; we note that
τ˜ = µ1 is the only time of interest in the latter case. We note further that in general,
the breakdown time is µ1 = µ1(), i.e. dependent on higher order terms of g˜, whereby
the leading order solves Ψ(µ˜1(0)) = 0. The time µ1(0) = µ
∗
1 for the bifurcation satisfies
Ψ(µ∗1) = 0
and
Ψ′(µ∗1) = 0,
which, on eliminating the exponential terms, leads to the critical dose concentration
P ∗S , where
P ∗S =
δ
δG
δG−1
G
φG
.
We note that the safe and overdose cases can be connected smoothly by analysis
in the region of PS = P
∗
S + θ. The results are omitted as they are not of biological
232
significance other than it reveals that the jump region observed in Figure 4 in the main
paper is of O() = O(k450/kG) in size. In the overdose case, breakdown occurs when
t ∼ µ1(), where Ψ (µ1(0)) = 0 and Ψ(τ˜) = O(), so that g˜ = O() and n˜ = O(1/).
Safe Dose Analysis
This section summarises the safe dose case i.e PS < P
∗
S .
Timescale 5. t = O(1)
In this timescale we see no depletion of GSH. The solutions for the previous timescale
are valid throughout the t = O(1) timescale, namely
p˜ = PSe
−τ˜ − 
(
− δS
φS
+ e−τ˜ (
δS
φS
− PS τ˜)
)
,
s˜ =
δSe
τ˜
αSφSPS
,
n˜ =
PSe
−τ˜
αG(
φGPS
δG−1 (e
−δGτ˜ − e−τ˜ ) + 1) ,
g˜ =
φGPS
δG − 1(e
−δGτ˜ − e−τ˜ ) + 1,
Csafe∞ =
∫ ∞
0
kPSHPSe
−τ˜
αG(
φGPS
δG−1 (e
−δGτ˜ − e−τ˜ ) + 1)dτ˜ ,
where Csafe∞ is the maximum, leading-order conjugate concentration; that which is
subsequently produced will not change Csafe∞ .
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We observe a breakdown in the solutions at τ˜ = ln(1/)+O(1), at this point leading
order APAP levels become O() and sulphate levels rise to become O(1) again.
Timescale 6. t = ln(1

) + τ˘
Our new scalings are
t = ln(1/) + τ˘ ,
p = p˘,
s = s˘,
n = 5n˘,
g = g˘,
c = 3Csafe∞ + 
4c˘,
and our rescaled ODE’s and expansions are
dp˘
dτ˘
= −αS s˘p˘− p˘− p˘+ kˆN n˘,
ds˘
dτ˘
= −αSφS s˘p˘+ δS(1− s˘),
2
dn˘
dτ˘
= p˘− (4kˆN + kˆPSH)n˘− αGn˘g˘,
dg˘
dτ˘
= −αGφGn˘g˘ + δG(1− g˘),
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dc˘
dτ˘
= kˆPSH n˘,
At leading order, the system is
dp˘0
dτ˘
= −αS s˘0p˘0 − p˘0,
ds˘0
dτ˘
= −αSφS s˘0p˘0 + δS(1− s˘0),
dg˘0
dτ˘
= −αGφGn˘0g˘0 + δG(1− g˘0),
dc˘0
dτ˘
= kˆPSH n˘0.
subject to αGn˘0g˘0 = p˘0 as τ˘ →∞. Unfortunately, the system of ODE’s are not solvable
in terms of an elementary solution. However, there is only one steady-state and it is a
stable attractor for non-negative initial conditions, hence
p˘→ 0,
s˘→ 1,
n˘→ 0,
g˘ → 1,
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as τ˘ →∞ and c˘ reaches its maximum concentration of O(3).
Overdose Analysis
The following sections concerns the overdose case (PS > P
∗
S) and it’s related timescales.
Preliminary analysis at t ∼ µ1()
From our O(1) timescale we reach a point in time, µ1, where the timescale collapses
and we see a divergence from our safe dose case.
Here, we have
p = PSe
−µ1 +O(),
s =
δSe
µ1
αSφSPS
+O(2),
g = g˘,
n = 3n˘,
c = 2c˘.
Before proceeding with the main analysis, we present a few results that guarantee
positivity of the forthcoming solutions.
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For PS > P
∗
S we have
Ψ(µ1) = 1 +
φGPS
δG − 1(e
−δGµ1 − e−µ1) = 0, (B.2.7)
and
Ψ′(µ1) = − φGPS
δG − 1(δGe
−δGµ1 − e−µ1) < 0. (B.2.8)
Now, from (8) we have δGe
−δGµ1/(δG − 1) > e−µ1/(δG − 1). This implies
0 = Ψ(µ1) >
φGPS
δG − 1(e
−δGµ1 − δGe−δGµ1) = 1− φGPSe−δGµ1
hence,
1 < φGPSe
−δGµ1 , (B.2.9)
and
0 = Ψ(µ1) >
φGPS
δG − 1(
e−µ1
δG
− e−µ1) = 1− φGPS
δG
e−µ1 ,
therefore,
1 <
φGPS
δG
e−µ1 . (B.2.10)
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It trivially follows that
φGPS > max(1, δG), (B.2.11)
and from (10),
0 < ln(φGPS/δG)− µ1. (B.2.12)
Matching condition for c as t→ µ−1
Using ideas from complex analysis, we note that n˜0 has a simple pole at t = µ1 and we
can therefore write
dc˜0
dτ˜
= kPSH n˜0 =
kPSHPSe
−τ˜
αGΨ(τ˜)
=
kPSHPS
αG
e−µ1F (τ˜)
(µ1 − τ˜) , (B.2.13)
where
F (τ˜) =
(µ1 − τ˜)e−τ˜
Ψ(τ˜)e−µ1
,
Applying L’Hopital’s rule we find that
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F (µ−1 ) = −
1
Ψ′(µ1)
=
δG − 1
φGPS(δGe−δGµ1 − e−µ1) .
Hence on integration of (B.2.13) by parts we have
c˜0 =
kPSHPSe
−µ1F (τ˜)
αG
ln
(
1
µ1 − τ˜
)
+ C˜0 + O((µ1 − τ˜) ln(µ1 − τ˜)),
where C˜0 = O(1) is a constant of integration. In particular, for τ˜ = µ1 − O() we
have
c˜0 ∼ kPSHPSe
−µ1F (µ−1 )
αG
ln(1/) + C˜0 + O( ln(1/)).
Timescale 5. t = µ1() + τ`
Our new scalings are
t = µ1 + τ` ,
p = p`,
s = s`,
n = 3n`,
g = g`,
c = 2
kPSHPSe
−µ1F (µ−1 )
αG
ln(1/) + 2c`,
239
leading to the system
dp`
dτ`
= −2s`p`− p`− 2p`+ 3kN n`,
ds`
dτ`
= −αSφS s`p`+ δS(1− s`),

dn`
dτ`
= p`− αGn`g` − 4kN n`− kPSH n`,
dg`
dt`
= −αGφGn`g` + δG(1− g`),
dc`
dτ`
= kPSH n`.
At leading order our system is
dp`0
dτ`
= 0,
ds`0
dτ`
= −αSφS s`0p`0 + δS,
dg`0
dτ`
= −φGp0 + δG,
dc`0
dτ`
= kPSH n`0,
and
n`0 = p`0/αGg`0.
Solving the ODE for p` we see that
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p`0 = d1,
where d1 is a constant of integration and
p˘0 = PSe
−µ1 ,
so the matching is simple (d1 = PSe
−µ1) and we see that
p`0 = PSe
−µ1 .
Solving for s` we have
s`0 =
δSe
µ1
αSφSPS
+ d2e
−αSφSPS τ`
and matching with the long time solution of s˘ leads to d2 = 0, hence
s˘0 =
δSe
µ1
αSφSPS
,
The equation for n` in this timescale gives the quasi-steady solution n` = PS
αGg`0
which
cancels with terms in the leading order ODE for g`0.
This leads to
g`0 = (−φGPSe−µ1 + δG)τ` + d3,
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n`0 =
PS
αG((−φGPSe−µ1 + δG)τ` + d3) ,
noting from (10) that −φGPSe−µ1 + δg < 0 and ∃t = η1 such that if t < η1 then
g`1 > 0 as required.
To match with the previous timescale we take
τ˘ = µ1() + 
βT,
τ` = β−1T.
Which allows us to match g˘0 and g`0 however, in order to find d3, we have to find g˘1
from the previous timescale. However, as the analysis can proceed without knowledge
of d3 and it has no influence on the key results, the analysis to determine d3 has not
been undertaken.
Our leading order ODE for c`0 is
dc`0
dτ`
=
kPSHPS
αG((−φGPSe−µ1 + δG)τ` + d3) ,
solving this leads to
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c`0 =
kPSHPS
αG(−φGPSe−µ1 + δG) ln((−φGPSe
−µ1 + δG)τ` + d3) + d4,
where d4 can in principle be determined by matching with the previous timescale
solutions.
The solutions at leading order are thus
p` ∼ PSe−µ1 ,
s` ∼ δSe
µ1
αSφSPS
,
g` ∼ (−φGPSe−µ1 + δG)τ` + d3,
n` ∼ PS
αG((−φGPSe−µ1 + δG)τ` + d3) ,
c` ∼ kPSHPSe
−µ1F (µ−1 )
αG
ln(1/) +
kPSHPS
αG(−φGPSe−µ1 + δG) ln((−φGPSe
−µ1 + δG)τ` + d3) + d4
From the solutions for g` and n` breakdown occurs at
τ` ∼ η1 = −d3
φGSHPSe−µ1 + δG
,
and so we seek an intermediate timescale.
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Intermediate timescale, general form
We look for a new timescale where
t = µ1() + η1() + 
βτ †,
p = p†,
s = s†,
n = 3−αn†,
g = 1+αg†,
c = 2 ln(1/)C†0 + 
2+β−αc†.
where C†0 is a constant dependent on α.
So the new system is
dp†
dτ †
= −1+βαSs†p† − β − 1+βp† + 5+β−αkNn†,
ds†
dτ †
= −β−1αSφSs†p† + β−1δS(1− s),
dn†
dτ †
= β+α−2p† − (2+βkNn† + β−1kPSH)n† − β+α−2αGn†g†,
dg†
dτ †
= −β−α−1αGφGn†g† + β−α−1δG(1− 1+αg†),
dc†
dτ †
= kPSHn
†.
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We know that g† → O(2) so we impose that α < 1 and we move from t = O() so
we know that β > 1. We want leading order solutions for g† and n† so need
β − α = 1,
β + α = 2.
So we take β = 3
2
and α = 1
2
indicating that our next timescale has an inteval of
size t = O(3/2).
Timescale 6. t = µ1() + η1 +O(
3/2)
We have new scalings of
t = µ1() + η1() + 
3
2 τ ‡,
p = p‡,
s = s‡,
n = 
5
2n‡,
g = 
3
2 g‡,
c = 2 ln(1/)C†0 + 
3c‡,
where C†0 =
kPSHPSe
−µ1F (µ−1 )
αG
+ kPSHPS
2αG(−φGPSe−µ1+δG) .
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The system of ODE’s is therefore
dp‡
dτ ‡
= −5/2αSs‡p‡ − 3/2p‡ − 5/2p‡ + 6kNn‡,
ds‡
dτ ‡
= −1/2αSφSs‡p‡ + 1/2δS(1− s‡),
dn‡
dτ ‡
= p‡ − (7/2kN + 1/2kPSH)n‡ − αGn‡g‡,
dg‡
dτ ‡
= −αGφGn‡g‡ + δG(1− 3/2g‡),
dc‡
dτ ‡
= kPSHn
‡.
We obtain p‡ = PSe−µ1 from matching.
Our ODE’s for n‡ and g‡ are dependant on each other so we look at both together.
φG
dn‡0
dτ ‡
− dg
‡
0
dτ ‡
= φGPSe
−µ1 − δG,
so
φGn
‡
0 − g‡0 = (φGPSe−µ1 − δG)τ ‡ + C.
Where C is a constant of integration, hence elimination of g‡0 leads to the Ricatti
equation for n‡0,
dn‡0
dτ ‡
= p‡0 − αGn‡0(φGn‡0 − ((φGPSe−µ1 − δG)τ ‡ + C)),
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for which a general solution can not be found in terms of elementary functions.
However, by balancing terms we have for n‡0,
n‡0 ∼
PSe
−µ1
αG(φGPSe−µ1 − δG)(−τ ‡) , as τ
‡ → −∞,
n‡0 ∼
(φGPSe
−µ1 − δG)τ ‡
φG
, as τ ‡ →∞,
and for g‡0,
g‡0 ∼ (φGPSe−µ1 − δG)(−τ ‡) as τ ‡ → −∞,
g‡0 ∼
δG
αG(φGPSe−µ1 − δG)τ ‡ as τ
‡ →∞.
These expansions break down in t = O(1/) when, for example, 1/2kPSHn
‡ = O(1).
Timescale 7. t = µ1() + η1 +O()
Our variables are scaled such that
t = µ1 + η1 + τ
,
p = p,
s = s,
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n = 2n,
g = 2g,
c = 2 ln(1/)C†0 + 
2c,
and our system of ODE’s is
dp
dτ 
= −2αSsp − p − 2p + 5kNn,
ds
dτ 
= −αSφSsp + δS(1− s),
dn
dτ 
= p − (3kN + kPSH)n − αGSHng,

dg
dτ 
= −αGφGng + δG(1− 2g),
dc
dτ 
= kPSHn
.
At leading order, the ODE for p is
dp0
dτ 
= 0,
so again, through matching with the previous timescale, we see
p0 = PSe
−µ1 .
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The leading order ODE for s is
ds0
dτ 
= −αsφSs0PSe−µ1 ,
and by integrating this we see
s0 =
dse
µ1
αsφSPS
+ c1e
−αSφSPSe−µ1τ .
By matching with the previous timescale we see c1 = 0 and
s0 =
dse
µ1
αsφSPS
.
The ODE for g is quasi steady at leading order and
g0 =
δG
αGφGn0
.
Currently the system of equations are driven by n where
dn0
dτ 
= PSe
−µ1 − δG
φG
− kPSHn0,
so
n0 =
PSe
−µ1 − δG
φG
kPSH
+ c2e
−τ .
We match as τ  → 0, hence
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n0 =
(φGPSe
−µ1 − δG)
kPSHφG
(1− e−τ),
and
g0 =
δG
αGφG(
(φGPSe
−µ1−δG)
kPSHφG
(1− e−τ))
.
The ODE for c in this timescale is
dc0
dτ 
= PSe
−µ − δG
φG
(1− e−τ),
so
c = PSe−µ1τ  + PSe−µ1−τ
 − δG
φG
(e−τ

+ τ ) + c3,
and matching as τ  → 0 give us
c = PS(e−µ1τ  + e−µ1−τ
 − e−µ)− δG
φG
(e−τ

+ τ  − 1).
Therefore, our leading order terms in this timescale are
p ∼ PSe−µ1 ,
s ∼ dse
µ1
αsφSPS
,
n ∼ (φGPSe
−µ1 − δG)
kPSHφG
(1− e−τ),
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g ∼ δG
αGφG(
(φGPSe
−µ1−δG)
kPSHφG
(1− e−τ))
,
c ∼ PS(e−µ1τ  + e−µ1−τ − e−µ)− δG
φG
(e−τ

+ τ  − 1).
The solution remains consistent as τ  →∞ however, there is a balance shift in the
system when τ  = O(1/).
Timescale 8. t = µ1() +O(1)
Our new scalings are
t = µ1 + τˇ
p = pˇ,
s = sˇ,
n = 2nˇ,
g = 2gˇ,
c = cˇ,
and the system of ODE’s is
dpˇ
dτˇ
= −αS sˇpˇ− pˇ− pˇ+ 4kN nˇ,
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
dsˇ
dτˇ
= −αSφS sˇpˇ+ δS(1− sˇ),

dnˇ
dτˇ
= pˇ− (3kN + kPSH)nˇ− αGnˇgˇ,
2
dgˇ
dτˇ
= −αGφGnˇgˇ + δG(1− 2gˇ),
dcˇ
dτˇ
= kPSH nˇ.
The ODE for pˇ at leading order is
dpˇ0
dτˇ
= −pˇ0,
and integrating this we see
pˇ0 = c1e
−τˇ .
Where c1 is a constant of integration and matching with the previous timescale we
see
pˇ0 = PSe
−µ1−τˇ .
The ODE for sˇ is quasi-steady state at leading order and therefore
sˇ0 =
δs
αSφS pˇ0
,
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and substituting pˇ0 gives
sˇ0 =
δse
µ1+τˇ
αSφSPS
.
The ODE’s for gˇ and nˇ are both quasi-steady state with each other at leading order
gˇ0 =
δG
αGφGnˇ0
,
and
nˇ0 =
pˇ0 − αGnˇ0gˇ0
kPSH
,
and after substituting pˇ0 and gˇ0 we see
nˇ0 =
φGPSe
−µ1−τˇ − δG
kPSHφG
.
Hence
gˇ0 =
δGkPSH
αG(φGPSe−µ1−τˇ − δG) .
At leading order cˇ is
cˇ0 = −PSe−µ1−τˇ − δG
φG
τˇ + c2.
We match as τˇ → 0 so
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cˇ0 = PS(e
−µ1 − e−µ1−τˇ )− δG
φG
τˇ .
So our leading order system of equations is
pˇ ∼ PSe−µ1−τˇ ,
sˇ ∼ δse
µ1+τˇ
αSφSPS
,
nˇ ∼ φGPSe
−µ1−τˇ − δG
kPSHφG
,
gˇ ∼ δGkPSH
αG(φGPSe−µ1−τˇ − δG) ,
cˇ ∼ PSe−µ1(1− e−τˇ )− δG
φG
τˇ .
We observe that there is a finite time collapse in nˇ and a corresponding explosion
in gˇ when τˇ = µ2() such that µ2(0) = τˇ = ln(φGPS/δG) − µ1, noting from (11) that
µ2(0) > 0. The next timescale occurs when nˇ = O() and gˇ = O(1/).
It turns out that, to leading order, the value of cˇ as τˇ → µ−2 is the maximum level
that conjugate attained, given by
C∞ ∼ cˇ∞0 = 
(
PSe
−µ1(1− e−µ2)− δG
φG
µ2
)
= 
(
PSe
−µ1 − δG
φG
(1 + µ2)
)
. (B.2.14)
Though lower order terms are still increasing (not investigated), this leading term re-
mains unchanged.
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Timescale 9. t = µ1 + µ2 +O(
2/3)
Our new scalings are
t = µ1 + µ2 + 
2/3τ,
p = p0 + 
2/3p1 ,
s = s,
n = 8/3n,
g = 4/3g,
c = cˇ∞0 + o()cˇ∞1 + 
7/3c,
where o()cˇ∞1 represents constants from the previous timescale between O() and
O(7/3).
The system of ODE’s is
dp
dτ
= −5/3αSsp − 2/3p − 5/3p − 16/3kNn,
1/3
ds
dτ
= −αsφSsp + δS(1− s),

dn
dτ
= p − (11/3kN + 2/3kPSH)n − αGng,
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2/3
dg
dτ
= −αGφGng + δG(1− 4/3g),
dc
dτ
= kPSHn
.
Expanding the dependent variables in the usual way, our ODEs for p is
dp0
dτ
= 0,
dp1
dτ
= −p0 ,
so by matching with the previous timescale we see
p0 = PSe
−µ1−µ2 ,
p1 = −PSe−µ1−µ2τ =
−δG
φG
τ.
At leading order s is quasi-steady and so
−αSφSPSe−µ1−µ2s0 + δS = 0,
and therefore,
s0 =
δSe
µ1+µ2
αSφSPS
.
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Both n and g are quasi-steady at leading order so we seek long time solutions for
them.

dn
dτ
=
δG
φG
(1− 2/3τ)− αGng − 2/3kPSHn,
2/3
dg
dτ
= −αGφGng + δG − δG4/3g,
φG
dn
dτ
− 2/3 dg

dτ
= −2/3τ − 2/3kPSHφGn.
So
n0 ∼
δG
αGφGg 0
,
dg0
dτ
= δGτ
 +
kPSHδG
αGg

0
.
This ODE does not have solutions in terms of elementary function, however, it is
straightforward to glean the important information, namely that as τ → −∞,
g0 ∼
kPSH
αGτ
,
n0 ∼
δGτ

φGkPSH
,
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and, in particular, as τ → +∞
g0 ∼
δGτ
2
2
n0 ∼
2
αGφGτ
2 .
The solution for c0 is unimportant given that C∞ has been found, nevertheless we see
that c0 = O(−1/τ) as τ → +∞.
So our leading order solutions in this timescale are
p ∼ PSe−µ1−µ2 ,
s ∼ δSe
µ1+µ2
αSφSPS
,
The solutions for this timescale breaks down when τ = O(−2/3) or t = µ1 + µ2 +
O(1) at which point we see g → O(1) and n→ O(4).
Timescale 10. t = µ1 + µ2 +O(1)
Our new scalings are
t = µ1 + µ2 + τ
◦,
p = p◦,
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s = s◦,
n = 4n◦,
g = g◦,
c = cˇ∞0 + o()cˇ∞1 + 
3c◦
and our leading order ODE’s are
dp◦
dτ ◦
= −αSs◦p◦ − p◦ − p◦ − 6kNn◦,

ds◦
dτ ◦
= −αsφSs◦p◦ + δS(1− s◦),
3
dn◦
dτ ◦
= p◦ − (5kN + 2kPSH)n◦ − αGn◦g◦,
dg◦
dτ ◦
= −αGφGn◦g◦ + δG(1− g◦).
dc◦
dτ ◦
= kPSHn
◦.
At leading order, the ODE for p◦ is
dp◦0
dτ ◦
= p◦0,
So, by integration, we find p◦0 = c1e
−τ◦ and by matching with the previous timescale
p◦0 = PSe
−µ1−µ2−τ◦ .
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The ODE for s◦ is quasi-steady in this timescale and
s◦0 =
δSe
µ1+µ2+τ◦
αSφSPS
.
The ODE for n is also quasi-steady and
n◦0 =
PSe
−µ1−µ2−τ
αGg◦0
,
using this we see
dg◦0
dτ ◦
= −φGPSe−µ1−µ2−τ◦ + δg(1− g◦0) = δG(e−τ
◦ − 1 + g◦),
and so
g◦0 = (
−φGPSe−µ1−µ2e(δG−1)τ◦
δG − 1 + e
δGτ
◦
+ c1)e
−δGτ◦ .
We match as τ ◦ → 0, so c2 = φGPSe−µ1−µ2δG−1 and therefore
g◦0 =
φGPSe
−µ1−µ2
δG − 1 (e
−δGτ◦ − e−τ◦) + 1,
and
n◦0 =
PSe
−µ1−µ2−τ◦
αG(
φGPSe
−µ1−µ2
δG−1 (e
−δGτ◦ − e−τ◦) + 1)
.
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Again, c◦ is constant at leading order and so the final system of leading order terms
is
p◦ ∼ PSe−µ1−µ2−τ◦
s◦ ∼ δSe
µ1+µ2+τ◦
αSφSPS
,
n◦ ∼ PSe
−µ1−µ2−τ◦
αG(
φGPSe
−µ1−µ2
δG−1 (e
−δGτ◦ − e−τ◦) + 1)
,
g◦ ∼ φGPSe
−µ1−µ2
δG − 1 (e
−δGτ◦ − e−τ◦) + 1,
and, trivially, c◦ ∼ kPSH
∫ τ◦
0
n◦0 dt.
The APAP and PAPS equations when τ ◦ ∼ ln(1/) leads to the final timescale.
Timescale 11. t = µ1 + µ2 + ln(1/) +O(1)
This only concerns PAPS recovery. Formally, we write t = ln(1/)+t◦◦, since µ1 +µ2 
ln(1/) as → 0, and letting p = p◦◦ and s = s◦◦ results with, at leading order,
dp◦◦
dt◦◦
= −αSp◦◦s◦◦ − p◦◦,
ds◦◦
dt◦◦
= −αSφSp◦◦s◦◦ + δS(1− s◦◦),
subject to p◦◦ ∼ PSe−t◦◦ and s◦◦ ∼ δSe t◦◦/αSφSPS as t◦◦ → −∞. There appears
not to be a simple solution to this problem, but since it is clear that p◦◦ → 0, then the
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leading behaviour in large time for PAPS is given by
s◦◦ ∼ 1− A◦◦e−δS t◦◦ ,
where A◦◦ is some constant. Hence, s returns to the pretreated state in this
timescale.
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Appendix C
Characteristic Equations For Nrf2
Steady State Model
In Chapter 4 we presented a steady state model of Nrf2 adaptation. In this appendix
we include the characteristic equations for the various scalings presented. Due to the
complexity of outputting from Maple to Latex we include direct pdf printouts of the
Maple worksheets.
Characteristic Equation for φ < φc
The characteristic equation for Section 4.5.2 is of the form
C1 = a0λ
7 + a1λ
6 + a2λ
5 + a3λ
4 + a4λ
3 + a5λ
2 + a6λ+ a7
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and we list the coefficients below.
(1)
a0 =
fc
3 C 3 fc
2 fssC 3 fc fss
2 C fss
3
fssC fc
3
a1 =
1
fssC fc
3 fss
3  nss aG fGC fc
3 nss aG fGC 3 fss
2  fc gss aGC 3 fss
2  fc nss aNBC 3 fss 
fc
2 gss aGC 3 fss fc
2 nss aNBC 3 fss
2  fc nss aG fGC 3 fss fc
2 nss aG fGC 3 dG fss fc
2 C
fss
3  nss aNBC fss fc
3 aHC fss
3  fc aHC 3 dG fss
2  fcC fss
3  gss aGC 3 dB fss
2  fcC 3 fss
2  fc gFBC
fc
3 gss aGC 2 fss
2  fc
2 aHC 3 dH fss
2  fcC 3 dB fss fc
2 C 3 fss fc
2 gFBC fc
3 nss aNBC 3 dH fss fc
2
C aS pss fSCaS sssC dSC 1  fc
3 C 3 fc
2 fssC 3 fc fss
2 C fss
3 C dB fss
3 C dB fc
3 C dG fss
3
C dG fc
3 C dH fss
3 C dH fc
3 C fss
3  gFBC fc
3 gFB
a2 =
1
fssC fc
3 3 dG fss
2  fc gFBC 3 dG fss fc
2 gFBC 3 dH fss
2  fc gFBC 3 dH fss fc
2 gFBC dB 
fss
3  fc aHC dB fss
3  gss aGC 2 dB fss
2  fc
2 aHC dB fss fc
3 aHC dB fc
3 gss aGC dG fss
3  fc aHC dG 
fss
3  gss aGC dG fss
3  nss aNBC 2 dG fss
2  fc
2 aHC dG fss fc
3 aHC dG fc
3 gss aGC dG fc
3 nss aNB
C dH fss
3  gss aGC dH fss
3  nss aNBC dH fc
3 gss aGC dH fc
3 nss aNBC fss
3  fc gFB aHC
fss
3  gss gFB aGC 2 fss
2  fc
2 gFB aHC fss fc
3 gFB aHC fc
3 gss gFB aGC 3 dB dG fss
2  fcC 3 dB dG fss 
fc
2 C 3 dB dH fss
2  fcC 3 dB dH fss fc
2 C 3 dB fss
2  fc gFBC 3 dB fss fc
2 gFBC 3 dG dH fss
2  fc
C 3 dG dH fss fc
2 C 3 fss fc
2 gss nss aG aNBC 3 fss fc
2 gFB nss aG fGC 3 fss
2  fc nss
2  aG aNB fG
C 3 fss fc
2 nss
2  aG aNB fGC 3 dB fss
2  fc nss aG fGC 3 dB fss fc
2 nss aG fGC 3 dH 
fss
2  fc nss aG fGC 3 dH fss fc
2 nss aG fGC 3 fss
2  fc gss nss aG aNBC 3 fss
2  fc gFB nss aG fGC fss 
fc
3 gss aG aHC fss fc
3 nss aH aNBC fc
3 gss nss aG aNBC fc
3 gFB nss aG fGC 3 dB fss
2  fc gss aG
C 3 dB fss fc
2 gss aGC 3 dG fss
2  fc gss aGC 3 dG fss
2  fc nss aNBC 3 dG fss fc
2 gss aGC 3 dG fss 
fc
2 nss aNBC 3 dH fss
2  fc gss aGC 3 dH fss
2  fc nss aNBC 3 dH fss fc
2 gss aGC 3 dH fss fc
2 nss aNB
C 3 fss
2  fc gss gFB aGC 3 fss fc
2 gss gFB aGC fss
3  nss
2  aG aNB fGC fc
3 nss
2  aG aNB fGC dB 
fss
3  nss aG fGC dB fc
3 nss aG fGK dH fss
3  fc aH fHC dH fss
3  nss aG fGK 2 dH fss
2  fc
2 aH fH
K dH fss fc
3 aH fHC dH fc
3 nss aG fGC fss
3  fc gss aG aHC fss
3  fc nss aH aNBC
fss
3  gss nss aG aNBC fss
3  gFB nss aG fGC 2 fss
2  fc
2 gss aG aHC 2 fss
2  fc
2 nss aH aNBC dG fss
3  gFB
C dB fc
3 gFBC dG fc
3 gFBC dB dH fc
3 C dG dH fc
3 C dH fss
3  gFBC dB dG fc
3 C dG dH fss
3 C dH 
fc
3 gFBC dB fss
3  gFBC dB dH fss
3 C dB dG fss
3 C aS dS sssCaS pss fSC dS  fc
3 C 3 fc
2 fss
(1)
C 3 fc fss
2 C fss
3 C aS pss fSCaS sssC dSC 1  aG fc
3 nss fGC 3 aG fc
2 fss nss fG
C 3 aG fc fss
2  nss fGCaG fss
3  nss fGCaG fc
3 gssC 3 aG fc
2 fss gssC 3 aG fc fss
2  gssCaG 
fss
3  gssCaH fc
3 fssC 2 aH fc
2 fss
2 CaH fc fss
3 CaNB fc
3 nssC 3 aNB fc
2 fss nssC 3 aNB fc fss
2  nss
CaNB fss
3  nssC dB fc
3 C 3 dB fc
2 fssC 3 dB fc fss
2 C dB fss
3 C dG fc
3 C 3 dG fc
2 fssC 3 dG fc fss
2
C dG fss
3 C dH fc
3 C 3 dH fc
2 fssC 3 dH fc fss
2 C dH fss
3 C fc
3 gFBC 3 fc
2 fss gFBC 3 fc fss
2  gFBC
fss
3  gFB
a3 =
1
fssC fc
3 3 dH fss
2  fc gFB nss aG fGC 3 dH fss fc
2 gss nss aG aNBC 3 dH fss 
fc
2 gFB nss aG fGC bss dG fc
3 nss aF aG aNBK dH fss
3  fc gss aG aH fHK dH 
fss
3  fc nss aH aNB fHK 2 dH fss
2  fc
2 gss aG aH fHK 2 dH fss
2  fc
2 nss aH aNB fHC 3 dH fss
2  fc 
nss
2  aG aNB fGK dH fss fc
3 gss aG aH fHK dH fss fc
3 nss aH aNB fHC 3 dH fss fc
2 
nss
2  aG aNB fGC fss
3  fc gss nss aG aH aNBC 2 fss
2  fc
2 gss nss aG aH aNBC fss 
fc
3 gss nss aG aH aNBC 3 dB dH fss
2  fc nss aG fGC 3 dB dH fss fc
2 nss aG fGC 3 dB 
fss
2  fc gFB nss aG fGC 3 dB fss fc
2 gFB nss aG fGC 3 dG fss
2  fc gss nss aG aNBC 3 dG fss 
fc
2 gss nss aG aNBC 3 dH fss
2  fc gss nss aG aNBC dB dG dH fss
3 C dB dG dH fc
3 C dB dG fss
3  gFB
C dB dG fc
3 gFBC dB dH fss
3  gFBC dB dH fc
3 gFBC dG dH fss
3  gFBC dG dH fc
3 gFBC bss fss 
fc
2 hss nss aG aH aNB fHC 3 dB dH fss
2  fc gss aGC 3 dB dH fss fc
2 gss aGC 3 dB 
fss
2  fc gss gFB aGC 3 dB fss fc
2 gss gFB aGC 3 dG dH fss
2  fc gss aGC 3 dG dH fss
2  fc nss aNB
C 3 dG dH fss fc
2 gss aGC 3 dG dH fss fc
2 nss aNBC 3 dG fss
2  fc gss gFB aGC 3 dG fss 
fc
2 gss gFB aGC 3 dH fss
2  fc gss gFB aGC 3 dH fss fc
2 gss gFB aGC dH fss
3  nss
2  aG aNB fGC dH 
fc
3 nss
2  aG aNB fGK dB dH fss
3  fc aH fHC dB dH fss
3  nss aG fGK 2 dB dH fss
2  fc
2 aH fH
K dB dH fss fc
3 aH fHC dB dH fc
3 nss aG fGC dB fss
3  fc gss aG aHC dB fss
3  gFB nss aG fG
C 2 dB fss
2  fc
2 gss aG aHC dB fss fc
3 gss aG aHC dB fc
3 gFB nss aG fGC dG fss
3  fc gss aG aH
C dG fss
3  fc nss aH aNBC dG fss
3  gss nss aG aNBC 2 dG fss
2  fc
2 gss aG aHC 2 dG fss
2  
fc
2 nss aH aNBC dG fss fc
3 gss aG aHC dG fss fc
3 nss aH aNBC dG fc
3 gss nss aG aNBK dH 
fss
3  fc gFB aH fHC dH fss
3  gss nss aG aNBC dH fss
3  gFB nss aG fGK 2 dH fss
2  fc
2 gFB aH fH
K dH fss fc
3 gFB aH fHC dH fc
3 gss nss aG aNBC dH fc
3 gFB nss aG fGC fss
3  fc gss gFB aG aH
(1)
C 2 fss
2  fc
2 gss gFB aG aHC fss fc
3 gss gFB aG aHC 3 dB dG fss
2  fc gss aGC 3 dB dG fss 
fc
2 gss aGC dG fss
3  fc gFB aHC dG fss
3  gss gFB aGC 2 dG fss
2  fc
2 gFB aHC dG fss fc
3 gFB aHC dG 
fc
3 gss gFB aGC dH fss
3  gss gFB aGC dH fc
3 gss gFB aGC 3 dB dG dH fss
2  fcC 3 dB dG dH fss fc
2
C 3 dB dG fss
2  fc gFBC 3 dB dG fss fc
2 gFBC 3 dB dH fss
2  fc gFBC 3 dB dH fss fc
2 gFBC 3 dG dH 
fss
2  fc gFBC 3 dG dH fss fc
2 gFBC dB dG fss
3  fc aHC dB dG fss
3  gss aGC 2 dB dG fss
2  fc
2 aH
C dB dG fss fc
3 aHC dB dG fc
3 gss aGC dB dH fss
3  gss aGC dB dH fc
3 gss aGC dB fss
3  fc gFB aH
C dB fss
3  gss gFB aGC 2 dB fss
2  fc
2 gFB aHC dB fss fc
3 gFB aHC dB fc
3 gss gFB aGC dG dH 
fss
3  gss aGC dG dH fss
3  nss aNBC dG dH fc
3 gss aGC dG dH fc
3 nss aNBC bss 
fc
3 hss nss aG aH aNB fHC bss dG fss fc
2 nss aF aG aNBC aS dS sssCaS pss fS
C dS  aG fc
3 nss fGC 3 aG fc
2 fss nss fGC 3 aG fc fss
2  nss fGCaG fss
3  nss fGCaG fc
3 gss
C 3 aG fc
2 fss gssC 3 aG fc fss
2  gssCaG fss
3  gssCaH fc
3 fssC 2 aH fc
2 fss
2 CaH fc fss
3 CaNB 
fc
3 nssC 3 aNB fc
2 fss nssC 3 aNB fc fss
2  nssCaNB fss
3  nssC dB fc
3 C 3 dB fc
2 fssC 3 dB fc fss
2
C dB fss
3 C dG fc
3 C 3 dG fc
2 fssC 3 dG fc fss
2 C dG fss
3 C dH fc
3 C 3 dH fc
2 fssC 3 dH fc fss
2
C dH fss
3 C fc
3 gFBC 3 fc
2 fss gFBC 3 fc fss
2  gFBC fss
3  gFB C aS pss fSCaS sssC dS
C 1  aG aNB fc
3 nss
2  fGC 3 aG aNB fc
2 fss nss
2  fGC 3 aG aNB fc fss
2  nss
2  fGCaG aNB fss
3  
nss
2  fGCaG aH fc
3 fss gssC 2 aG aH fc
2 fss
2  gssCaG aH fc fss
3  gssCaG aNB fc
3 gss nss
C 3 aG aNB fc
2 fss gss nssC 3 aG aNB fc fss
2  gss nssCaG aNB fss
3  gss nssCaG dB fc
3 nss fG
C 3 aG dB fc
2 fss nss fGC 3 aG dB fc fss
2  nss fGCaG dB fss
3  nss fGCaG dH fc
3 nss fG
C 3 aG dH fc
2 fss nss fGC 3 aG dH fc fss
2  nss fGCaG dH fss
3  nss fGCaG fc
3 gFB nss fG
C 3 aG fc
2 fss gFB nss fGC 3 aG fc fss
2  gFB nss fGCaG fss
3  gFB nss fGCaH aNB fc
3 fss nss
C 2 aH aNB fc
2 fss
2  nssCaH aNB fc fss
3  nssKaH dH fc
3 fss fHK 2 aH dH fc
2 fss
2  fHKaH dH fc 
fss
3  fHCaG dB fc
3 gssC 3 aG dB fc
2 fss gssC 3 aG dB fc fss
2  gssCaG dB fss
3  gssCaG dG fc
3 gss
C 3 aG dG fc
2 fss gssC 3 aG dG fc fss
2  gssCaG dG fss
3  gssCaG dH fc
3 gssC 3 aG dH fc
2 fss gss
C 3 aG dH fc fss
2  gssCaG dH fss
3  gssCaG fc
3 gss gFBC 3 aG fc
2 fss gss gFBC 3 aG fc 
fss
2  gss gFBCaG fss
3  gss gFBCaH dB fc
3 fssC 2 aH dB fc
2 fss
2 CaH dB fc fss
3 CaH dG fc
3 fss
C 2 aH dG fc
2 fss
2 CaH dG fc fss
3 CaH fc
3 fss gFBC 2 aH fc
2 fss
2  gFBCaH fc fss
3  gFBCaNB dG 
fc
3 nssC 3 aNB dG fc
2 fss nssC 3 aNB dG fc fss
2  nssCaNB dG fss
3  nssCaNB dH fc
3 nss
(1)
C 3 aNB dH fc
2 fss nssC 3 aNB dH fc fss
2  nssCaNB dH fss
3  nssC dB dG fc
3 C 3 dB dG fc
2 fss
C 3 dB dG fc fss
2 C dB dG fss
3 C dB dH fc
3 C 3 dB dH fc
2 fssC 3 dB dH fc fss
2 C dB dH fss
3 C dB 
fc
3 gFBC 3 dB fc
2 fss gFBC 3 dB fc fss
2  gFBC dB fss
3  gFBC dG dH fc
3 C 3 dG dH fc
2 fss
C 3 dG dH fc fss
2 C dG dH fss
3 C dG fc
3 gFBC 3 dG fc
2 fss gFBC 3 dG fc fss
2  gFBC dG fss
3  gFBC dH 
fc
3 gFBC 3 dH fc
2 fss gFBC 3 dH fc fss
2  gFBC dH fss
3  gFB
a4 =
1
fssC fc
3 3 dG dH fss
2  fc gss gFB aGC 3 dG dH fss fc
2 gss gFB aGC dB dG dH fss
3  gFB
C dB dG dH fc
3 gFBC bss dB fss fc
2 hss nss aG aH aNB fHC bss dH fss fc
2 hss nss aG aH aNB fH
C dB dG fss
3  fc gss aG aHC 2 dB dG fss
2  fc
2 gss aG aHC dB dG fss fc
3 gss aG aHK dB dH 
fss
3  fc gFB aH fHC dB dH fss
3  gFB nss aG fGK 2 dB dH fss
2  fc
2 gFB aH fHK dB dH fss fc
3 gFB aH fH
C dB dH fc
3 gFB nss aG fGC dB fss
3  fc gss gFB aG aHC 2 dB fss
2  fc
2 gss gFB aG aHC dB fss 
fc
3 gss gFB aG aHC dG dH fss
3  gss nss aG aNBC dG dH fc
3 gss nss aG aNBC dG 
fss
3  fc gss gFB aG aHC 2 dG fss
2  fc
2 gss gFB aG aHC dG fss fc
3 gss gFB aG aHC 3 dB dG dH 
fss
2  fc gss aGC 3 dB dG dH fss fc
2 gss aGC 3 dB dG fss
2  fc gss gFB aGC 3 dB dG fss fc
2 gss gFB aG
C 3 dB dH fss
2  fc gss gFB aGC 3 dB dH fss fc
2 gss gFB aGK dH fss
3  fc gss nss aG aH aNB fH
K 2 dH fss
2  fc
2 gss nss aG aH aNB fHK dH fss fc
3 gss nss aG aH aNB fHC bss dB dG fss 
fc
2 nss aF aG aNBC bss dG dH fss fc
2 nss aF aG aNBC bss dB fc
3 hss nss aG aH aNB fH
C bss dG fss fc
3 nss aF aG aH aNBC bss dH fc
3 hss nss aG aH aNB fHC dB dG fss
3  gss gFB aG
C 2 dB dG fss
2  fc
2 gFB aHC dB dG fss fc
3 gFB aHC dB dG fc
3 gss gFB aGC dB dH fss
3  gss gFB aG
C dB dH fc
3 gss gFB aGC dG dH fss
3  gss gFB aGC dG dH fc
3 gss gFB aGC 3 dB dG dH fss
2  fc gFB
C 3 dB dG dH fss fc
2 gFBC dB dG dH fss
3  gss aGC dB dG dH fc
3 gss aGC dB dG fss
3  fc gFB aH
C 2 dG fss
2  fc
2 gss nss aG aH aNBC 3 dB dH fss
2  fc gFB nss aG fGK dB dH fss fc
3 gss aG aH fH
C 3 dG dH fss
2  fc gss nss aG aNBK dH fss fc
3 gss gFB aG aH fHC bss dG dH fc
3 nss aF aG aNB
C 3 dB dH fss fc
2 gFB nss aG fGC dG fss
3  fc gss nss aG aH aNBC dG fss fc
3 gss nss aG aH aNB
K dB dH fss
3  fc gss aG aH fHK 2 dH fss
2  fc
2 gss gFB aG aH fHC bss dB dG fc
3 nss aF aG aNB
K dH fss
3  fc gss gFB aG aH fHK 2 dB dH fss
2  fc
2 gss aG aH fHC 3 dG dH fss fc
2 gss nss aG aNB
C aS dS sssCaS pss fSC dS  aG aNB fc
3 nss
2  fGC 3 aG aNB fc
2 fss nss
2  fGC 3 aG aNB fc 
(1)
fss
2  nss
2  fGCaG aNB fss
3  nss
2  fGCaG aH fc
3 fss gssC 2 aG aH fc
2 fss
2  gssCaG aH fc fss
3  gss
CaG aNB fc
3 gss nssC 3 aG aNB fc
2 fss gss nssC 3 aG aNB fc fss
2  gss nssCaG aNB fss
3  gss nss
CaG dB fc
3 nss fGC 3 aG dB fc
2 fss nss fGC 3 aG dB fc fss
2  nss fGCaG dB fss
3  nss fG
CaG dH fc
3 nss fGC 3 aG dH fc
2 fss nss fGC 3 aG dH fc fss
2  nss fGCaG dH fss
3  nss fGCaG 
fc
3 gFB nss fGC 3 aG fc
2 fss gFB nss fGC 3 aG fc fss
2  gFB nss fGCaG fss
3  gFB nss fGCaH aNB 
fc
3 fss nssC 2 aH aNB fc
2 fss
2  nssCaH aNB fc fss
3  nssKaH dH fc
3 fss fHK 2 aH dH fc
2 fss
2  fH
KaH dH fc fss
3  fHCaG dB fc
3 gssC 3 aG dB fc
2 fss gssC 3 aG dB fc fss
2  gssCaG dB fss
3  gss
CaG dG fc
3 gssC 3 aG dG fc
2 fss gssC 3 aG dG fc fss
2  gssCaG dG fss
3  gssCaG dH fc
3 gss
C 3 aG dH fc
2 fss gssC 3 aG dH fc fss
2  gssCaG dH fss
3  gssCaG fc
3 gss gFBC 3 aG 
fc
2 fss gss gFBC 3 aG fc fss
2  gss gFBCaG fss
3  gss gFBCaH dB fc
3 fssC 2 aH dB fc
2 fss
2 CaH dB fc 
fss
3 CaH dG fc
3 fssC 2 aH dG fc
2 fss
2 CaH dG fc fss
3 CaH fc
3 fss gFBC 2 aH fc
2 fss
2  gFBCaH fc 
fss
3  gFBCaNB dG fc
3 nssC 3 aNB dG fc
2 fss nssC 3 aNB dG fc fss
2  nssCaNB dG fss
3  nss
CaNB dH fc
3 nssC 3 aNB dH fc
2 fss nssC 3 aNB dH fc fss
2  nssCaNB dH fss
3  nssC dB dG fc
3
C 3 dB dG fc
2 fssC 3 dB dG fc fss
2 C dB dG fss
3 C dB dH fc
3 C 3 dB dH fc
2 fssC 3 dB dH fc fss
2
C dB dH fss
3 C dB fc
3 gFBC 3 dB fc
2 fss gFBC 3 dB fc fss
2  gFBC dB fss
3  gFBC dG dH fc
3 C 3 dG dH 
fc
2 fssC 3 dG dH fc fss
2 C dG dH fss
3 C dG fc
3 gFBC 3 dG fc
2 fss gFBC 3 dG fc fss
2  gFBC dG fss
3  gFB
C dH fc
3 gFBC 3 dH fc
2 fss gFBC 3 dH fc fss
2  gFBC dH fss
3  gFB C aS pss fSCaS sssC dS
C 1  aG aH aNB bss fc
3 hss nss fHCaG aH aNB bss fc
2 fss hss nss fHCaF aG aNB bss dG 
fc
3 nssCaF aG aNB bss dG fc
2 fss nssCaG aH aNB fc
3 fss gss nssC 2 aG aH aNB fc
2 fss
2  gss nss
CaG aH aNB fc fss
3  gss nssKaG aH dH fc
3 fss gss fHK 2 aG aH dH fc
2 fss
2  gss fH
KaG aH dH fc fss
3  gss fHCaG aNB dH fc
3 nss
2  fGC 3 aG aNB dH fc
2 fss nss
2  fG
C 3 aG aNB dH fc fss
2  nss
2  fGCaG aNB dH fss
3  nss
2  fGKaH aNB dH fc
3 fss nss fH
K 2 aH aNB dH fc
2 fss
2  nss fHKaH aNB dH fc fss
3  nss fHCaG aH dB fc
3 fss gssC 2 aG aH dB 
fc
2 fss
2  gssCaG aH dB fc fss
3  gssCaG aH dG fc
3 fss gssC 2 aG aH dG fc
2 fss
2  gssCaG aH dG fc 
fss
3  gssCaG aH fc
3 fss gss gFBC 2 aG aH fc
2 fss
2  gss gFBCaG aH fc fss
3  gss gFBCaG aNB dG 
fc
3 gss nssC 3 aG aNB dG fc
2 fss gss nssC 3 aG aNB dG fc fss
2  gss nssCaG aNB dG fss
3  gss nss
CaG aNB dH fc
3 gss nssC 3 aG aNB dH fc
2 fss gss nssC 3 aG aNB dH fc fss
2  gss nss
(1)
CaG aNB dH fss
3  gss nssCaG dB dH fc
3 nss fGC 3 aG dB dH fc
2 fss nss fGC 3 aG dB dH fc 
fss
2  nss fGCaG dB dH fss
3  nss fGCaG dB fc
3 gFB nss fGC 3 aG dB fc
2 fss gFB nss fG
C 3 aG dB fc fss
2  gFB nss fGCaG dB fss
3  gFB nss fGCaG dH fc
3 gFB nss fGC 3 aG dH 
fc
2 fss gFB nss fGC 3 aG dH fc fss
2  gFB nss fGCaG dH fss
3  gFB nss fGCaH aNB dG fc
3 fss nss
C 2 aH aNB dG fc
2 fss
2  nssCaH aNB dG fc fss
3  nssKaH dB dH fc
3 fss fHK 2 aH dB dH fc
2 fss
2  fH
KaH dB dH fc fss
3  fHKaH dH fc
3 fss gFB fHK 2 aH dH fc
2 fss
2  gFB fHKaH dH fc fss
3  gFB fH
CaG dB dG fc
3 gssC 3 aG dB dG fc
2 fss gssC 3 aG dB dG fc fss
2  gssCaG dB dG fss
3  gss
CaG dB dH fc
3 gssC 3 aG dB dH fc
2 fss gssC 3 aG dB dH fc fss
2  gssCaG dB dH fss
3  gss
CaG dB fc
3 gss gFBC 3 aG dB fc
2 fss gss gFBC 3 aG dB fc fss
2  gss gFBCaG dB fss
3  gss gFB
CaG dG dH fc
3 gssC 3 aG dG dH fc
2 fss gssC 3 aG dG dH fc fss
2  gssCaG dG dH fss
3  gss
CaG dG fc
3 gss gFBC 3 aG dG fc
2 fss gss gFBC 3 aG dG fc fss
2  gss gFBCaG dG fss
3  gss gFB
CaG dH fc
3 gss gFBC 3 aG dH fc
2 fss gss gFBC 3 aG dH fc fss
2  gss gFBCaG dH fss
3  gss gFB
CaH dB dG fc
3 fssC 2 aH dB dG fc
2 fss
2 CaH dB dG fc fss
3 CaH dB fc
3 fss gFBC 2 aH dB fc
2 
fss
2  gFBCaH dB fc fss
3  gFBCaH dG fc
3 fss gFBC 2 aH dG fc
2 fss
2  gFBCaH dG fc fss
3  gFB
CaNB dG dH fc
3 nssC 3 aNB dG dH fc
2 fss nssC 3 aNB dG dH fc fss
2  nssCaNB dG dH fss
3  nss
C dB dG dH fc
3 C 3 dB dG dH fc
2 fssC 3 dB dG dH fc fss
2 C dB dG dH fss
3 C dB dG fc
3 gFB
C 3 dB dG fc
2 fss gFBC 3 dB dG fc fss
2  gFBC dB dG fss
3  gFBC dB dH fc
3 gFBC 3 dB dH fc
2 fss gFB
C 3 dB dH fc fss
2  gFBC dB dH fss
3  gFBC dG dH fc
3 gFBC 3 dG dH fc
2 fss gFBC 3 dG dH fc fss
2  gFB
C dG dH fss
3  gFB
a5 =
1
fssC fc
3 aS dS sssCaS pss fSC dS  aG aH aNB bss fc
3 hss nss fH
CaG aH aNB bss fc
2 fss hss nss fHCaF aG aNB bss dG fc
3 nssCaF aG aNB bss dG fc
2 fss nss
CaG aH aNB fc
3 fss gss nssC 2 aG aH aNB fc
2 fss
2  gss nssCaG aH aNB fc fss
3  gss nss
KaG aH dH fc
3 fss gss fHK 2 aG aH dH fc
2 fss
2  gss fHKaG aH dH fc fss
3  gss fHCaG aNB dH 
fc
3 nss
2  fGC 3 aG aNB dH fc
2 fss nss
2  fGC 3 aG aNB dH fc fss
2  nss
2  fGCaG aNB dH fss
3  nss
2  fG
KaH aNB dH fc
3 fss nss fHK 2 aH aNB dH fc
2 fss
2  nss fHKaH aNB dH fc fss
3  nss fH
CaG aH dB fc
3 fss gssC 2 aG aH dB fc
2 fss
2  gssCaG aH dB fc fss
3  gssCaG aH dG fc
3 fss gss
(1)
C 2 aG aH dG fc
2 fss
2  gssCaG aH dG fc fss
3  gssCaG aH fc
3 fss gss gFBC 2 aG aH fc
2 fss
2  gss gFB
CaG aH fc fss
3  gss gFBCaG aNB dG fc
3 gss nssC 3 aG aNB dG fc
2 fss gss nss
C 3 aG aNB dG fc fss
2  gss nssCaG aNB dG fss
3  gss nssCaG aNB dH fc
3 gss nssC 3 aG aNB dH 
fc
2 fss gss nssC 3 aG aNB dH fc fss
2  gss nssCaG aNB dH fss
3  gss nssCaG dB dH fc
3 nss fG
C 3 aG dB dH fc
2 fss nss fGC 3 aG dB dH fc fss
2  nss fGCaG dB dH fss
3  nss fGCaG dB 
fc
3 gFB nss fGC 3 aG dB fc
2 fss gFB nss fGC 3 aG dB fc fss
2  gFB nss fGCaG dB fss
3  gFB nss fG
CaG dH fc
3 gFB nss fGC 3 aG dH fc
2 fss gFB nss fGC 3 aG dH fc fss
2  gFB nss fGCaG dH 
fss
3  gFB nss fGCaH aNB dG fc
3 fss nssC 2 aH aNB dG fc
2 fss
2  nssCaH aNB dG fc fss
3  nss
KaH dB dH fc
3 fss fHK 2 aH dB dH fc
2 fss
2  fHKaH dB dH fc fss
3  fHKaH dH fc
3 fss gFB fH
K 2 aH dH fc
2 fss
2  gFB fHKaH dH fc fss
3  gFB fHCaG dB dG fc
3 gssC 3 aG dB dG fc
2 fss gss
C 3 aG dB dG fc fss
2  gssCaG dB dG fss
3  gssCaG dB dH fc
3 gssC 3 aG dB dH fc
2 fss gss
C 3 aG dB dH fc fss
2  gssCaG dB dH fss
3  gssCaG dB fc
3 gss gFBC 3 aG dB fc
2 fss gss gFB
C 3 aG dB fc fss
2  gss gFBCaG dB fss
3  gss gFBCaG dG dH fc
3 gssC 3 aG dG dH fc
2 fss gss
C 3 aG dG dH fc fss
2  gssCaG dG dH fss
3  gssCaG dG fc
3 gss gFBC 3 aG dG fc
2 fss gss gFB
C 3 aG dG fc fss
2  gss gFBCaG dG fss
3  gss gFBCaG dH fc
3 gss gFBC 3 aG dH fc
2 fss gss gFB
C 3 aG dH fc fss
2  gss gFBCaG dH fss
3  gss gFBCaH dB dG fc
3 fssC 2 aH dB dG fc
2 fss
2
CaH dB dG fc fss
3 CaH dB fc
3 fss gFBC 2 aH dB fc
2 fss
2  gFBCaH dB fc fss
3  gFBCaH dG 
fc
3 fss gFBC 2 aH dG fc
2 fss
2  gFBCaH dG fc fss
3  gFBCaNB dG dH fc
3 nssC 3 aNB dG dH fc
2 fss nss
C 3 aNB dG dH fc fss
2  nssCaNB dG dH fss
3  nssC dB dG dH fc
3 C 3 dB dG dH fc
2 fss
C 3 dB dG dH fc fss
2 C dB dG dH fss
3 C dB dG fc
3 gFBC 3 dB dG fc
2 fss gFBC 3 dB dG fc fss
2  gFB
C dB dG fss
3  gFBC dB dH fc
3 gFBC 3 dB dH fc
2 fss gFBC 3 dB dH fc fss
2  gFBC dB dH fss
3  gFB
C dG dH fc
3 gFBC 3 dG dH fc
2 fss gFBC 3 dG dH fc fss
2  gFBC dG dH fss
3  gFB C aS pss fS
CaS sssC dSC 1  aF aG aH aNB bss dG fc
3 fss nssCaG aH aNB bss dB fc
3 hss nss fH
CaG aH aNB bss dB fc
2 fss hss nss fHCaG aH aNB bss dH fc
3 hss nss fHCaG aH aNB bss dH 
fc
2 fss hss nss fHKaG aH aNB dH fc
3 fss gss nss fHK 2 aG aH aNB dH fc
2 fss
2  gss nss fH
KaG aH aNB dH fc fss
3  gss nss fHCaF aG aNB bss dB dG fc
3 nssCaF aG aNB bss dB dG 
fc
2 fss nssCaF aG aNB bss dG dH fc
3 nssCaF aG aNB bss dG dH fc
2 fss nssCaG aH aNB dG 
(1)
fc
3 fss gss nssC 2 aG aH aNB dG fc
2 fss
2  gss nssCaG aH aNB dG fc fss
3  gss nssKaG aH dB dH 
fc
3 fss gss fHK 2 aG aH dB dH fc
2 fss
2  gss fHKaG aH dB dH fc fss
3  gss fHKaG aH dH 
fc
3 fss gss gFB fHK 2 aG aH dH fc
2 fss
2  gss gFB fHKaG aH dH fc fss
3  gss gFB fHCaG aH dB dG 
fc
3 fss gssC 2 aG aH dB dG fc
2 fss
2  gssCaG aH dB dG fc fss
3  gssCaG aH dB fc
3 fss gss gFB
C 2 aG aH dB fc
2 fss
2  gss gFBCaG aH dB fc fss
3  gss gFBCaG aH dG fc
3 fss gss gFB
C 2 aG aH dG fc
2 fss
2  gss gFBCaG aH dG fc fss
3  gss gFBCaG aNB dG dH fc
3 gss nss
C 3 aG aNB dG dH fc
2 fss gss nssC 3 aG aNB dG dH fc fss
2  gss nssCaG aNB dG dH fss
3  gss nss
CaG dB dH fc
3 gFB nss fGC 3 aG dB dH fc
2 fss gFB nss fGC 3 aG dB dH fc fss
2  gFB nss fG
CaG dB dH fss
3  gFB nss fGKaH dB dH fc
3 fss gFB fHK 2 aH dB dH fc
2 fss
2  gFB fHKaH dB dH fc 
fss
3  gFB fHCaG dB dG dH fc
3 gssC 3 aG dB dG dH fc
2 fss gssC 3 aG dB dG dH fc fss
2  gss
CaG dB dG dH fss
3  gssCaG dB dG fc
3 gss gFBC 3 aG dB dG fc
2 fss gss gFBC 3 aG dB dG fc 
fss
2  gss gFBCaG dB dG fss
3  gss gFBCaG dB dH fc
3 gss gFBC 3 aG dB dH fc
2 fss gss gFB
C 3 aG dB dH fc fss
2  gss gFBCaG dB dH fss
3  gss gFBCaG dG dH fc
3 gss gFBC 3 aG dG dH 
fc
2 fss gss gFBC 3 aG dG dH fc fss
2  gss gFBCaG dG dH fss
3  gss gFBCaH dB dG fc
3 fss gFB
C 2 aH dB dG fc
2 fss
2  gFBCaH dB dG fc fss
3  gFBC dB dG dH fc
3 gFBC 3 dB dG dH fc
2 fss gFB
C 3 dB dG dH fc fss
2  gFBC dB dG dH fss
3  gFB C bss dB dG fss fc
3 nss aF aG aH aNB
C bss dB dH fss fc
2 hss nss aG aH aNB fHC bss dB dH fc
3 hss nss aG aH aNB fH
C bss dB dG dH fss fc
2 nss aF aG aNBC bss dB dG dH fc
3 nss aF aG aNBK dB dH 
fss
3  fc gss gFB aG aH fHK 2 dB dH fss
2  fc
2 gss gFB aG aH fHK dB dH fss fc
3 gss gFB aG aH fH
C dB dG fss
3  fc gss gFB aG aHC 2 dB dG fss
2  fc
2 gss gFB aG aHC dB dG fss fc
3 gss gFB aG aH
C dB dG dH fss
3  gss gFB aGC 3 dB dG dH fss
2  fc gss gFB aGC 3 dB dG dH fss fc
2 gss gFB aG
C dB dG dH fc
3 gss gFB aG
a6 =
1
fssC fc
3 aS dS sssCaS pss fSC dS  aF aG aH aNB bss dG fc
3 fss nss
CaG aH aNB bss dB fc
3 hss nss fHCaG aH aNB bss dB fc
2 fss hss nss fHCaG aH aNB bss dH 
fc
3 hss nss fHCaG aH aNB bss dH fc
2 fss hss nss fHKaG aH aNB dH fc
3 fss gss nss fH
K 2 aG aH aNB dH fc
2 fss
2  gss nss fHKaG aH aNB dH fc fss
3  gss nss fHCaF aG aNB bss dB dG 
fc
3 nssCaF aG aNB bss dB dG fc
2 fss nssCaF aG aNB bss dG dH fc
3 nss
CaF aG aNB bss dG dH fc
2 fss nssCaG aH aNB dG fc
3 fss gss nssC 2 aG aH aNB dG fc
2 
fss
2  gss nssCaG aH aNB dG fc fss
3  gss nssKaG aH dB dH fc
3 fss gss fHK 2 aG aH dB dH fc
2 
fss
2  gss fHKaG aH dB dH fc fss
3  gss fHKaG aH dH fc
3 fss gss gFB fHK 2 aG aH dH fc
2 
fss
2  gss gFB fHKaG aH dH fc fss
3  gss gFB fHCaG aH dB dG fc
3 fss gssC 2 aG aH dB dG fc
2 
fss
2  gssCaG aH dB dG fc fss
3  gssCaG aH dB fc
3 fss gss gFBC 2 aG aH dB fc
2 fss
2  gss gFB
CaG aH dB fc fss
3  gss gFBCaG aH dG fc
3 fss gss gFBC 2 aG aH dG fc
2 fss
2  gss gFB
CaG aH dG fc fss
3  gss gFBCaG aNB dG dH fc
3 gss nssC 3 aG aNB dG dH fc
2 fss gss nss
C 3 aG aNB dG dH fc fss
2  gss nssCaG aNB dG dH fss
3  gss nssCaG dB dH fc
3 gFB nss fG
C 3 aG dB dH fc
2 fss gFB nss fGC 3 aG dB dH fc fss
2  gFB nss fGCaG dB dH fss
3  gFB nss fG
KaH dB dH fc
3 fss gFB fHK 2 aH dB dH fc
2 fss
2  gFB fHKaH dB dH fc fss
3  gFB fHCaG dB dG dH 
fc
3 gssC 3 aG dB dG dH fc
2 fss gssC 3 aG dB dG dH fc fss
2  gssCaG dB dG dH fss
3  gssCaG dB dG 
fc
3 gss gFBC 3 aG dB dG fc
2 fss gss gFBC 3 aG dB dG fc fss
2  gss gFBCaG dB dG fss
3  gss gFB
CaG dB dH fc
3 gss gFBC 3 aG dB dH fc
2 fss gss gFBC 3 aG dB dH fc fss
2  gss gFBCaG dB dH 
fss
3  gss gFBCaG dG dH fc
3 gss gFBC 3 aG dG dH fc
2 fss gss gFBC 3 aG dG dH fc fss
2  gss gFB
CaG dG dH fss
3  gss gFBCaH dB dG fc
3 fss gFBC 2 aH dB dG fc
2 fss
2  gFBCaH dB dG fc fss
3  gFB
C dB dG dH fc
3 gFBC 3 dB dG dH fc
2 fss gFBC 3 dB dG dH fc fss
2  gFBC dB dG dH fss
3  gFB
C aS pss fSCaS sssC dSC 1  aF aG aH aNB bss dB dG fc
3 fss nss
CaG aH aNB bss dB dH fc
3 hss nss fHCaG aH aNB bss dB dH fc
2 fss hss nss fH
CaF aG aNB bss dB dG dH fc
3 nssCaF aG aNB bss dB dG dH fc
2 fss nssKaG aH dB dH 
fc
3 fss gss gFB fHK 2 aG aH dB dH fc
2 fss
2  gss gFB fHKaG aH dB dH fc fss
3  gss gFB fH
CaG aH dB dG fc
3 fss gss gFBC 2 aG aH dB dG fc
2 fss
2  gss gFBCaG aH dB dG fc fss
3  gss gFB
CaG dB dG dH fc
3 gss gFBC 3 aG dB dG dH fc
2 fss gss gFBC 3 aG dB dG dH fc fss
2  gss gFB
CaG dB dG dH fss
3  gss gFB
a7 =
1
fssC fc
3 aS dS sssCaS pss fSC dS  aF aG aH aNB bss dB dG fc
3 fss nss
CaG aH aNB bss dB dH fc
3 hss nss fHCaG aH aNB bss dB dH fc
2 fss hss nss fH
(1)
CaF aG aNB bss dB dG dH fc
3 nssCaF aG aNB bss dB dG dH fc
2 fss nssKaG aH dB dH 
fc
3 fss gss gFB fHK 2 aG aH dB dH fc
2 fss
2  gss gFB fHKaG aH dB dH fc fss
3  gss gFB fH
CaG aH dB dG fc
3 fss gss gFBC 2 aG aH dB dG fc
2 fss
2  gss gFBCaG aH dB dG fc fss
3  gss gFB
CaG dB dG dH fc
3 gss gFBC 3 aG dB dG dH fc
2 fss gss gFBC 3 aG dB dG dH fc fss
2  gss gFB
CaG dB dG dH fss
3  gss gFB
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Characteristic Equation for φ > φc
The characteristic equation for Section 4.5.4 is of the form
C2 = a0λ
7 + a1λ
6 + a2λ
5 + a3λ
4 + a4λ
3 + a5λ
2 + a6λ+ a7
and we list the coefficients below.
(1)
a0 = 1
a1 = aG nss fGCaS pss fSCaG gssCaH fcCaS sssC kpshC dBC dFC dHC dSC 1
a2 = dS sss aSC pss aS fSC dSC aS pss fSCaS sssC dSC 1  aG nss fGCaG gssCaH fc
C kpshC dH C dH nss aG fGC fc gss aG aHC kpsh nss aG fGC dH gss aGC fc kpsh aH
C dH kpshC aG nss fGCaS pss fSCaG gssCaH fcCaS sssC kpshC dHC dS
C 1  dFC dB aG nss fGCaS pss fSCaG gssCaH fcCaS sssC kpshC dFC dHC dS
C 1
a3 = aS dS sssCaS pss fSC dS  aG nss fGCaG gssCaH fcC kpshC dH C aS pss fS
CaS sssC dSC 1  kpsh aG nss fGCaG aH fc gssCaG dH nss fGC kpsh aH fc
CaG dH gssC kpsh dH C dH kpsh nss aG fGC dS sss aSC pss aS fSC dSC aS pss fS
CaS sssC dSC 1  aG nss fGCaG gssCaH fcC kpshC dH C dH nss aG fG
C fc gss aG aHC kpsh nss aG fGC dH gss aGC fc kpsh aHC dH kpsh  dFC dS sss aS
C pss aS fSC dSC aS pss fSCaS sssC dSC 1  aG nss fGCaG gssCaH fcC kpsh
C dH C dH nss aG fGC fc gss aG aHC kpsh nss aG fGC dH gss aGC fc kpsh aH
C dH kpshC aG nss fGCaS pss fSCaG gssCaH fcCaS sssC kpshC dHC dS
C 1  dF  dB
a4 = aS dS sssCaS pss fSC dS  kpsh aG nss fGCaG aH fc gssCaG dH nss fGC kpsh aH fc
CaG dH gssC kpsh dH C aS pss fSCaS sssC dSC 1  dH kpsh nss aG fG
C aS dS sssCaS pss fSC dS  aG nss fGCaG gssCaH fcC kpshC dH
C aS pss fSCaS sssC dSC 1  kpsh aG nss fGCaG aH fc gssCaG dH nss fG
C kpsh aH fcCaG dH gssC kpsh dH C dH kpsh nss aG fG  dFC aS dS sssCaS pss fS
C dS  aG nss fGCaG gssCaH fcC kpshC dH C aS pss fSCaS sssC dS
C 1  kpsh aG nss fGCaG aH fc gssCaG dH nss fGC kpsh aH fcCaG dH gss
C kpsh dH C dH kpsh nss aG fGC dS sss aSC pss aS fSC dSC aS pss fSCaS sss
C dSC 1  aG nss fGCaG gssCaH fcC kpshC dH C dH nss aG fGC fc gss aG aH
C kpsh nss aG fGC dH gss aGC fc kpsh aHC dH kpsh  dF  dB
a5 = dH kpsh nss aG fG aS dS sssCaS pss fSC dS C aS dS sssCaS pss fS
C dS  kpsh aG nss fGCaG aH fc gssCaG dH nss fGC kpsh aH fcCaG dH gss
C kpsh dH C aS pss fSCaS sssC dSC 1  dH kpsh nss aG fG  dFC aS dS sss
CaS pss fSC dS  kpsh aG nss fGCaG aH fc gssCaG dH nss fGC kpsh aH fc
CaG dH gssC kpsh dH C aS pss fSCaS sssC dSC 1  dH kpsh nss aG fG
C aS dS sssCaS pss fSC dS  aG nss fGCaG gssCaH fcC kpshC dH
C aS pss fSCaS sssC dSC 1  kpsh aG nss fGCaG aH fc gssCaG dH nss fG
C kpsh aH fcCaG dH gssC kpsh dH C dH kpsh nss aG fG  dF  dB
a6 = dF dH kpsh nss aG fG aS dS sssCaS pss fSC dS C dH kpsh nss aG fG aS dS sss
CaS pss fSC dS C aS dS sssCaS pss fSC dS  kpsh aG nss fGCaG aH fc gss
CaG dH nss fGC kpsh aH fcCaG dH gssC kpsh dH C aS pss fSCaS sssC dS
C 1  dH kpsh nss aG fG  dF  dB
a7 = dB dF dH kpsh nss aG fG aS dS sssCaS pss fSC dS
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Characteristic Equation for φ >> φc
The characteristic equation for Section 4.5.5 is of the form
C3 = a0λ
7 + a1λ
6 + a2λ
5 + a3λ
4 + a4λ
3 + a5λ
2 + a6λ+ a7
and we list the coefficients below.
a0 = 1
a1 = aG nss fGCaS pss fSCaH fcC kpshC dBC dFC dHC 1
a2 = pss aS fSC kpsh aS pss fSC 1 C aS pss fSC kpshC 1  aG nss fGCaH fcC dH
C dH nss aG fGC aG nss fGCaS pss fSCaH fcC kpshC dHC 1  dFC dB aG nss fG
CaS pss fSCaH fcC kpshC dFC dHC 1
a3 = kpsh pss aS fSC pss aS fSC kpsh aS pss fSC 1  aG nss fGCaH fcC dH
C aS pss fSC kpshC 1  dH nss aG fGC pss aS fSC kpsh aS pss fSC 1
C aS pss fSC kpshC 1  aG nss fGCaH fcC dH C dH nss aG fG  dFC pss aS fS
C kpsh aS pss fSC 1 C aS pss fSC kpshC 1  aG nss fGCaH fcC dH
C dH nss aG fGC aG nss fGCaS pss fSCaH fcC kpshC dHC 1  dF  dB
a4 = kpsh pss aS fS aG nss fGCaH fcC dH C pss aS fSC kpsh aS pss fS
C 1  dH nss aG fGC kpsh pss aS fSC pss aS fSC kpsh aS pss fSC 1  aG nss fG
CaH fcC dH C aS pss fSC kpshC 1  dH nss aG fG  dFC kpsh pss aS fS
C pss aS fSC kpsh aS pss fSC 1  aG nss fGCaH fcC dH C aS pss fSC kpsh
C 1  dH nss aG fGC pss aS fSC kpsh aS pss fSC 1 C aS pss fSC kpsh
C 1  aG nss fGCaH fcC dH C dH nss aG fG  dF  dB
a5 = dH kpsh nss pss aG aS fG fSC kpsh pss aS fS aG nss fGCaH fcC dH C pss aS fS
C kpsh aS pss fSC 1  dH nss aG fG  dFC kpsh pss aS fS aG nss fGCaH fcC dH
C pss aS fSC kpsh aS pss fSC 1  dH nss aG fGC kpsh pss aS fSC pss aS fS
C kpsh aS pss fSC 1  aG nss fGCaH fcC dH C aS pss fSC kpsh
C 1  dH nss aG fG  dF  dB
a6 = dF dH kpsh nss pss aG aS fG fSC dH kpsh nss pss aG aS fG fS
C kpsh pss aS fS aG nss fGCaH fcC dH C pss aS fSC kpsh aS pss fS
C 1  dH nss aG fG  dF  dB
a7 = dB dF dH kpsh nss pss aG aS fG fS
Appendix D
Glossary for Chapter 7
Liquid-Chromatography-Mass Spectrometry
Liquid-Chromatography-Mass Spectrometry (LC-MS) analysis is a technique for iden-
tification, quantification and mass analysis of chemicals. A sample is dissolved in a
solvent and pumped through an analytical column. The various compounds in the
mixture are then separated by this column and analysed in a mass detector. The
results of this can then be compared to a reference compound.
Human Liver Cytosol
Cytosol refers to the liquid found inside cells. In our experiments we used human liver
cytosol, prepared from human hepatocytes. Cytosol contains the various chemicals
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involved in metabolism inside the given cell and so can be used for in vitro testing of
metabolism of a given drug in a specific cell type.
Acetonitrile
Acetonitrile is a chemical compound which acts as a solvent. It is used to halt the
reactions in our experiments and can then be evaporated off to leave the proteins we
wish to examine.
Phosphate Buffer
Phosphate buffer is a buffer solution comprised of water and a number of salts. It
is isotonic, meaning it has the same solute concentration as a cell, as well as being
non-toxic to most cells.
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